

Biuletyn Polskiego Towarzystwa Onkologicznego

Nowotwory

NOWOTWORY 2023, tom 8, numer 5, 325-406



Retrospective analysis of the treatment of *BRCA1* and *BRCA2* mutation carriers – the experience of a single-center tertiary institution

G.J. Stępień, T. Wow, A. Kołacińska-Wow

Pharmacological prevention methods in patients with cardiovascular disease with breast cancer – when, how, and for whom?

M. Dyrbuś, I. Skoczylas, A. Majsnerowska, M. Gąsior, M. Tajstra

The influence of fluid therapy on short- and long-term outcomes in patients undergoing liver resection for malignant indications

M. Dec, W. Figiel, P. Andruszkiewicz, M. Grąt

Anemia in cancer patients: addressing a neglected issue – diagnostics and therapeutic algorithm

K. Tałasiewicz, A. Kapala

100 lat
czasopisma
Nowotwory



5/2023

Nowotwory. Journal of Oncology – indeksacja:
Scopus, EMBASE, Google Scholar, CrossRef, 100 punktów MEIN

Warsaw Skin Cancer Conference 2023



Warszawa, 24 listopada 2023 roku

Przewodniczący Komitetu Naukowego
prof. dr hab. n. med. Piotr Rutkowski

SZCZEGÓŁY



www.wsc.viamedica.pl

Konferencja jest skierowana tylko do osób uprawnionych do wystawiania recept lub osób prowadzących obrót produktami leczniczymi – podstawa prawna: Ustawa z dnia 6 września 2001 r. Prawo farmaceutyczne (t. j. Dz.U. z 2019 r. poz. 499).

PATRONAT



PATRONAT MEDIALNY

tvmed



PARTNER



Biuletyn Polskiego Towarzystwa Onkologicznego

Nowotwory

Redaktor naczelny

Wojciech M. Wysocki

Epidemiologia nowotworów – Redaktor działu: Marta Mańczuk

Profilaktyka nowotworów i zdrowie publiczne – Redaktor działu: Paweł Koczkodaj

Nowotwory wątroby – Redaktor działu: Andrzej L. Komorowski

Żywność kliniczna w onkologii – Redaktor działu: Aleksandra Kapała

Rada redakcyjna

M. Baum (Wielka Brytania)
B. Bobek-Billewicz
L. Cataliotti (Włochy)
M. Dębiec-Rychter (Belgia)
J. Didkowska
R. Duchnowska
R. Dziadziuszko
A. Eggermont (Francja)
J. Fijuth
K. Herman
S. Grodecka-Gazdecka
H. zur Hausen (Niemcy)
J. Jassem
A. Jeziorski
A. Kawecki
R. Kordek
M. Krawczyk
M. Krzakowski
J. Kuźdżał
M. Litwiniuk
A. Maciejczyk
B. Maciejewski
S. Mrowiec
A. Nasierowska-Guttmejer

Z.I. Nowecki
J. Overgaard (Dania)
J. Piekarski
W. Polkowski
J. Reguła
R. Rosell (Hiszpania)
P. Rutkowski
B. Sas-Korczyńska
M.I. Saunders (Wielka Brytania)
J.A. Siedlecki
E. Sierko
K. Skłodowski
I.E. Smith (Wielka Brytania)
H.D. Suit (Kanada)
R. Suwiński
I. Tannock (Kanada)
A. Turrisi (USA)
C.J.H. van de Velde (Holandia)
J.B. Vermorken (Belgia)
J. Walewski
M. Wełnicka-Jaśkiewicz
P. Wysocki

Redaktor honorowy

Edward Towpik

Biuletyn Polskiego Towarzystwa Onkologicznego

Nowotwory

dwumiesięcznik

oficjalny organ



POLSKIEGO TOWARZYSTWA
ONKOLOGICZNEGO



im. Marii Skłodowskiej-Curie
Państwowy Instytut Badawczy

czasopismo



POLSKIEGO TOWARZYSTWA
CHIRURGII ONKOLOGICZNEJ

Redaktorzy prowadzący: Agnieszka Wrzesień, Aleksandra Cielecka

Journal Club: Anna Kowalczyk, Ewa Szutowicz-Zielińska, Magdalena Dróżka, Anna Kaczmarczyk

Adres redakcji:

Narodowy Instytut Onkologii im. M. Skłodowskiej-Curie – Państwowy Instytut Badawczy
ul. Roentgena 5
02-781 Warszawa

Adres korespondencyjny:

Krakowska Akademia im. Andrzeja Frycza-Modrzewskiego
ul. Gustawa Herlinga-Grudzińskiego 1
30-705 Kraków
pokój 309
tel. 512 177 774
e-mail: redakcja@nowotwory.edu.pl
www.nowotwory.edu.pl

Adres wydawcy:

VM Media Group sp. z o.o.
ul. Świętokrzyska 73, 80-180 Gdańsk
tel. (48) 58 320 94 94, faks (48) 58 320 94 60
e-mail: viamedica@viamedica.pl, www.viamedica.pl

ISSN: 2543-5248

e-ISSN: 2543-8077



22-6131.005.001

Spis treści

Artykuły oryginalne / Original articles

Genetyka nowotworów / Cancer genetics

- Retrospective analysis of the treatment of *BRCA1* and *BRCA2* mutation carriers – the experience of a single-center tertiary institution325**

Grzegorz J. Stępień, Thomas Wow, Agnieszka Kołacińska-Wow

Epidemiologia nowotworów / Cancer epidemiology

- Socioeconomic factors and suicide risk in Polish cancer patients – a population-based cohort study exploring associations and implications331**

Irmina M. Michalek, Florentino L. Caetano dos Santos, Urszula Wojciechowska, Joanna Didkowska

Artykuły przeglądowe / Review articles

Kardioonkologia / Cardiooncology

- Pharmacological prevention methods in patients with cardiovascular disease with breast cancer – when, how, and for whom?336**

Maciej Dyrbuś, Ilona Skoczylas, Aleksandra Majsnerowska, Mariusz Gąsior, Mateusz Tajstra

Biomarkery / Biomarkers

- The importance of selected biomarkers in the clinical practice of breast cancer patients. . . .345**

Agata Makówka, Beata Kotowicz

Radioterapia / Radiotherapy

- Have innovations in radiotherapy for head and neck cancer improved the curability of the disease?354**

Bogusław Maciejewski, Dorota Gabryś, Justyna Rembak-Szynkiewicz, Aleksandra Napieralska, Małgorzata Stąpór-Fudzińska

Białaczka / Leukemia

- Methotrexate-associated oral mucositis in children with acute lymphoblastic leukemia.....362**

Ewa Pustelnik, Katarzyna Pikora, Katarzyna Pawelec

Nowotwory wątroby / Liver tumors

- The influence of fluid therapy on short- and long-term outcomes in patients undergoing liver resection for malignant indications.371**

Marta Dec, Wojciech Figiel, Paweł Andruszkiewicz, Michał Grąt

Żywnienie kliniczne w onkologii / Clinical nutrition in oncology

- Anemia in cancer patients: addressing a neglected issue – diagnostics and therapeutic algorithm377**

Konrad Tałasiewicz, Aleksandra Kapala

Profilaktyka nowotworów i zdrowie publiczne / Cancer prevention and public health

- The European Code Against Cancer – new evidence and recommendations385**

Ariadna Feliu, David Ritchie, Joachim Schüz, Carolina Espina

Obrazy w onkologii / Pictures in oncology

Rare case of recurrent myofibroblastoma in a female patient391

Stanisław Ciechanowicz, Piotr Kupidłowski, Mateusz Wichtowski

Pneumoconiosis mimicking lung metastases of medullary thyroid carcinoma 392

Karolina Gasz, Agnieszka Żyłka, Joanna Długosińska, Marek Dedecjus

Rozmowy na 100-lecie / Conversations for the 100th anniversary

**Prof. Maciej Krzakowski: Nowotwory stanowiły dla mnie zawsze platformę
współpracy ze znakomitymi onkologami393**

**Prof. Jan Skołyszewski: System punktowania, moim zdaniem, nie zawsze rozstrzyga o tym,
czy dana praca jest wartościowa394**

Kronika / Chronicle

Z kalendarium Zarządu PTO (sierpień–wrzesień 2023)395

Journal Club398

Komunikaty406

Retrospective analysis of the treatment of *BRCA1* and *BRCA2* mutation carriers – the experience of a single-center tertiary institution

Grzegorz J. Stępień¹ , Thomas Wow² , Agnieszka Kołacińska-Wow^{1,3} 

¹Department of Oncological Physiotherapy, Medical University of Lodz, Lodz, Poland

²Department of Surgical Oncology and Breast Diseases, Polish Mother's Memorial Hospital – Research Institute, Lodz, Poland

³Breast Unit Cancer Center, Copernicus Memorial Hospital, Lodz, Poland

Introduction. Breast cancer gene 1 and 2 (*BRCA1/2*) mutation carriers are at a higher risk of developing breast cancer. There are several established risk-reducing therapies. Our study aimed to characterize the *BRCA1/2* mutation carriers, and to evaluate the implemented treatment methods.

Material and methods. A retrospective analysis of clinical records of 96 female patients hospitalized from October 2019 to December 2022 in the Breast Cancer Unit in Lodz, Poland.

Results. Out of 85 *BRCA1* and 11 *BRCA2* mutation carriers, 96.88% received nipple-sparing or skin-sparing, unilateral or bilateral risk-reducing mastectomies. Out of all the patients, 36 developed 38 breast cancers. One patient was diagnosed with breast cancer 2 years after a bilateral risk-reducing mastectomy. The most common breast cancer subtype was triple-negative breast cancer (73.68%). The patients could receive surgery, chemotherapy, endocrine therapy and radiotherapy. 18 patients had neoadjuvant chemotherapy, in 6 of these patients a complete pathological response (ypT0N0) was achieved.

Conclusions. Oncoplastic bilateral risk-reducing mastectomies are effective and safe procedures.

Key words: breast cancer gene 1/2, breast cancer, risk-reducing mastectomy, hereditary breast cancer, breast cancer unit

Introduction

Breast cancer (BC) is the most commonly diagnosed cancer in the world. It accounted for 24.5% of new oncological cases and 15.5% of cancer-associated deaths in the female population worldwide in 2020 [1]. Several conditions increase the risk of developing BC, they can be divided into modifiable and unmodifiable risk factors. One of the most important genetic factors associated with familial susceptibility is a mutation in the genes: breast cancer gene 1 (*BRCA1*) or breast cancer gene 2 (*BRCA2*) [2, 3]. Women that carry mutations have a lifetime risk of breast cancer development up to 87% for *BRCA1*, and up to 69% for *BRCA2* [4–6].

Early detection of mutations in the above genes enables patients to reduce the incidence of breast malignancies by risk-reducing therapies like risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO), or early detection by means of regular MRI and mammography screening, or chemoprevention with tamoxifen [7–10].

The aim of our study was to characterize and describe the population of female *BRCA1* or *BRCA2* mutation carriers admitted to the Breast Cancer Unit in Lodz, Poland, and to evaluate treatment methods for breast cancer and susceptibility due to *BRCA1/2* mutations.

Jak cytować / How to cite:

Stępień GJ, Wow T, Kołacińska-Wow A. *Retrospective analysis of the treatment of BRCA1 and BRCA2 mutation carriers – the experience of a single-center tertiary institution.* NOWOTWORY J Oncol 2023; 73: 257–262.

Material and methods

The Medical University of Lodz Ethics Committee stated that this study is not a medical experiment and does not require the opinion of the Bioethical Commission (RNN/29/23/KE; 14 February 2023). We retrospectively identified 96 female patients who tested positive for a mutation in the *BRCA1* or *BRCA2* genes. We included women hospitalized from October 2019 to December 2022 in the Breast Cancer Unit, Lodz, Poland. The clinical and histopathological data were obtained from the hospital records. Statistical analysis was performed using Microsoft Excel.

Results

Out of the included patients, 85 (88.54%) were *BRCA1* mutation carriers, and 11 (11.46%) were *BRCA2* mutation carriers. 93 (96.88%) of the patients underwent a risk-reducing mastectomy (n = 82 in *BRCA1*, n = 11 in *BRCA2*). Three women did not receive risk-reducing procedures and at the time of data collection, they were treated due to breast cancer. The median age on the day of the RRM procedure was 40 (25–65) in the *BRCA1* group and 42 (33–48) in the *BRCA2* group. The patients in our study underwent bilateral (mutation carriers) or unilateral risk-reducing procedures (mutation carriers who developed breast cancer in one breast). All these women received oncoplastic and reconstructive techniques – NSM (nipple-sparing mastectomy) or SSM (skin-sparing mastectomy) or SRM (skin-reducing mastectomy). The characteristics of patients in view of the above procedures are shown in table I.

36 (37.5%) women developed 38 breast cancers. 34 patients developed one cancer in one breast (left n = 13, right n = 21), one patient had two independent, non-simultaneous cancers in the left breast and one woman developed bilateral breast cancer. In one patient, a 9 mm cancer of the breast was incidentally found in the left breast specimen after risk-reducing mastectomy, not visualized on preoperative breast MRI. One patient developed breast cancer 2 years after a bilateral risk-reducing mastectomy performed in another institution.

In the group of *BRCA1* mutation carriers (fig. 1), 52 (61.18%) did not develop breast cancer, 31 (36.47%) developed one cancer in one breast, one (1.18%) developed 2 cancers in one breast (left breast), and one (1.18%) developed bilateral breast cancer. In the *BRCA2* group, 8 (72.73%) patients did not

develop breast cancer, 3 (27.27%) developed breast cancer in one breast (all cancers in the right breast).

The most common molecular subtype of breast cancer in the described group of patients was triple negative; it accounted for 28 (73.68%) cases. Other subtypes included: luminal A (n = 5) and luminal B (HER2-negative) (n = 5). The only histopathological subtype was no special type (NST) (38; 100%). We found grade 3 (G3) in 26 cases (68.42%), G2 in 9, G1 in 1 and GX in 2 tumors. We stated Ki-67 expression ≤20–29% as low and >30% as high. High Ki-67 expression was found in 28 cancers, and in 10 tumor samples it was identified as low. A description of the histological and molecular features of the cancers is shown in table II.




Figure 1. Patients who tested positive for the *BRCA1* or *BRCA2* mutation

Table II. Histopathological characteristics of the tumors

Histopathological subtype	Mutation	
	BRCA1 (n = 35)	BRCA2 (n = 3)
no special type (NST)	35	3
grading		
GX	2	0
G1	0	1
G2	9	0
G3	24	2
Ki-67 expression		
low (≤20–29%)	8	2
high (>30%)	27	1
molecular subtype		
triple-negative (basal-like)	27	1
luminal A	3	2
luminal B (HER2–)	5	0

Table I. Risk-reducing mastectomies (RRM) in the described groups of mutation carriers

Procedure	Mutation	
	BRCA1 (n = 82)	BRCA2 (n = 11)
left RRM	14	3
right RRM	12	0
bilateral RRM	56	8

Table III. Breast cancer staging in the described patients

TNM classification	Mutation	
	<i>BRCA1</i> (n = 34)	<i>BRCA2</i> (n = 3)
primary tumor (T)		
yT0	5	1
T1	14	1
T2	15	0
T3	0	1
regional lymph nodes (N)		
yN0	10	1
N0	15	1
N1	9	1
distant metastases (M)		
M0	33	3
M1	1	0

Among the patients, tumor sizes T1 (n = 15) and T2 (n = 15) were predominant. Most commonly, in 16 patients, there was no axillary lymph node involvement (N0). Only one woman (*BRCA1*+) developed bone metastases (stage IV), this patient received a mastectomy with delayed breast reconstruction, and postoperative radiotherapy + hormone therapy. The staging of tumors in the characterized group can be seen in table III.

Patients who developed breast cancer could undergo surgery, chemotherapy (neoadjuvant and adjuvant), adjuvant endocrine therapy and postoperative radiotherapy. In relation to surgical cancer treatment, patients received such techniques (n = 37):

- nipple-sparing mastectomy with immediate prepectoral breast reconstruction (n = 13),
- skin-sparing mastectomy with immediate prepectoral breast reconstruction (n = 6),
- breast-conserving therapy (n = 6),
- mastectomy with delayed reconstruction (n = 8),
- mastectomy (n = 4).

Breast-conserving therapy (BCT) was offered to patients who met the criteria to receive this treatment and they were not stated as *BRCA1/2* mutation carriers at the time of breast cancer diagnosis. Because of a strong family history of breast cancer, after the surgery, women consulted with geneticists, and all of these patients were proven to carry mutations. 26 patients underwent a sentinel lymph node biopsy, the rest received an axillary lymph node dissection. 18 patients had neoadjuvant chemotherapy, in 6 of these patients (33.33%) a complete pathological response (ypT0N0) was achieved. The description of treatment methods is shown in table IV.

Table IV. Treatment (other than surgical excision) received by the patients

Treatment	Mutation	
	<i>BRCA1</i> (n = 33)	<i>BRCA2</i> (n = 3)
HT	4	0
RTH + HT	1	2
preop CHT	10	1
preop CHT + RTH	5	0
preop CHT + RTH + HT	1	0
preop CHT + CHT + RTH	1	0
CHT	8	0
CHT + RTH	2	0
CHT + RTH + HT	1	0

preop CHT – preoperative chemotherapy; CHT – adjuvant chemotherapy; RTH – radiotherapy; HT – hormone therapy

Discussion

With over 2.2 million newly diagnosed cases and over 680,000 deaths recorded in 2020, female breast cancer is considered the most common cancer and the fifth cause of cancer mortality worldwide [1]. Breast cancer may manifest as sporadic (90–95% of all BCs) or hereditary (5–10%) disease [5, 11, 12]. Cases of multiple breast and/or ovarian cancer incidents in families and individuals, those diagnosed at a young age, and male breast cancers may suggest hereditary syndromes [3]. Studies have shown that mutations in several genes can be associated with familial susceptibility to breast cancer development. Commonly mentioned genes include *BRCA1/BRCA2*, *TP53*, *PALB2*, *PTEN*, *CHEK2*, and *ATM* [6, 11–13].

The *BRCA1* (17q21) and *BRCA2* (13q12-q13) genes are tumor suppressors whose main functions are the maintenance of genomic stability and negative regulation of tumor growth. Mutation-carrying individuals, whose gene functions are lost or reduced, are at higher risk of developing breast and ovarian cancer [5, 6, 14]. What is more, abnormal functions of the *BRCA2* gene lead to increased susceptibility to cancers of organs such as the pancreas and prostate [11, 12].

Concerning BC, individuals with a mutation in the *BRCA1* gene most commonly develop TNBC (triple negative breast cancer), where there is no expression of estrogen-receptors, progesterone-receptors, and no overexpression of *HER2/neu* [11, 12]. In our study, the triple-negative subtype was also the most common molecular type in the *BRCA1* group (n = 27; 77.14%). Due to the lack of drug targets, chemotherapy plays a crucial role in the treatment of TNBC [15]. In the context of the histologic grade of tumors, *BRCA1*+ breast cancers are rather considered to be poorly differentiated (G3) [12]. In the described group of patients, out of 35 *BRCA1*+ tumors, 24 (68.57%) were stated as high-grade (G3) cancers.

Surgical oncologists' approach to breast cancer surgery and risk-reducing procedures has been transformed from radical mastectomy to conservative mastectomy with immediate reconstruction. Present oncoplastic surgery focuses on providing oncologically safe procedures with possibly the best aesthetic outcomes. Techniques such as NSM, concentrated on preserving the NAC (nipple-areolar complex), and SSM, where NAC is excised with glandular tissue (but may be reconstructed in a subsequent procedure), are considered to achieve the above-mentioned goals [16, 17]. As was reported, the patients involved in our study received various types of surgical operations for breast cancer, including NSM, SSM, BCT, and radical mastectomy with or without delayed reconstruction. Novel surgical techniques, NSM and SSM with immediate prepectoral breast reconstruction, were provided in 19 cases of breast cancer. 8 women received delayed reconstruction after mastectomy.

As regards the risk-reducing mastectomy, studies have proven that it offers >90% breast cancer risk reduction [18, 19]. Several research papers, regarding the effects of RRM, described such positive outcomes as a gain in life expectancy, decreased all-cause and breast cancer-specific mortality rates, and decreased breast cancer incidence rate, compared to surveillance [8, 20, 21]. In the study of Heemskerk-Gerritsen et al., BRRM (bilateral risk-reducing mastectomy), compared with surveillance (mammography + clinical-and self-examination), was proven to have higher ten-year breast cancer-free survival (100% vs. 74%) and higher ten-year overall survival (99% vs. 96%) [8]. Besides, the proactive surgical approach can ensure psychological well-being by mitigating cancer-related anxiety [19]. Like any other surgical procedure, oncoplastic risk-reducing mastectomies with immediate reconstruction entail the risk of complications. These include nipple-areola or mastectomy skin flap necrosis, wound infection, breast asymmetry, BIA-ALCL (breast implant-associated anaplastic large cell lymphoma), and unsatisfying aesthetic results [17, 22, 23]. There is also a chance after RRM that a patient might have to undergo revisional surgery [19]. Even after the NSM procedure there still remains a low risk of cancer development, due to the possibility of remaining a portion of glandular tissue in the NAC. In our analyzed group, we documented a case of a woman who was treated for breast cancer that developed after bilateral RRM. In contraposition to our evaluation, in the study of Jakub et al., after 548 risk-reducing NSMs in 346 *BRCA1/2* mutation carriers, there was no case of primary breast cancer on both sides after the bilateral procedure, or ipsilateral side after the unilateral risk-reducing procedure [24]. Surgeons' doubts about glandular breast tissue that can be left in the NAC after NSM and the associated risk of cancer were partly resolved. Baltzer et al., in a study of 105 female patients, found that NAC represents a tiny fraction (1.3%) of the entire breast tissue. With an extremely small chance of breast cancer development, this study supports the safety of the described procedure [25].

Women carrying *BRCA1/2* mutations, who were diagnosed with a primary cancer of one of the breasts, are still vulnerable to the next malignancy incidence. They have a higher risk of contralateral breast cancer compared to the general population [22, 26].

In the study of Kuchenbaecker et al., the cumulative risk for ovarian cancer development in *BRCA1* and *BRCA2* patients was estimated at 44% (95% confidence interval [CI], 36–53%) and 17% (95% CI, 11–25%) respectively [4]. There is scientific evidence that risk-reducing salpingo-oophorectomy is effective in decreasing ovarian cancer incidence and mortality [27]. In regard to breast cancer, besides RRM, the mutation carriers may also opt for RRSO. In patients without previous breast cancer diagnosis, it was shown that risk-reducing salpingo-oophorectomy can reduce all-cause mortality, breast cancer-specific mortality, ovarian cancer-specific mortality, and risk of breast cancer development [9].

For the good of women, it seems important to spread public awareness of hereditary syndromes related to breast and ovarian cancer, and ways to handle them. Evans, D Gareth et al., showed increased genetic consultations uptake in the United Kingdom after the famous decision of the actress Angelina Jolie who, in May 2013, chose to undergo BRRM because of being a *BRCA1* mutation carrier [28].

It is believed that the best quality of care for breast cancer patients can be accessible in breast cancer units (BCU). These centers, organized in one location, provide highly qualified specialists and services that focus particularly on breast cancer detection and its treatment. Units consist of a multidisciplinary team involving geneticists, radiologists, pathologists, surgeons, oncologists, radiation oncologists and psychologists [29, 30].

There are limitations to our study. A relatively small number of mutation carriers were involved in the analysis. There is a need for further research in the field of *BRCA*-mutation carriers treatment and its associated outcomes.

Conclusions

The *BRCA1* and *BRCA2* mutations are related to a higher risk of breast cancer development, especially triple-negative subtypes. Knowledge of being a mutation carrier enables the patients to take steps to minimize the risk of malignancy occurrence. A bilateral risk-reducing mastectomy, performed with oncoplastic techniques, remains an effective oncological procedure for women who test positive for *BRCA1* or *BRCA2* mutations. Due to the possibility of finding malignant tissue not visualized on preoperative imaging scans, a proper histological examination of post-RRM specimens is essential.

Surgical oncologists must clearly inform the patients about various risk-reducing approaches and potential post-surgical complications, changes in body image and self-perception after the surgery.

Article information and declarations

Data availability statement

The data presented in this study are available on request from the corresponding author.

Ethics statement

The Medical University of Lodz Ethics Committee stated that this study is not a medical experiment and does not require the opinion of the Bioethical Commission (RNN/29/23/KE; 14 February 2023).

Author contributions

Grzegorz Stępień – writing, original draft preparation, data collection.

Thomas Wow – supervision, review.

Agnieszka Kołacińska-Wow – data collection, supervision, conceptualization, review.

Funding

None declared

Conflict of interest

None declared

Grzegorz J. Stępień

Medical University of Lodz

Department of Oncological Physiotherapy

ul. Paderewskiego 4

93-509 Łódź, Poland

e-mail: grzegorz.stepien@stud.umed.lodz.pl

Received: 2 Jul 2023



Accepted: 1 Aug 2023

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021; 71(3): 209–249, doi: 10.3322/caac.21660, indexed in Pubmed: 33538338.
2. Pujol P, Barberis M, Beer P, et al. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. *Eur J Cancer*. 2021; 146: 30–47, doi: 10.1016/j.ejca.2020.12.023, indexed in Pubmed: 33578357.
3. Kamińska M, Ciszewski T, Łopacka-Szatan K, et al. Breast cancer risk factors. *Prz Menopauzalny*. 2015; 14(3): 196–202, doi: 10.5114/pm.2015.54346, indexed in Pubmed: 26528110.
4. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. BRCA1 and BRCA2 Cohort Consortium. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. *JAMA*. 2017; 317(23): 2402–2416, doi: 10.1001/jama.2017.7112, indexed in Pubmed: 28632866.
5. Rosen E, Fan S, Pestell R, et al. BRCA1 gene in breast cancer. *J Cell Physiol*. 2003; 196(1): 19–41, doi: 10.1002/jcp.10257.
6. Filippini SE, Vega A. Breast cancer genes: beyond BRCA1 and BRCA2. *Front Biosci (Landmark Ed)*. 2013; 18(4): 1358–1372, doi: 10.2741/4185, indexed in Pubmed: 23747889.
7. Garcia C, Wendt J, Lyon L, et al. Risk management options elected by women after testing positive for a BRCA mutation. *Gynecol Oncol*. 2014; 132(2): 428–433, doi: 10.1016/j.ygyno.2013.12.014, indexed in Pubmed: 24355485.
8. Heemskerk-Gerritsen BAM, Menke-Pluijmers MBE, Jager A, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. *Ann Oncol*. 2013; 24(8): 2029–2035, doi: 10.1093/annonc/mdt134, indexed in Pubmed: 23576707.
9. Domchek SM, Friebel TM, Singer CF, et al. Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality. *JAMA*. 2010; 304(9): 967, doi: 10.1001/jama.2010.1237.
10. Schwartz MD, Isaacs C, Graves KD, et al. Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. *Cancer*. 2012; 118(2): 510–517, doi: 10.1002/cncr.26294, indexed in Pubmed: 21717445.
11. Wendt C, Margolin S. Identifying breast cancer susceptibility genes - a review of the genetic background in familial breast cancer. *Acta Oncol*. 2019; 58(2): 135–146, doi: 10.1080/0284186X.2018.1529428, indexed in Pubmed: 30606073.
12. van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. *Cell Oncol (Dordr)*. 2011; 34(2): 71–88, doi: 10.1007/s13402-011-0010-3, indexed in Pubmed: 21336636.
13. Ghossaini M, Pharoah PDP. Polygenic susceptibility to breast cancer: current state-of-the-art. *Future Oncol*. 2009; 5(5): 689–701, doi: 10.2217/fon.09.29, indexed in Pubmed: 19519208.
14. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science*. 1994; 266(5182): 66–71, doi: 10.1126/science.7545954, indexed in Pubmed: 7545954.
15. Yin Li, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Res*. 2020; 22(1): 61, doi: 10.1186/s13058-020-01296-5, indexed in Pubmed: 32517735.
16. Nowecki Z, Jagiello-Grusfeld A, Pogoda K, et al. Leczenie przedoperacyjne chorych na raka piersi i jego wpływ na postępowanie operacyjne oraz radioterapeutyczne (część 2.). *Nowotwory. Journal of Oncology*. 2021; 71(2): 79–93, doi: 10.5603/njo.2021.0021.
17. Galimberti V, Vicini E, Corso G, et al. Nipple-sparing and skin-sparing mastectomy: Review of aims, oncological safety and contraindications. *Breast*. 2017; 34 Suppl 1(Suppl 1): S82–S84, doi: 10.1016/j.breast.2017.06.034, indexed in Pubmed: 28673535.
18. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. *N Engl J Med*. 1999; 340(2): 77–84, doi: 10.1056/NEJM199901143400201, indexed in Pubmed: 9887158.
19. Baildam AD. Current knowledge of risk reducing mastectomy: Indications, techniques, results, benefits, harms. *Breast*. 2019; 46: 48–51, doi: 10.1016/j.breast.2019.03.011, indexed in Pubmed: 31082761.
20. Schrag D, Kuntz KM, Garber JE, et al. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. *N Engl J Med*. 1997; 336(20): 1465–1471, doi: 10.1056/NEJM199705153362022, indexed in Pubmed: 9148160.
21. Heemskerk-Gerritsen BAM, Jager A, Koppert LB, et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat*. 2019; 177(3): 723–733, doi: 10.1007/s10549-019-05345-2, indexed in Pubmed: 31302855.
22. Evans DG, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. *Breast Cancer Res Treat*. 2013; 140(1): 135–142, doi: 10.1007/s10549-013-2583-1, indexed in Pubmed: 23784379.
23. K Groth A, Graf R. Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) and the Textured Breast Implant Crisis. *Aesthetic Plast Surg*. 2020; 44(1): 1–12, doi: 10.1007/s00266-019-01521-3, indexed in Pubmed: 31624894.
24. Jakub JW, Peled AW, Gray RJ, et al. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. *JAMA Surg*. 2018; 153(2): 123–129, doi: 10.1001/jamasurg.2017.3422, indexed in Pubmed: 28903167.
25. Baltzer HL, Alonzo-Proulx O, Mainprize JG, et al. MRI volumetric analysis of breast fibroglandular tissue to assess risk of the spared nipple in BRCA1 and BRCA2 mutation carriers. *Ann Surg Oncol*. 2014; 21(5): 1583–1588, doi: 10.1245/s10434-014-3532-x, indexed in Pubmed: 24526546.
26. Heemskerk-Gerritsen BAM, Rookus MA, Aalfs CM, et al. HEBON. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. *Int J Cancer*. 2015; 136(3): 668–677, doi: 10.1002/ijc.29032, indexed in Pubmed: 24947112.
27. Liu YL, Breen K, Catchings A, et al. Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. *JCO Oncol Pract*. 2022; 18(3): 201–209, doi: 10.1200/OP.21.00382, indexed in Pubmed: 34582274.

28. Evans DG, Barwell J, Eccles DM, et al. FH02 Study Group, RGC teams. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. *Breast Cancer Res.* 2014; 16(5): 442, doi: 10.1186/s13058-014-0442-6, indexed in Pubmed: 25510853.
29. Wilson ARM, Marotti L, Bianchi S, et al. EUSOMA (European Society of Breast Cancer Specialists). The requirements of a specialist Breast Centre. *Eur J Cancer.* 2013; 49(17): 3579–3587, doi: 10.1016/j.ejca.2013.07.017, indexed in Pubmed: 23968730.
30. Kufel-Grabowska J, Radecka B, Streb J, et al. Breast-conserving surgeries in HER-positive breast cancer patients are performed too rarely in Poland. *Nowotwory. Journal of Oncology.* 2020; 70(6): 225–229, doi: 10.5603/njo.2020.0047.

Socioeconomic factors and suicide risk in Polish cancer patients – a population-based cohort study exploring associations and implications

Irmina M. Michałek¹ , Florentino L. Caetano dos Santos² , Urszula Wojciechowska¹ ,
Joanna Didkowska¹ 

¹Polish National Cancer Registry, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

²Harvard Business School, Harvard University, Boston, MA, USA

Introduction. This study aimed to explore socioeconomic factors influencing the suicide rate in Polish cancer patients.

Material and methods. Data on cancer cases and socioeconomic covariates were obtained from the Polish National Cancer Registry and Statistics Poland. Suicide rates were calculated for each year. Multivariable linear regression analyses explored associations between unemployment, income, university education, access to physicians overall and to psychiatry hospitals, and suicide incidence.

Results. The study included 1.43 million cancer patients diagnosed between 2009 and 2019. Among them, 830 suicides were identified, with higher rates among men. Income *per capita* and higher education degrees were significant predictors of suicide among male cancer patients ($p = 0.05$ and 0.01 , respectively). However, no significant associations were found for female cancer patients. The regression models explained 13% of the variation in male suicide incidence.

Conclusions. Lower income and higher education levels increase suicide risk in male cancer patients, highlighting the need for targeted interventions.

Key words: cancer, suicide, risk, epidemiology, cohort study

Introduction

Extensive evidence suggests that various socioeconomic factors significantly influence suicide rates in the general population. Protective factors such as marriage, parenting, and religiosity play a role in preventing suicides, although their impact varies by gender. Economic factors, including unemployment and low socioeconomic status, strongly predict suicide risk at an individual level [1].

A study examining gender-specific suicide rates across 35 countries found that higher suicide rates among both males and females were associated with increased female labor

force participation, unemployment, and a larger proportion of elderly individuals. However, increased health spending *per capita* was linked to lower suicide rates for both genders. The study highlighted the influence of labor market and economic factors on suicide rates, surpassing the significance of population-level indicators of interpersonal relationships. Additionally, males exhibited greater sensitivity to changes in the social environment compared to females [2, 3].

Furthermore, evidence indicates that environmental factors can impact suicide rates among cancer patients. A study utilizing the American Surveillance, Epidemiology, and End

Jak cytować / How to cite:

Michałek IM, Caetano dos Santos FL, Wojciechowska U, Didkowska J. *Socioeconomic factors and suicide risk in Polish cancer patients – a population-based cohort study exploring associations and implications.* NOWOTWORY J Oncol 2023; 73: 263–267.

Results Program (SEER) database investigated sociological risk factors for suicide death in leukemia patients and revealed a significantly higher death rate in areas with a high proportion of individuals holding at least a bachelor's degree [4].

However, there remains a gap in our knowledge regarding the socioeconomic factors associated with suicide incidence among cancer patients in the Polish population. Thus, this study aims to fill this gap and provide insights into the specific factors influencing suicide risk in this population.

Material and methods

Data source for cancer patient suicides

The data for this study were derived from the Polish Suicidality in Cancer Patients study (PoISCa), which is a cohort study previously described in the literature [5, 6]. Information on cancer cases was obtained from the Polish National Cancer Registry (PLCR), a non-profit national institution responsible for statistical and epidemiological cancer research in Poland. The PLCR encompasses all newly diagnosed cancer cases in the country and requires mandatory reporting. Rigorous validation processes, including verification by trained PLCR coders and adherence to recommendations from the European Network of Cancer Registries, ensure data accuracy. The unique Polish personal identification number (PESEL) is utilized within the PLCR system to prevent duplicate coding for the same patient. Detailed information regarding the operational principles of the PLCR can be found elsewhere [7].

The study population comprised individuals aged 15 years or older diagnosed with primary malignant neoplasms, excluding non-melanoma skin cancers (ICD-10 codes: C00–C43, C45–C76, C80–C96). In cases where patients had multiple independent coexisting neoplasms, only the most recent diagnosis was considered. All eligible cases diagnosed between January 1, 2009, and December 31, 2019, were included in the study. The follow-up period extended until the occurrence of suicide (ICD-10 codes: X60–X84), death from other causes, or December 31, 2019, whichever came first.

Data source for covariates

Based on existing literature [2, 3], several variables were identified as potential covariates influencing the suicide rate among patients diagnosed with cancer. These covariates included the unemployment rate, income *per capita*, the proportion of individuals holding at least a bachelor's degree (referred to as the higher education degree rate), overall access to physicians (referred to as the physician access index), and access to psychiatric services (referred to as the psychiatry access index). Data for all these variables were obtained from Statistics Poland, spanning the years 2009 to 2019 and encompassing 16 of the highest level administrative regions (voivodships).

The unemployment rate was defined as the registered unemployment rate, representing the ratio of registered unemployed individuals to the active civilian population. This rate in-

cludes individuals employed in individual farming households, considered as part of the active civilian workforce.

Income *per capita* was defined as the average monthly gross remuneration, including income tax advances and mandatory social security contributions (pension, disability, and sickness) paid by the insured employee. The data pertained to entities within the national economy with a workforce of 10 or more individuals, as well as budgetary entities regardless of the workforce size.

The higher education degree rate was defined as the number of university graduates with at least a bachelor's degree per 10,000 population. The physician access index was defined as the number of physicians working at their primary workplace per 10,000 population. The psychiatry access index was defined as the number of psychiatric hospital beds per 10,000 population.

Statistical analysis

Initially, we calculated the suicide rate per 1,000 previously diagnosed cancer patients. The numerator consisted of the number of suicides that occurred within a given year among patients previously diagnosed with cancer. The denominator included the mid-year population of cancer patients, representing the number of individuals living with a malignant tumor diagnosis on June 30th of the respective year. We calculated this rate for each calendar year, stratified by patient gender and region (voivodship).

To explore the association between suicide incidence (dependent variable) in patients with cancer and several independent variables (unemployment rate, income *per capita*, higher education degree rate, the physician access index, and psychiatry access index), separate multivariable linear regression analyses were conducted for males and females.

To examine the correlation between the physician access index and psychiatry access index, we calculated the correlation coefficient, which measures the strength and direction of the linear relationship between the two variables. The resulting correlation coefficient was 0.30, indicating a positive but weak correlation. Considering the comprehensive evaluation of healthcare resource impact on suicide incidence among patients with cancer, we decided to include both variables in the analysis.

The regression model was constructed using the formula "suicide incidence ~ unemployment rate + income *per capita* + education degree rate + physician access index + psychiatry access index". The model was summarized by presenting coefficient estimates, standard errors, t-values, and associated p-values for each independent variable. All statistical analyses were conducted using R software (version 2023.06.0+421).

Compliance with ethical standards

The utilization of individual-level data from the Polish National Cancer Registry (PLCR) for statistical and scientific purposes

complies with Polish legislation. The PLCR adheres to stringent regulations to ensure the confidentiality and protection of individuals. This study was conducted in accordance with the guidelines provided by Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) [8].

Results

Study population characteristics

The study encompassed a total of 1.43 million individuals (717,144 man and 709,517 women) who were diagnosed with cancer between January 1, 2009, and December 31, 2019. Over the course of the follow-up period, a total of 830 suicide cases were identified among the patients diagnosed with primary cancer, with 683 cases occurring in men and 147 cases in women. Throughout the study period spanning from 2009 to 2019, the incidence rate of suicide per 1,000 patients with cancer ranged from 0.0 to 2.9, depending on voivodship, gender, and year.

Socioeconomic factors and risk of suicide in patients with cancer

A multiple linear regression analysis was performed to investigate the association between socioeconomic factors and suicide incidence among cancer patients in the Polish population (tab. I).

Among male cancer patients, the regression analysis revealed that income *per capita* ($p = 0.05$) and the rate of higher education degrees ($p = 0.01$) were statistically significant predictors of suicide incidence (tab. I). The results indicated that a decrease in income and an increase in educational attainment were associated with a higher incidence of suicide. Additionally, the psychiatry access index ($p = 0.03$) demonstrated a statistically significant positive association with suicide incidence among male cancer patients. However, the unemployment rate ($p = 0.44$) and the physician access index ($p = 0.34$) did not exhibit statistically significant associations with suicide incidence among male cancer patients. The multiple R-squared value for the model was 0.13, suggesting that approximately

13% of the variability in suicide incidence among male cancer patients was explained by the included independent variables. The adjusted R-squared value, accounting for predictors and degrees of freedom, was 0.10. The F-statistic (4.516) with a p-value of <0.01 indicated that the overall regression model was statistically significant, demonstrating a significant combined effect of the independent variables on suicide incidence among male cancer patients.

In contrast, none of the independent variables reached statistical significance in predicting suicide incidence among female cancer patients (tab. I). The estimates for unemployment rate ($p = 0.60$), income *per capita* ($p = 0.08$), educational attainment ($p = 0.15$), psychiatry access index ($p = 0.80$), and physician access index ($p = 0.13$) did not show statistically significant associations with suicide incidence among female cancer patients.

The multiple R-squared value for the model was 0.06, and the adjusted R-squared value was 0.03. The F-statistic (1.958) with a p-value of 0.09 indicated that the overall regression model did not reach statistical significance, suggesting that the combined effect of the independent variables did not significantly impact suicide incidence among female cancer patients in the Polish population.

Discussion

Added value of the study in the context of the literature

The literature on population-based studies examining the association between socioeconomic factors and the risk of suicide in cancer patients is limited. To date, only two relevant studies have been conducted, both in the United States, and focused on factors such as urbanization, financial status, and university education [4, 9]. However, there is a lack of research exploring the impact of access to healthcare resources on suicide risk in the oncological patient population. To the best of our knowledge, our study is the first to comprehensively analyze the influence of healthcare resource access, including physicians and psychiatry services, on the risk of suicide among cancer patients.

Table I. Linear regression results for suicide incidence among male and female cancer patients

Variable	Men [†]				Women [‡]			
	estimate	std. error	t-value	p-value	estimate	std. error	t-value	p-value
(intercept)	0.47	0.30	1.55	0.12	0.11	0.11	1.02	0.31
unemployment rate	−0.01	0.01	−0.77	0.44	−0.00	0.00	−0.53	0.60
income <i>per capita</i>	−0.00	0.00	−2.02	0.05	−0.00	0.00	−1.79	0.08
the higher education degree rate	0.00	0.00	2.60	0.01	0.00	0.00	1.46	0.15
the physician access index	0.01	0.01	0.96	0.34	0.00	0.00	1.51	0.13
the psychiatry access index	0.08	0.03	2.22	0.03	−0.00	0.01	−0.25	0.80

[†] – multiple R-squared: 0.13, adjusted R-squared: 0.10, F-statistic: 4.52, p-value: <0.01 ; [‡] – multiple R-squared: 0.06, adjusted R-squared: 0.03, F-statistic: 1.96, p-value: 0.09; intercept – a mathematical constant, no clinical interpretation

This study adds to the growing body of evidence on the association between socioeconomic factors and suicide incidence in cancer patients. By specifically examining variables such as income *per capita* and the higher education degree rate, the study identifies these factors as significant predictors of suicide incidence among male cancer patients. These findings align with a study conducted in the United States, which also highlights the importance of addressing economic disparities and educational attainment in understanding suicide risk among individuals with cancer [9].

Moreover, this study explores the impact of healthcare resource access on suicide risk in cancer patients. The inclusion of the physician access index and psychiatry access index provides insights into the relationship between the availability of medical professionals and suicide incidence. The finding of a positive association between the number of psychiatric beds and suicide incidence among male cancer patients may initially seem counterintuitive. Several potential explanations can shed light on this result. Reverse causality suggests that areas with higher suicide rates allocate more resources, including psychiatric beds, to address increased mental health needs. Improved accessibility and identification may lead to higher detection rates in areas with more psychiatric beds. The complexity of cases or regional differences in mental health infrastructure, policies, or cultural factors could also play a role. The multifactorial nature of suicide and potential confounding variables should be considered.

Furthermore, this study adds value by considering gender-specific differences in the associations between socioeconomic factors and suicide incidence. While the study identifies significant predictors of suicide among male cancer patients, none of the independent variables reached statistical significance for female cancer patients. This finding highlights the need for further investigation into gender-specific factors and the complex interplay between socioeconomic variables and suicide risk in female cancer patients.

Overall, this study's added value lies in its comprehensive examination of socioeconomic factors and healthcare resource access as potential determinants of suicide incidence in cancer patients. By identifying significant predictors and exploring gender differences, the study contributes to a deeper understanding of the complex relationships between these factors and suicide risk, which can inform targeted interventions and support strategies to mitigate suicide risk in this vulnerable population.

Implications for the field of the study

The findings of this study have important implications for the field of suicide prevention and cancer care. The identification of socioeconomic factors associated with suicide risk in cancer patients provides valuable insights for targeted interventions and support programs. Specifically, the significant associations observed between income *per capita* and higher

education degree rate with suicide incidence among male cancer patients highlight the importance of addressing economic disparities and promoting educational opportunities to mitigate suicide risk. These findings emphasize the importance of implementing comprehensive and tailored strategies to address the multifaceted challenges faced by cancer patients at risk of suicide, ultimately improving their overall well-being and quality of life.

Strengths and limitations of the study

The present study has several strengths. First, the data were derived from the PolSCa, a cohort study with a comprehensive design that provides a reliable and representative sample of cancer patients in Poland. The use of the PLCR data ensured the inclusion of all newly diagnosed cancer cases in the country, while strict validation processes guaranteed data accuracy. Furthermore, the study considered a wide range of potential covariates, including socioeconomic factors and access to healthcare resources, to explore their association with suicide incidence among cancer patients.

However, certain limitations must be acknowledged. Firstly, although the study covered a substantial period from 2009 to 2019, the follow-up period was limited, and longer-term outcomes could not be assessed. Moreover, the study focused on the Polish population, which may limit the generalizability of the findings to other populations or settings. Lastly, while multiple socioeconomic factors were considered, the inclusion of additional variables, such as social support or mental health status, could have provided a more comprehensive understanding of the factors influencing suicide incidence among cancer patients.

Conclusions

In this study examining the association between socioeconomic factors and suicide incidence among cancer patients in the Polish population, several key findings emerged. Among male cancer patients, income *per capita* and a higher education degree rate were significant predictors of suicide incidence, indicating that lower income and higher university-level education rate were associated with an increased risk of suicide. However, the unemployment rate and the physician access index did not show significant associations. In contrast, none of the independent variables reached statistical significance in predicting suicide incidence among female cancer patients. These findings emphasize the need for targeted interventions and support for at-risk subgroups in cancer patients to mitigate the risk of suicide.

Article information and declarations

Data availability

We complied with all relevant ethical regulations. The data analyzed in this study were obtained from the PLCR and are available upon reasonable request by contacting the PLCR

at krn@nio.gov.pl and subject to ethical approvals in place and material transfer agreements. Following national regulations, these data were exempt from institutional review board reviews. There were no participants in the study; thus, there was no consent form. Detailed legislative aspects of the National Polish Cancer Registry are regulated by Polish Law (Dz.U. 2018 poz. 1197). Waiver of ethics approval was deemed unnecessary according to national legislation (reference to the relevant legislation <https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=WDU20180001197>).

Ethics statement

The utilization of individual-level data from the Polish National Cancer Registry (PLCR) for statistical and scientific purposes complies with Polish legislation. The PLCR adheres to stringent regulations to ensure the confidentiality and protection of individuals. This study was conducted in accordance with the guidelines provided by Strengthening the Reporting of Observational Studies in Epidemiology (STROBE).

Author contributions

All the authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Irmína M. Michálek – study concept and design, acquisition, analysis, and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, statistical analysis, obtained funding.

Florentino L. Caetano dos Santos – acquisition, analysis, and interpretation of data, critical revision of the manuscript for important intellectual content, statistical analysis, obtained funding.

Urszula Wojciechowska – acquisition, analysis, and interpretation of data, critical revision of the manuscript for important intellectual content, obtained funding.

Joanna Didkowska – acquisition, analysis, and interpretation of data, critical revision of the manuscript for important intellectual content.

Funding

This research was supported, in part, by a pilot grant from the Polish Cancer League (Grant number 4/2022 – Risk

of suicide after cancer diagnosis – Identification of risk groups and the best time for intervention).

Conflict of interest

None declared

Irmína M. Michálek

*Maria Skłodowska-Curie National Research Institute of Oncology
Polish National Cancer Registry
ul. Wawelska 15B
02-093 Warszawa, Poland
e-mail: irmina.michalek@nio.gov.pl*

Received: 14 Jul 2023

Accepted: 18 Jul 2023

References

1. Stack S. Contributing factors to suicide: Political, social, cultural and economic. *Prev Med.* 2021; 152(Pt 1): 106498, doi: 10.1016/j.ypmed.2021.106498, indexed in Pubmed: 34538366.
2. Milner A, McClure R, De Leo D. Socio-economic determinants of suicide: an ecological analysis of 35 countries. *Soc Psychiatry Psychiatr Epidemiol.* 2012; 47(1): 19–27, doi: 10.1007/s00127-010-0316-x, indexed in Pubmed: 21079912.
3. Ying YH, Chang K. A study of suicide and socioeconomic factors. *Suicide Life Threat Behav.* 2009; 39(2): 214–226, doi: 10.1521/suli.2009.39.2.214, indexed in Pubmed: 19527162.
4. Yang J, Liu Q, Zhao F, et al. Incidence of and sociological risk factors for suicide death in patients with leukemia: A population-based study. *J Int Med Res.* 2020; 48(5): 300060520922463, doi: 10.1177/0300060520922463, indexed in Pubmed: 32383398.
5. Michálek IM, Caetano Dos Santos FL, Wojciechowska U, et al. Suicide risk among adolescents and young adults after cancer diagnosis: analysis of 34 cancer groups from 2009 to 2019. *J Cancer Surviv.* 2023; 17(3): 657–662, doi: 10.1007/s11764-023-01358-5, indexed in Pubmed: 36930435.
6. Michálek IM, Caetano Dos Santos FL, Wojciechowska U, et al. Risk of suicide in patients with cancer aged 75 years or more - Follow-up of over 400,000 individuals. *Maturitas.* 2023; 175: 107785, doi: 10.1016/j.maturitas.2023.107785, indexed in Pubmed: 37348282.
7. Didkowska J, Wojciechowska U, Michálek IM, et al. Cancer incidence and mortality in Poland in 2019. *Sci Rep.* 2022; 12(1): 10875, doi: 10.1038/s41598-022-14779-6, indexed in Pubmed: 35760845.
8. Vandenbroucke JP, von Elm E, Altman DG, et al. STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *PLoS Med.* 2007; 4(10): e297, doi: 10.1371/journal.pmed.0040297, indexed in Pubmed: 17941715.
9. Suk R, Hong YR, Wasserman RM, et al. Analysis of Suicide After Cancer Diagnosis by US County-Level Income and Rural vs Urban Designation, 2000–2016. *JAMA Netw Open.* 2021; 4(10): e2129913, doi: 10.1001/jamanetworkopen.2021.29913, indexed in Pubmed: 34665238.

Pharmacological prevention methods in patients with cardiovascular disease with breast cancer – when, how, and for whom?

Maciej Dyrbuś^{ID}, Ilona Skoczylas, Aleksandra Majsnerowska,
Mariusz Gąsior^{ID}, Mateusz Tajstra^{ID}

3rd Department of Cardiology, School of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland

Breast cancer is the leading cause of cancer-related deaths in women worldwide. Patients with breast cancer are at an increased risk of cardiovascular toxicity, presently defined as cancer therapy-related cardiovascular toxicity (CTR-CVT). This article provides a summary of the current knowledge on pharmacological cardiovascular prevention in breast cancer patients. The European Society of Cardiology (ESC) guidelines on cardio-oncology have defined CTR-CVT. Baseline risk stratification with widely accepted risk scores is essential to identify patients at higher risk of CTR-CVT. The guidelines recommend the use of angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARBs), and β -blockers as preventive medications in high-risk patients. Clinical trials have shown ambiguous results for ACE-I/ARBs and β -blockers in reducing cardiotoxicity, while co-administration of ACE-I/ARBs and β -blockers did not show additional benefits in preventing cardiac dysfunction. Further research is needed to verify the efficacy of novel cardio-protective medication and optimize pharmacological strategies for cardiovascular prevention in breast cancer patients.

Key words: cardio-toxicity, cardiovascular prevention

Introduction

Breast cancer is the most diagnosed cancer and the leading cause of deaths due to cancer among women worldwide. In the United States, it is the second most common cancer among female patients and is the second leading cause of cancer deaths with incidence being relatively stable over the past two decades [1, 2]. As well as in the US, in Europe breast cancer is the most common cancer among female patients, with an estimated 522,000 new cases and 137,000 deaths in 2020 [3, 4]. It should be noted that both in Europe and the USA, the mortality rates of breast cancer have been declining likely due to advances in its successful detection and introduction of more efficacious therapeutic protocols.

Nonetheless, breast cancer patients are often at an increased risk of developing cardiovascular disease, due to a wide variety of factors, including baseline disease, cancer treatment strategies, as well as lifestyle changes associated with cancer [5, 6]. In the recent years, attempts have been made to stratify the risk of development of cardiovascular disease, especially a rather acutely developing cardiac dysfunction, labelled as “cancer therapy-related cardiovascular toxicity (CTR-CVT)” [7]. In patients at risk of CTR-CVT development, the introduction of preventive methods prior to cancer treatment might reduce the risk of the development of such conditions. Among those, pharmacological strategies can play a critical role in reducing this risk of cardio-toxicity, with a possible influence on

Jak cytować / How to cite:

Dyrbuś M, Skoczylas I, Majsnerowska A, Gąsior M, Tajstra M. *Pharmacological prevention methods in patients with cardiovascular disease with breast cancer – when, how, and for whom?* NOWOTWORY J Oncol 2023; 73: 268–276.

a patient's quality of life, the efficacy of cancer treatment, and long-term outcomes. The aim of the manuscript is to briefly summarize the current knowledge on pharmacological cardiovascular prevention in patients with breast cancer.

Definition and clinical significance of cancer treatment-related cardiovascular toxicity

The definition of cardiotoxicity, or as it should be named at present, CTR-CVT, has been established in the recent European Society of Cardiology (ESC) guidelines on cardio-oncology [7]. The guidelines have divided the broad spectrum of CTR-CVT on the basis of the pathomechanism and clinical manifestation, including the development of heart failure (HF), myocarditis, toxicity to the vascular structures, or the presence of hypertension, or rhythm disorders. Most notable is the definition of cancer therapy-related cardiac dysfunction (CTRCD), which encompasses the wide spectrum of myocardial damage associated with anticancer therapy. The definition of CTRCD according to the ESC guidelines is presented in table I. It should be noted that the definition allows to diagnose CTRCD solely on the basis of echocardiography, even in the absence of any clinical signs or symptoms of HF, although the guidelines recommend other imaging modalities, including magnetic

resonance imaging in certain clinical situations [8]. The other important definitions, including the specific criteria for diagnosing myocarditis, defining vascular complications and arterial hypertension or arrhythmias were also thoroughly defined in the guidelines. The unification of those definitions is crucial, since it will allow to more cautiously monitor their real prevalence, as in the past the frequencies reported in the literature could have varied significantly due to differences in diagnostic criteria for each condition [9].

Similar to patients with other types of cancer, patients with breast cancer who receive treatment are at risk of developing CTRCD, which can lead to serious complications and may significantly impact the quality of life. The most prevalent types of cardiovascular adverse effects are presented in table II. Moreover, cardiac failure can interfere with assumed cancer treatment protocol, and result in a necessity to either reduce the dosing or the frequency of administered therapies, thus affecting the effectiveness of the cancer treatment, and affecting outcomes [10–12]. Finally, it has been demonstrated that the development of CTRCD is associated with an increased long-term risk of HF in patients who experienced CTRCD [13, 14].

The years of experience with treatment of patients with cancer have demonstrated how to – at the present stage

Table I. Definitions of cancer therapy-related cardiac dysfunction (CTRCD) on the basis of the 2022 ESC guidelines on cardio-oncology [7]

Cardiac dysfunction		Recommendations
symptomatic	very severe	HF requiring support with inotropic drugs, mechanical circulatory support or consideration of heart transplantation
	severe	HF requiring hospitalization
	moderate	need for intensification of diuretic therapy or escalation of HF treatment in the outpatient setting
	mild	mild HF symptoms without necessity to modify the therapy
asymptomatic	severe	new reduction in LVEF to <40%
	moderate	new reduction in LVEF by ≥10% to LVEF of 40–49% or new reduction in LVEF of <10% to LVEF of 40–49% and new relative decrease in GLS of ≥15% or new increase in cardiac biomarkers ^a
	mild	LVEF of ≥50% and new relative decrease in GLS of >15% from baseline and/or new increase in cardiac biomarkers

LVEF – left ventricle ejection fraction; GLS – global longitudinal strain; BNP – B-type natriuretic peptide; HF – heart failure; NT-proBNP – N-terminal pro-B-type natriuretic peptide; ^a – cTnI/cTnT ≥ 99th percentile; BNP ≥ 35 pg/ml; NT-proBNP ≥ 125 pg/ml or a new significant increase from baseline beyond the biological and analytical variability of the test used

Table II. The most common adverse cardiovascular events associated with anti-cancer drugs

Anti-cancer drug group	Cardiovascular adverse events reported most frequently
anthracyclines	heart failure, arrhythmias, pericarditis
HER2-targeted therapies	heart failure, arrhythmias, hypertension
tyrosine kinase inhibitors	QT interval prolongation, hypertension, arrhythmias
aromatase Inhibitors	low risk of cardiotoxicity, potentially: dyslipidemia, atherosclerosis progression, arrhythmias

of knowledge – stratify patients according to their baseline risk for development of CTRCD. As a rule of thumb, an early identification of patients at higher risk of medical procedures has been widely proven to improve prognosis and is therefore recommended. Similarly, the ESC guidelines on cardio-oncology specify that it's best to define the baseline risk right at the time of cancer diagnosis, even before initiation and planning of treatment. Although there is no single, established pathway on how to optimally screen and then risk-stratify patients according to their baseline CV risk, the parameters which according to the ESC should be taken into consideration before initiation of anti-cancer treatment are listed in table III, while the detailed guidelines on cardiovascular prevention in patients with cancer are presented in table IV.

Table III. Parameters requiring verification at baseline in order to define CV risk prior to cancer treatment initiation according to the 2022 ESC guidelines on cardio-oncology [7]

Parameters requiring verification at baseline in order to define CV risk prior to cancer treatment initiation
CV risk factors (with emphasis on the modifiable risk factors)
CVD history
cancer history
cancer treatment history
physical examination (including vital parameters)
baseline ECG (including QTc analysis)
transthoracic echocardiography (including GLS, and 3D echocardiography if possible)
laboratory parameters: BNP/NT-proBNP, cTn, FPG/HbA1c, creatinine/eGFR, lipid profile

BNP – B-type natriuretic peptide; cTn – cardiac troponin; CV – cardiovascular; CVD – cardiovascular disease; ECG – electrocardiography; eGFR – estimated glomerular filtration rate; FPG – fasting plasma glucose; GLS – global longitudinal strain; HbA1c – glycated hemoglobin; NT-proBNP – N-terminal pro-B-type natriuretic peptide; QTc – corrected QT interval

After thorough assessment of patients' baseline cardiovascular risk, the physicians should stratify the patient's therapeutic toxicity risk. In recent years, multiple risk scores for identification of CV toxicity were analyzed, although the detailed risk score, would be recommended to remain as it is. Heart Failure Association–International Cardio-Oncology Society (HFA-ICOS) provides the most comprehensive data and thus has been included in the recent ESC guidelines as the preferred one, with a class IIa recommendation [15–17]. The HFA-ICOS classification is based on almost every factor assessed at baseline and defines the risk with regards to the strategy of anti-cancer treatment, depending on the possible influence of every individual drug group on every risk factor. For instance, the very high risk of cardiotoxicity in patients with cardiac amyloidosis has been highly documented only for multiple myeloma therapies. With regard to chemotherapy schemes utilized in the treatment of breast cancer, most often anthracyclines and/or anti-HER2 drugs, the risk of CTR-CVT is very high only if the patients have had HF or CTR-CVT in the past, or if the patient scheduled for trastuzumab had received trastuzumab before. With regard to other chemotherapeutic groups used in the treatment of breast cancer, such as VEGF inhibitors, there are plenty of factors associated with a very high risk of CTR-CVT, including any history of HF or even asymptomatic left ventricular contractile dysfunction, as well as a history of any significant atherosclerotic cardiovascular disease. Any other factors of known significance, including the history of MI/PCI, decreased LVEF or advanced age should be noted, and, based on their calculable association with CTR-CVT, the total risk score could be then evaluated and subsequently divided into low-, moderate- or high-risk.

The stratification of CV toxicity risk at baseline is important, because on the basis of the initial assessment, all further surveillance should be performed. Those could include routine follow-up visits in the oncology clinic if the patient is at low-risk of CTR-CVT, or a more detailed follow-up if the patient is in the moderate risk group. However, the general rule should

Table IV. Recommendations on the appropriate primary prevention of cancer therapy-related cardiovascular toxicity according to the 2022 ESC guidelines on cardio-oncology [7]

Recommendations	Class of recommendation, level of evidence
management of CVRF according to the 2021 ESC guidelines on CVD prevention in clinical practice is recommended before, during, and after cancer therapy	I, C
dexrazoxane should be considered in adult patients with cancer at high and very high CV toxicity risk when anthracycline chemotherapy is indicated	IIa, B
liposomal anthracyclines should be considered in adult patients with cancer at high and very high CV toxicity risk when anthracycline chemotherapy is indicated	IIa, B
ACE-I or ARB and β-blockers recommended for HF should be considered for primary prevention in high- and very high-risk patients receiving anthracyclines and/or anti-HER2 therapies	IIa, B
ACE-I or ARB and β-blockers recommended for HF should be considered for primary prevention in high- and very high-risk patients receiving targeted cancer therapies that may cause HF	IIa, C
statins should be considered for primary prevention in adult patients with cancer at high and very high CV toxicity risk	IIa, B

ACE-I – angiotensin-converting enzyme inhibitors; ARB – angiotensin receptor blockers; CV – cardiovascular; CVD – CV disease; CVRF – CV risk factors; ESC – European Society of Cardiology; HER2 – human epidermal receptor 2; HF – heart failure

be that patients with low- and moderate risk of CTR-CVT should not have the anti-cancer therapy delayed and should initiate treatment at the earliest possible stage. In those categories, a referral to a cardiology clinic or at least to an experienced cardiologist is necessary only if the CTR-CVT develops; an exception being that a treating oncologist might consider referral to the cardiology department regardless of the development of CTR-CVT in patients at moderate risk.

If the patient is considered as high- or very-high risk of CTR-CVT, after a baseline assessment, a referral to a cardio-oncology clinic is mandatory, and cardioprotective medication should be considered at baseline to mitigate that risk during cancer treatment. Moreover, for those patients, the guidelines recommend discussing all the risks and benefits associated with potentially cardiotoxic treatment in a multidisciplinary team to establish the most optimal strategy going forward.

Cardiovascular prevention

In the general population, the present ESC guidelines on cardiovascular prevention specify non-pharmacological, and pharmacological interventions which should be initiated to reduce the cardiovascular risk [18]. However, many of the suggested preventive strategies were deemed ineffective in patients with cancer. Although a straightforward answer to such discrepancy in outcomes is difficult to be presented, it could be speculated that among patients with cancer, it is the baseline disease, and often the presence of various CV risk factors, that in combination increase the baseline CV risk and thus reduce the reckoned efficacy of preventive strategies.

The ESC guidelines on cardio-oncology recommend initiation of “cardio-preventive” medication in patients with high- or very-high risk of CTR-CVT, stratified according to the initial baseline risk assessment. In those patients, an anti-cancer drug with the lowest possible cardiotoxicity risk should be selected. Moreover, the guidelines recommend consideration of administration of specific cardioprotective drugs in those patients. Those, apart from implementation of strategies mitigating the risk of anthracycline-induced cardiotoxicity, including treatment with dexrazoxane or liposomal anthracyclines, refer to the introduction of neurohormonal therapies, including angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARBs), β -blockers, and preventive treatment with statins [19]. ACE-I/ARBs and β -blockers are the groups of drugs commonly used as a first-line therapy in patients with heart failure, or hypertension, and have been also shown to improve cardiovascular outcomes in patients with cancer [20].

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers

Two large, randomized trials – Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) and Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab (SAFE) investigat-

ed the role of primary prevention of CTR-CVT with the use of ACE-I or ARBs specifically in patients with breast cancer. In PRADA, 130 patients with early breast cancer, treated with anthracyclines, underwent randomization to either candesartan (member of ARBs) or metoprolol (a β -blocker). Prevention with candesartan but not with metoprolol was associated with a statistically significantly lower LVEF reduction (candesartan vs. non-candesartan: 0.8% vs. 2.6%, $p = 0.026$). On the contrary, treatment with metoprolol was associated with smaller increases in levels of cardiac troponins [21]. However, in the long-term analysis, no differences in LVEF were observed in any of the studied groups [22].

In the SAFE trial, which was performed in a 4-arm design, an interim analysis performed after 12 months of follow-up revealed that in patients with no prior cardiovascular disease, cardioprotective therapy with ramipril (an ACE-I) or bisoprolol (a β -blocker), was associated with improved echocardiography outcomes than in patients treated with a placebo [23]. In detail, patients treated preventively with both drugs demonstrated a slight (0.1%) improvement in left ventricular global longitudinal strain (GLS), while GLS was reduced in the placebo arm (by 6.0%) as well as in patients treated with ramipril or bisoprolol monotherapy (respectively by 1.5% and 0.6%, $p < 0.001$). Moreover, the number of patients experiencing a major reduction of LVEF (by $\geq 10\%$ in the 3D-echocardiography) was lower in the group treated with ramipril and/or bisoprolol, with 6.8%, 11.5%, and 11.4% of patients experiencing such an endpoint when treated with respectively combined therapy, ramipril or bisoprolol monotherapy. In patients administered with placebo, 19% experienced a major LVEF reduction [23].

The molecular rationale for prevention of CTRCD with either ACE-I or ARB is broad, although it is speculated that it is mostly based on preclinical studies in which mice with knockout of angiotensin II type 1a receptor gene, are at a significantly reduced risk of anthracycline-induced cardiotoxicity [24]. Moreover, in the general population, administration of ACE-I or ARBs was associated with improvements on both macroscopic and microscopic levels. Inhibition of RAA resulted in a reduction of myocardial fibrosis, while intracellularly, in an improvement of mitochondrial function, reduction of oxidative stress, and positive alterations in the calcium homeostasis [25, 26], all mechanisms which might explain the benefits associated with ACE-I/ARBs in patients with cancer.

β -blockers

The efficacy of β -adrenolytics in the prevention of CTR-CVT has already been discussed in the two aforementioned trials, which evaluated metoprolol and bisoprolol, two of four β -blockers recommended in the treatment of heart failure in the overall population. The efficacy of the third was evaluated in the Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity (CECCY) trial [27]. In this placebo-controlled trial performed on 200 patients with HER2-negative breast cancer, chemotherapy

and parallel treatment with carvedilol, a non-cardioselective β -blocker did not reduce the occurrence of cardiotoxicity (defined as the proportion of patients with a $\geq 10\%$ reduction in LVEF, carvedilol vs placebo: 14.5% vs. 13.5%; $p = 0.99$) and did not influence the LVEF assessed as a continuous variable at 6-month follow-up when compared with the placebo. However, the trial did provide results analogous to those from the PRADA trial, as the use of carvedilol was associated with a lower increase in cardiac troponin I during anthracycline treatment. Thus, it may be speculated that there might be a class-effect of β -blockers in reducing the risk of myocardial injury associated with anthracycline treatment. Among the potential mechanisms of such cardioprotective activity, the anti-oxidative effect exhibited by β -blockers has been proposed, which is demonstrated e.g. in a lower risk of intracellular lipid peroxidation and mitochondrial dysfunction [28].

In general, both ACE-I, ARBs, and β -adrenolytics have constituted the cornerstone of modern treatment of heart failure, as they significantly attenuate the pathophysiological neurohormonal pathways in patients with HF. In patients with a decreased cardiac contractile function, a pathological cascade based on the sustained activation of neurohormonal responses develops. The elements of the cascade include the hyperactivity of the adrenergic system, and activation of the renin-angiotensin-aldosterone pathway. All the aforementioned drug groups act as inhibitors of those pathways, and by stabilizing the cardiac homeostasis they were proved to reduce morbidity and mortality in patients with chronic heart failure [29].

Finally, based solely on the data presented above, it could be speculated that if both preventive strategies (ACE-I/ARB and β -blockers) were proved effective, their co-administration might further increase the efficacy of prevention of CTR-CVT. However, in the previously mentioned PRADA trial, one arm of patients were randomized to a parallel preventive strategy with candesartan and metoprolol, and, in comparison with the monotherapy groups, no significant differences were observed with regard to LVEF reduction. Then, on the other hand, there is the important OVERCOME trial, in which 90 patients with malignant hemopathies treated with intensive chemotherapy were randomized to either preventive administration of enalapril and carvedilol, or matching placebo. During a 6-month follow-up, a significantly lower reduction of LVEF was noted in the arm taking ACEI and β -blockers than the placebo (a statistically significant difference of 3.1% in echocardiography and a difference of 3.4% on the verge of significance in magnetic resonance imaging), with a lower risk of combined clinical endpoint demonstrated in the intervention arm [30]. Thus, it appears that by recommending a simultaneous introduction of preventive ACE-I/ARB and β -blockers in patients with high or very high risk of CTR-CVT, the ESC guidelines on cardio-oncology, at least partially follow the newly introduced strategy of an early introduction of all four major

“game-changing” drugs for treatment of chronic HF advocated in the ESC guidelines on HF. Nonetheless, at present, the evidence supporting preventive co-administration of ACE-I/ARB + β -blocker is rather scarce.

Statins

Statins are cholesterol-lowering drugs that in patients with high or very high cardiovascular risk have been shown to reduce the risk of myocardial infarction, stroke, and mortality [31]. Research has shown that patients with breast cancer treated with statins might have a lower risk of cardiovascular events compared to those who do not receive this treatment. Moreover, some retrospective data report that a chronic treatment with statins might even increase the LVEF [32]. The postulated molecular mechanisms included pleiotropic effects of statins, including their anti-inflammatory, anti-apoptotic, and even anti-proliferative effect on the tumor cells [33, 34]. Moreover, as cholesterol is a biochemical precursor molecule for estrogens, the modifications to the lipid metabolism equilibrium caused by statins might in result indirectly modulate the response to estrogens at a cellular level [35].

However, data on the efficacy of statins in prevention of CTR-CVT are based mostly on retrospective, observational studies. A recently published PREVENT trial, which included patients with early breast cancer or lymphoma, did not confirm the cardioprotective effect of statins, as the mean (\pm SD) LVEF values were $61.7 \pm 5.5\%$ before treatment and $57.4 \pm 6.8\%$ at 24 months in the placebo group and $62.6 \pm 6.4\%$ before treatment and $57.7 \pm 5.6\%$ at 24 months in patients treated with 40 mg of one of the most potent statins – atorvastatin [36]. Moreover, no difference in the percentages of patients with a major (defined as by $\geq 10\%$) reduction of LVEF, or changes in LV strain, LV mass, cognitive function, or levels of inflammation biomarkers were noted between patients treated with atorvastatin and placebo. The results of the Statins to Prevent the Cardiotoxicity From Anthracyclines (STOP-CA) and Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracyclines Pilot Study (SPARE-HF) are eagerly anticipated in either confirming, or repudiating the cardioprotective effect of statins in patients with cancer [37, 38].

Spirolactone, flozins, ARNI

The ESC guidelines on cardio-oncology do not specifically address the subject of the introduction of preventive treatment with other groups which are at present considered the golden standard in patients with chronic HF. It should be noted that all of them might potentially be beneficial in preventing CTR-CVT in patients with breast cancer who are beginning oncological treatment. Spirolactone, the mineralocorticoid receptor antagonist (MRA), has been proven to reduce morbidity and mortality in patients with HF [39–41]. Its major mechanism of action lies in the inhibition of aldosterone receptors. In patients with HF, when the activity of the RAA axis is pathologically increased,

and subsequently so is the concentration of aldosterone, the end-product of this axis, the hyperactivity of aldosterone increases the myocardial fibrosis developing in response to the myocardial injury. Thus, there might be a pathophysiological rationale for preventive treatment with MRA in patients treated with potentially cardio-toxic drugs.

However, the evidence supporting MRA in such a setting is rather scarce, as to date there has only been one randomized trial, which included only 83 patients with breast cancer treated with either doxorubicin or epirubicin. Those were randomized to preventive therapy with 25 mg daily of spironolactone or placebo. After the completion of a follow-up of approximately 24 weeks, preventive therapy with spironolactone resulted in a lower reduction of LVEF assessed echocardiographically (LVEF decrease from 67.0 ± 6.1 to 65.7 ± 7.4 in the spironolactone group, and from 67.7 ± 6.3 to 53.6 ± 6.8 in the control group between-group $p < 0.001$) [42]. Moreover, similar to the findings from the studies with β -adrenolytic drugs, the trial showed that spironolactone resulted in an attenuated increase in cardiac troponin I elevation, and while in the control group, levels of all serum biomarkers were altered by chemotherapy, no significant difference in any of the measured parameters (including NT-proBNP, troponin, creatinine kinase – myocardial) was observed in patients taking spironolactone. Finally, the authors point a remark that the left ventricular diastolic function was maintained in patients from the spironolactone group, while a progression of diastolic dysfunction was observed in the group administered with a placebo, which further confirms that the mechanism of action of spironolactone might lay in reduced fibrosis caused by excessive aldosterone levels.

The results of the CECY, PRADA, SAFE, and aforementioned spironolactone trial clearly indicate the possible benefit of RAA axis inhibitors on cardiac contractile function. Moreover, in the preclinical studies it was demonstrated that apart from the RAA axis, an increased activation of natriuretic peptide cellular pathways decreases the risk of anthracycline-induced cardiomyopathy. Another rather novel drug in the treatment of HF is sacubitril-valsartan. Its mechanism of action lays on the inhibition of the RAA axis, owing to the activity of valsartan – an ARB – and activation of the natriuretic peptide pathway mediated by sacubitril – an inhibitor of neprilysin, an enzyme responsible for the degradation of many important molecules, including natriuretic peptides. Thus, the use of a cardioprotective strategy with sacubitril-valsartan in patients treated with potentially cardiotoxic drugs has a strong pathophysiological rationale.

The data on the administration of sacubitril/valsartan in patients with cardiac damage caused by cancer therapy come mostly from retrospective analyses. A Spanish registry investigated 67 patients (of whom 45% were patients with breast cancer) with symptomatic HF caused by cancer therapy, in whom sacubitril/valsartan was introduced. In those subjects, significant increases in LVEF and reductions in NT-proBNP

levels, and left ventricular dimensions were noted, followed by a clinically meaningful improvement in patients' HF symptoms [43]. In another single-center analysis, echocardiographically determined cardiotoxicity developed in 28 of 635 patients, most of whom were treated with anthracyclines, and approximately a quarter with anti-HER2 therapy. Treatment with sacubitril/valsartan reduced NT-proBNP and increased patients' exertional capacity and left ventricular ejection fraction ($32.3 \pm 5.5\%$ vs. $26.7 \pm 5.4\%$; $p < 0.001$) [44].

At present, there are data from only one randomized trial investigating the use of sacubitril-valsartan in patients with cancer. The study has been performed in Russia and was restricted to 112 subjects with cancer and a preexisting HF who were administered a preventive treatment with nebivolol and eplerenone, and randomized to either sacubitril-valsartan or candesartan. After 6 months, there was a benefit of smaller LVEF reduction and improvement of quality of life with the former [45].

It should be noted that a multi-center, double-blinded trial evaluating the efficacy and safety of sacubitril/valsartan in the prevention of CTR-CVT in patients with cancer will shortly be starting recruitment [46]. The study, which will be performed in three tertiary oncological centers in Poland will randomize a total of 480 patients with early breast cancer undergoing treatment with anthracyclines and/or anti-HER2 drugs to the highest-tolerated dose of sacubitril/valsartan or placebo in 1:1 ratio. The patients will be monitored, including a routine transthoracic echocardiography (TTE) for 24 months, and the primary endpoint of the trial will be the occurrence of a decrease in LVEF by $\geq 5\%$ in TTE within 24 months. The first results are expected at the beginning of 2028, pending recruitment of participants.

Finally, the last group of drugs recommended in HF are SGLT-2 inhibitors. In the last years, several clinical trials have demonstrated their beneficial effects on heart failure outcomes, with a reduction in the risk of cardiovascular death and hospitalization for heart failure, regardless of the presence of diabetes [47, 48]. The mechanism of action of SGLT2 inhibitors, which involves blocking glucose reabsorption in the SGLT-2 sodium-glucose co-transporters in kidneys, also leads to other effects that are beneficial in HF. By reducing sodium and water reuptake in the kidneys, SGLT-2 inhibitors increase diuresis and thus decrease blood volume, which can improve cardiac contractility. Additionally, SGLT-2 inhibitors have been shown to improve endothelial function, reduce oxidative stress, and improve myocardial cellular metabolic pathways [49]. To date, no randomized study investigated the efficacy of SGLT-2 inhibitors in the prevention of CTR-CVT, and the sole evidence for their potential benefit is derived from a recent retrospective analysis, which included diabetic patients with cancer treated with SGLT-2 inhibitors; they were compared in a 1:3 ratio to control subjects not being administered SGLT-2 inhibitors. When compared to the control group, patients

Table V. Recommendations for baseline risk assessment and monitoring during endocrine therapy for patients with breast cancer, according to the 2022 ESC guidelines on cardio-oncology [7]

Recommendations	Class of recommendation, level of evidence
baseline CV risk assessment and estimation of 10-year fatal and non-fatal CVD risk with SCORE2 or SCORE2-OP is recommended in BC patients receiving endocrine therapies without pre-existing CVD	I, C
dexrazoxane should be considered in adult patients with cancer at high and very high CV toxicity risk when anthracycline chemotherapy is indicated	IIa, B
liposomal anthracyclines should be considered in adult patients with cancer at high and very high CV toxicity risk when anthracycline chemotherapy is indicated	IIa, B

BC – breast cancer; CV – cardiovascular; CVD – cardiovascular disease; ECG – electrocardiogram; SCORE2 – systematic coronary risk estimation 2; SCORE2-OP – systematic coronary risk estimation 2 – older persons

pretreated with SGLT-2 inhibitors were at a significantly reduced risk of a composite endpoint of cardiac events, including the incidence of HF, admissions due to HF, the development of new cardiomyopathy, or clinically significant arrhythmias (3% vs. 20%; $p = 0.025$) [50]. Moreover, the risk of all-cause death was significantly lower (9% vs. 43%; $p < 0.001$), albeit such a strong effect on mortality is hardly attributable solely to the action of SGLT-2 inhibitors. Nonetheless, a randomized trial evaluating the efficacy of one of the SGLT-2 inhibitors, empagliflozin (Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines – EMPACT) will soon start recruitment in Polish centers, and the first results are expected in 2028 [51].

Non-pharmacological preventive measures

In addition to medication, lifestyle modifications such as exercise, a healthy diet, and smoking cessation are essential for reducing cardiovascular disease risk in breast cancer patients. Prior studies have shown that due to various factors, patients after diagnosis of cancer tend to reduce physical activity and gain weight by an average of 2.7 kg [52, 53]. Physical activity has been shown to reduce the intracellular oxidative stress, and improve exertional capacity in patients with breast cancer. This might suggest a rationale for improvement in prognosis and reduction of the risk of development of CTR-CVT [54, 55]. However, to date, no clear guidelines defining the optimal exertion thresholds for groups at risk of cardiotoxicity were presented. Nonetheless, the guidelines of the American College of Sports Medicine specify the optimal physical exercise type and intensiveness for cancer survivors [56].

Endocrine treatment and its clinical implications

Approximately 65–70% of patients with breast cancer might have a hormone receptor-positive tumor, and in some of those patients therapy with either selective estrogen receptor modulators (SERM) or aromatase inhibitors (AI) might be initiated [57]. Although treatment with SERM or AI does not lead to the development of CTRCD to a degree similar to the one observed in anthracyclines or anti-HER2 treatment, therapy with those two groups of drugs confers an increased risk of dyslipidemia, metabolic syndrome,

hypertension, and thus major cardiovascular events such as myocardial infarction [58–60]. Moreover, tamoxifen has consistently been demonstrated to increase the risk of venous thromboembolism (VTE) and therefore therapy based on tamoxifen should not be recommended for patients with an increased risk of thrombotic events [61]. The ESC guidelines on cardio-oncology specify that prior to the introduction of the endocrine therapies in patients with breast cancer, a 10-year risk of fatal and non-fatal cardiovascular events should be assessed, and in those perceived as high risk, such risk should be re-evaluated every year. The detailed recommendations on baseline risk assessment and monitoring during endocrine therapy for breast cancer are listed in table V. The risk scores recommended in the guidelines are either SCORE2 or SCORE2-OP, however other validated risk scores can also be accepted [62, 63]. After risk assessment, it is of the utmost importance to discuss the risks of VTE, and major vascular events with patients at risk, while recognizing that the benefits of breast cancer treatment usually outweigh the cardiovascular risks. However, an emphasis should be placed on the optimal control of CV risk factors, including optimal lipid-lowering therapy, control of blood pressure, with exercise and a healthy diet encouraged.

Article information and declarations

Author contributions

Maciej Dyrbuś – conception and design, analysis and interpretation of data, drafting of the manuscript.

Ilona Skoczylas – acquisition of data.

Aleksandra Majsnerowska – acquisition of data.

Mariusz Gąsior – analysis and Interpretation of data, critical revision of the manuscript for important intellectual content, supervision.

Mateusz Tajstra – conception and design, analysis and Interpretation of data, critical revision of the manuscript for important intellectual content, supervision.

Funding

None declared

Conflict of interest

None declared

Maciej Dyrbus

Medical University of Silesia
School of Medical Sciences in Zabrze
3rd Department of Cardiology
ul. M. Skłodowskiej-Curie 9
41-800 Zabrze, Poland
e-mail: mdyrbus@op.pl

Received: 7 Jul 2023

Accepted: 11 Jul 2023

References

1. American Cancer Society. Breast Cancer Facts & Figures 2022-2024. <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2022-2024-breast-cancer-fact-figures-acf.pdf>.
2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021; 71(3): 209–249, doi: 10.3322/caac.21660, indexed in Pubmed: 33538338.
3. Ferlay J. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2020. <https://gco.iarc.fr/today/home>.
4. Miklewska MJ, Klaudia B, Urszula W, et al. Morbidity and mortality trends of the most common cancers in 1990–2019. Poland's position compared to other European countries. *Nowotw J Oncol*. 2023; 73(1): 46–55, doi: 10.5603/NJO.a2022.0065.
5. Cherukuri SP, Chikattimalla R, Dasaradhan T, et al. Breast Cancer and the Cardiovascular Disease: A Narrative Review. *Cureus*. 2022; 14(8): e27917, doi: 10.7759/cureus.27917, indexed in Pubmed: 36110451.
6. Koric A, Chang CP, Mark B, et al. Cardiovascular disease risk in long-term breast cancer survivors: A population-based cohort study. *Cancer*. 2022; 128(14): 2826–2835, doi: 10.1002/cncr.34224, indexed in Pubmed: 35561317.
7. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J*. 2022; 43(41): 4229–4361, doi: 10.1093/eurheartj/ehac244, indexed in Pubmed: 36017568.
8. Bobek-Billewicz B, Jurkowski M. The role of magnetic resonance imaging in the diagnosis of breast cancer. *Nowotwory. Journal of Oncology*. 2017; 67(3): 185–192, doi: 10.5603/njo.2017.0031.
9. Perez IE, Taveras Alam S, Hernandez GA, et al. Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. *Clin Med Insights Cardiol*. 2019; 13: 1179546819866445, doi: 10.1177/1179546819866445, indexed in Pubmed: 31384135.
10. Yeh E, Bickford C. Cardiovascular Complications of Cancer Therapy. *J Am Coll Cardiol*. 2009; 53(24): 2231–2247, doi: 10.1016/j.jacc.2009.02.050.
11. Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. *CA Cancer J Clin*. 2016; 66(4): 309–325, doi: 10.3322/caac.21341, indexed in Pubmed: 26919165.
12. Bowles EJ, Wellman R, Feigelson HS, et al. Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. *J Natl Cancer Inst*. 2012; 104(17): 1293–1305, doi: 10.1093/jnci/djs317, indexed in Pubmed: 22949432.
13. Armenian SH, Xu L, Ky B, et al. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. *J Clin Oncol*. 2016; 34(10): 1122–1130, doi: 10.1200/JCO.2015.64.0409, indexed in Pubmed: 26834065.
14. Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of Anthracyclines. *Front Cardiovasc Med*. 2020; 7: 26, doi: 10.3389/fcvm.2020.00026, indexed in Pubmed: 32258060.
15. Santana BR, Codon JC, Olmos VJ, et al. HFA-ICOS cardiovascular toxicity risk score validation in CARDIOTOX registry. *European Heart Journal*. 2022; 43(Supplement_2), doi: 10.1093/eurheartj/ehac2591.
16. Tini G, Cuomo A, Battistoni A, et al. Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice. *Int J Cardiol*. 2022; 349: 134–137, doi: 10.1016/j.ijcard.2021.11.059, indexed in Pubmed: 34848212.
17. Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society. 2020.
18. Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. 2021; 42(34): 3227–3337, doi: 10.1093/eurheartj/ehab484, indexed in Pubmed: 34458905.
19. Yamaguchi N, Fujii T, Aoi S, et al. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. *Eur J Cancer*. 2015; 51(16): 2314–2320, doi: 10.1016/j.ejca.2015.07.031, indexed in Pubmed: 26343314.
20. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021; 42(36): 3599–3726, doi: 10.1093/eurheartj/ehab368, indexed in Pubmed: 34447992.
21. Gulati G, Heck S, Ree A, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. *Eur Heart J*. 2016; 37(21): 1671–1680, doi: 10.1093/eurheartj/ehw022.
22. Heck SL, Mecinaj A, Ree AH, et al. Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol. *Circulation*. 2021; 143(25): 2431–2440, doi: 10.1161/CIRCULATIONAHA.121.054698, indexed in Pubmed: 33993702.
23. Livi L, Barletta G, Martella F, et al. Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial. *JAMA Oncol*. 2021; 7(10): 1544–1549, doi: 10.1001/jamaoncol.2021.3395, indexed in Pubmed: 34436523.
24. Toko H, Oka T, Zou Y, et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. *Hypertens Res*. 2002; 25(4): 597–603, doi: 10.1291/hyres.25.597, indexed in Pubmed: 12358147.
25. Brilla CG, Rupp H, Maisch B. Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. Retrospective analysis of 120 patients with left ventricular endomyocardial biopsies. *Herz*. 2003; 28(8): 744–753, doi: 10.1007/s00059-003-2524-6, indexed in Pubmed: 14689110.
26. Lou Q, Janardhan A, Efimov IR. Remodeling of calcium handling in human heart failure. *Adv Exp Med Biol*. 2012; 740: 1145–1174, doi: 10.1007/978-94-007-2888-2_52, indexed in Pubmed: 22453987.
27. Avila M, Ayub-Ferreira S, Wanderley Md, et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity. *J Am Coll Cardiol*. 2018; 71(20): 2281–2290, doi: 10.1016/j.jacc.2018.02.049.
28. Abreu RV, Santos DL, Moreno AJ. Effects of carvedilol and its analog BM-910228 on mitochondrial function and oxidative stress. *J Pharmacol Exp Ther*. 2000; 295(3): 1022–1030, indexed in Pubmed: 11082437.
29. Lueder Tv, Kotecha D, Atar D, et al. Neurohormonal Blockade in Heart Failure. *Cardiac Failure Review*. 2017; 03(01): 19, doi: 10.15420/cfr.2016.22.2.
30. Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). *J Am Coll Cardiol*. 2013; 61(23): 2355–2362, doi: 10.1016/j.jacc.2013.02.072, indexed in Pubmed: 23583763.
31. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010; 376(9753): 1670–1681, doi: 10.1016/S0140-6736(10)61350-5, indexed in Pubmed: 21067804.
32. Chotenimitkhun R, D'Agostino R, Lawrence JA, et al. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. *Can J Cardiol*. 2015; 31(3): 302–307, doi: 10.1016/j.cjca.2014.11.020, indexed in Pubmed: 25662284.
33. Sim Y, Lim C, Phyu N, et al. The Impact of Statin Use and Breast Cancer Recurrence - A Retrospective Study in Singapore. *Front Oncol*. 2022; 12: 835320, doi: 10.3389/fonc.2022.835320, indexed in Pubmed: 35433431.
34. Van Wyhe RD, Rahal OM, Woodward WA. Effect of statins on breast cancer recurrence and mortality: a review. *Breast Cancer (Dove Med*

- Press). 2017; 9: 559–565, doi: 10.2147/BCTT.S148080, indexed in PubMed: 29238220.
35. Casaburi I, Chimento A, De Luca A, et al. Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment. *Front Endocrinol (Lausanne)*. 2018; 9: 525, doi: 10.3389/fendo.2018.00525, indexed in PubMed: 30254608.
 36. Hundley WG, D'Agostino R, Crotts T, et al. Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment. *NEJM Evid*. 2022; 1(9), doi: 10.1056/evidoa2200097, indexed in PubMed: 36908314.
 37. Clinicaltrials.gov Identifier: STOP-CA (Statins TO Prevent the Cardio-toxicity From Anthracyclines). <https://clinicaltrials.gov/ct2/show/NCT02943590>.
 38. Clinicaltrials.gov identifier: Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study (SPARE-HF). <https://clinicaltrials.gov/ct2/show/NCT03186404>.
 39. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med*. 1999; 341(10): 709–717, doi: 10.1056/NEJM199909023411001, indexed in PubMed: 10471456.
 40. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med*. 2003; 348(14): 1309–1321, doi: 10.1056/NEJMoa030207, indexed in PubMed: 12668699.
 41. Zannad F, Gattis Stough W, Rossignol P, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. *Eur Heart J*. 2012; 33(22): 2782–2795, doi: 10.1093/eurheartj/ehs257, indexed in PubMed: 22942339.
 42. Akpek M, Ozdogru I, Sahin O, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. *Eur J Heart Fail*. 2015; 17(1): 81–89, doi: 10.1002/ehf.196, indexed in PubMed: 25410653.
 43. Martín-García A, López-Fernández T, Mitroi C, et al. Effectiveness of sacubitril-valsartan in cancer patients with heart failure. *ESC Heart Fail*. 2020; 7(2): 763–767, doi: 10.1002/ehf2.12627, indexed in PubMed: 32022485.
 44. Gregorietti V, Fernandez TL, Costa D, et al. Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. *Cardiooncology*. 2020; 6(1): 24, doi: 10.1186/s40959-020-00078-4, indexed in PubMed: 33292750.
 45. Kanorskiy SG, Pavlovets VP. First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy. *Medical Coun*. 2019(16): 42–48, doi: 10.21518/2079-701x-2019-16-42-48.
 46. Clinicaltrials.gov identifier: Sacubitril/Valsartan in PriMAry prevention of the Cardiotoxicity of Systematic breast cancer treatment (MAINSTREAM).
 47. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med*. 2015; 373(22): 2117–2128, doi: 10.1056/NEJMoa1504720, indexed in PubMed: 26378978.
 48. McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2019; 381(21): 1995–2008, doi: 10.1056/NEJMoa1911303, indexed in PubMed: 31535829.
 49. Joshi S, Singh T, Newby D, et al. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. *Heart*. 2021; 107(13): 1032–1038, doi: 10.1136/heartjnl-2020-318060.
 50. Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, et al. Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines. *JACC Heart Fail*. 2022; 10(8): 559–567, doi: 10.1016/j.jchf.2022.03.006, indexed in PubMed: 35902159.
 51. Clinicaltrials.gov Identifier: Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines (EMPACT).
 52. Rock CL, Flatt SW, Newman V, et al. Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group. *J Am Diet Assoc*. 1999; 99(10): 1212–1221, doi: 10.1016/s0002-8223(99)00298-9, indexed in PubMed: 10524383.
 53. Irwin ML, Crumley D, McTiernan A, et al. Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. *Cancer*. 2003; 97(7): 1746–1757, doi: 10.1002/cncr.11227, indexed in PubMed: 12655532.
 54. Ma ZY, Yao SS, Shi YY, et al. Effect of aerobic exercise on cardiotoxic outcomes in women with breast cancer undergoing anthracycline or trastuzumab treatment: a systematic review and meta-analysis. *Support Care Cancer*. 2022; 30(12): 10323–10334, doi: 10.1007/s00520-022-07368-w, indexed in PubMed: 36322246.
 55. Tranchita E, Murri A, Grazioli E, et al. The Beneficial Role of Physical Exercise on Anthracyclines Induced Cardiotoxicity in Breast Cancer Patients. *Cancers (Basel)*. 2022; 14(9), doi: 10.3390/cancers14092288, indexed in PubMed: 35565417.
 56. Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. *Med Sci Sports Exerc*. 2010; 42(7): 1409–1426, doi: 10.1249/MSS.0b013e3181e0c112, indexed in PubMed: 20559064.
 57. Curigliano G, Lenihan D, Fradley M, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. *Ann Oncol*. 2020; 31(2): 171–190, doi: 10.1016/j.annonc.2019.10.023, indexed in PubMed: 31959335.
 58. Yang H, Bhoo-Pathy N, Brand JS, et al. Risk of heart disease following treatment for breast cancer - results from a population-based cohort study. *Elife*. 2022; 11, doi: 10.7554/eLife.71562, indexed in PubMed: 35293856.
 59. Bundred NJ. The effects of aromatase inhibitors on lipids and thrombosis. *Br J Cancer*. 2005; 93 Suppl 1(Suppl 1): S23–S27, doi: 10.1038/sj.bjc.6602692, indexed in PubMed: 16100522.
 60. Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. *J Natl Cancer Inst*. 2011; 103(17): 1299–1309, doi: 10.1093/jnci/djr242, indexed in PubMed: 21743022.
 61. Hernandez RK, Sørensen HT, Pedersen L, et al. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. *Cancer*. 2009; 115(19): 4442–4449, doi: 10.1002/cncr.24508, indexed in PubMed: 19569248.
 62. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration, SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. *Eur Heart J*. 2021; 42(25): 2439–2454, doi: 10.1093/eurheartj/ehab309, indexed in PubMed: 34120177.
 63. SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. *Eur Heart J*. 2021; 42(25): 2455–2467, doi: 10.1093/eurheartj/ehab312, indexed in PubMed: 34120185.

The importance of selected biomarkers in the clinical practice of breast cancer patients

Agata Makówka , Beata Kotowicz 

Cancer Biomarker and Cytokines Laboratory Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Breast cancer is considered the most commonly diagnosed tumors. Biomarkers used for the diagnosis and treatment of breast cancer are: tissue biomarkers (PR, ER, HER2, Ki-67) and serum biomarkers (CA-15-3, CA-125, CA-27-29, CEA, cytokeratins). ECD HER2, metalloproteinases and leptin are emerging as promising biomarkers for breast cancer. There is a growing need for personalized diagnostics based on tumour genome characterization, relying on a liquid biopsy containing components such as CTC and ctDNA, cell-free RNA. Biomarkers can also be used as a target for anti-breast cancer treatment (PGRN and sortilin, AR, PD-1/PD-L1). Another potential field of application of breast cancer biomarkers is monitoring treatment side effects, such as inflammatory biomarkers causing cardiotoxicity, thyroiditis biomarkers (TSH, FT4, TPOab TgAb) in IrAE, NF-L and MCP-1 in ICI-associated neurotoxicity. It is expected that new prognostic and predictive biomarkers will be developed that can provide accurate and reliable information for clinical application. Through the recognition of emerging biomarkers, it is possible to identify subgroups of patients who benefit from targeted therapies and managing treatment by monitoring side effects. However, these new biomarkers need to be validated and tested for their suitability before entering clinical use.

Key words: breast cancer, biomarkers, personalized diagnostics, anti-cancer therapy, adverse events

Introduction

According to Global Cancer Statistics 2020, breast cancer is considered the most commonly diagnosed tumor with 2.3 million new cases of breast cancer reported in 2020. It is the fifth leading cause of cancer mortality globally, whereas in women it is the leading cause of cancer death [1]. The highest incidence rates of breast cancer in 2020 were reported in Belgium and the Netherlands with the highest mortality in Barbados and Fiji [2]. In Poland in 2020, the most common cancer in women was breast (23.8%), and it is the second (15%) leading cause of death after lung cancer (18%) [3]. The risk factors for breast cancer are gender, age, genetic factors, ethnicity, early menstruation, late menopause and shorter periods

of breastfeeding. The increased incidence rate is associated with lifestyle such as alcohol consumption, obesity, use of hormonal therapy and contraceptives [4].

Treatment of breast cancer depends on its clinical stage, the histological type and its accompanying biomarkers. Nowadays there are many available methods for molecular profiling, hormone indications etc. The general classification of breast cancer is based on the division into sarcomas and carcinomas [5]. Carcinomas are divided into two histopathological types: pre-invasive *in situ* cancer and invasive cancer. Pre-invasive *in situ* carcinomas are further divided into ductal *in situ* carcinomas (DCIS) and lobular *in situ* carcinomas (LCIS).

Jak cytować / How to cite:

Makówka A, Kotowicz B. *The importance of selected biomarkers in the clinical practice of breast cancer patients*. NOWOTWORY J Oncol 2023; 73: 277–285.

Independently from histological subtypes, breast cancers have been classified by molecular examination: luminal A and B subtypes, epidermal growth factor receptor 2 (HER2)-positive breast cancer and triple negative breast cancer (TNBC). The luminal A type of breast cancer is characterized by the presence of an estrogen-receptor (ER) and/or progesterone-receptor (PR), the absence of *HER2* and low expression of genes associated with proliferation (Ki-67). The luminal B subtype includes either HER-positive or HER-negative tumors. Progesterone and estrogen receptors are also found here. In contrast to luminal A, luminal B tumors have higher expression of proliferation-related genes assessed by the Ki-67 designation [6]. Luminal A tumors grow slowly and have a better prognosis, while luminal B tumors are higher grade and have a poorer prognosis. ER is similarly expressed in both A and B subtypes and is used to distinguish luminal from non-luminal disease. Triple-negative breast cancer (TNBC) is a type of breast cancer that lacks the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It is characterized by an unfavorable prognosis and aggressive biology since patients with TNBC do not benefit from endocrine or anti-HER2 therapy [7].

The presence of proteins or other substances in the serum, body fluids and tissues allow for an early diagnosis of cancer and recurrence of the disease. A biomarker is a substance (nucleic acids, proteins, carbohydrates, lipids) which is either qualitatively or quantitatively abnormally expressed by the tumor tissue or released after cell death by apoptosis, necrosis or destruction by immune cells in biological fluids such as blood serum, urine, saliva or the cerebrospinal fluid. A biomarker can be measured as an indicator of normal biological or pathogenic processes. Some of these biomarkers can be used by physicians to identify the type of cancer and stages of progression, as well as determining a specific treatment and further monitoring response to treatment. However, a lack of specificity is observed for some biomarkers, which is a barrier for their use in cancer screening. As a non-specific tool they complement imaging tests.

Based on their clinical use, two major types of biomarkers can be distinguished: prognostic and predictive. Prognostic markers predict the natural course of a cancer and differentiate good-outcome tumors from poor-outcome tumors. However, no prognostic marker can exactly predict an outcome for a particular patient. It informs about the outcome for a heterogeneous patient population. A predictive marker delivers in advance information on whether the patient is or is not likely to benefit from a particular therapy. The absence of a given marker or a decrease in its concentration during therapy is also of prognostic importance. Therefore, the use of predictive markers enables reducing the overtreatment of patients with benign malignancy and avoiding undertreatment of patients with aggressive tumors [8, 9].

This review covers information about biomarkers currently available for breast cancer management, as well as new promising biomarkers and their potential use in the future.

Biomarkers for the diagnosis and treatment of breast cancer

Biomarkers used in clinical practice are helpful in:

- risk assessment for patients who are unaffected and considering preventive strategies,
- screening for detection of early-stage cancer,
- diagnosis in staging, grading and choice of therapy,
- for prognostic purposes, predicting and monitoring treatment response,
- detecting recurrence after therapy.

Some biomarkers are only used for specific purposes, whereas another can serve in more than one type of application.

Tissue biomarkers

Biomarkers in the biopsy material play an important role in the diagnosis of breast cancer and the choice of treatment.

Determination of various subtypes of breast cancer based on diagnostic evaluation of hormone receptors (ER and PR), HER2 is recommended to be assessed by American Society of Clinical Oncology (ASCO) guidelines due to their prognostic and predictive relevance [10]. These markers are highly specific, and nowadays are routinely used for the diagnostic of breast cancer. Additionally, Ki-67 proliferation index is helpful in differentiating luminal A and luminal B molecular subtypes. The detection of ER, PR, HER2 and Ki-67 affects decisions on the type of undertaken therapy. They are tissue biomarkers, their disadvantage is that an invasive surgical biopsy is required.

At present, the most important predictive biomarker for breast cancer is the estrogen receptor (ER). The measurement of ER is mandatory in all newly diagnosed cases of breast cancer. Its main application is as a predictive marker for endocrine therapy, since ER levels may be correlated with the beneficial effects of antiestrogen therapy. The occurrence of ER helps to identify patients with early breast cancer for adjuvant treatment with drugs such as estrogen receptor modulators (tamoxifen) or aromatase inhibitors (AI), preventing the stimulation of breast cancer proliferation [11]. Two isoforms of estrogen receptor have been identified ER- α , and - β [12]. They have different effects on cancer cells. ER- α stimulates transcription while ER- β inhibits it. The proportions of ER- α and ER- β in the cell determine cell division or inhibition and resistance to hormonal treatment. ER- β is a negative regulator of ER- α [13]. ER- α plays a crucial role in the progression and proliferation of breast cancer. There are some inconsistencies about the role of the ER- β , since there are studies indicating its anticancer and carcinogenic role in breast cancer [14]. The progesterone receptor (PR) is routinely examined together with ER in breast cancer as an important biomarker. PR is involved in molecular

subtyping and plays a substantial role in treatment decisions. It is thought that the absence of PR reflected a nonfunctional ER pathway and was less responsive to tamoxifen [15]. ER+/PR+ breast cancers respond better to hormone therapy than ER+/PR– breast cancers and have a better breast cancer-specific survival rate [16, 17]. The tumors that are ER– and PR+ demonstrate an intermediate response to endocrine therapy [18]. The expression of ER and PR receptors is not permanent and may change spontaneously during the course of the disease or as a result of therapy. The complete loss of ER during endocrine therapy is rare, whereas about half of tumors lose PR completely becoming resistant to therapy. Metastatic tumors have a much more aggressive course after the loss of PR in comparison with tumors with PR expression [19].

Hormonal resistance of breast cancer can be primary or acquired. Primary resistance occurs from the beginning of treatment. It may result from an inappropriate proportion between the level of ER- α and ER- β receptors. This results in the transcription of estrogen-dependent genes and the synthesis of proteins leading to breast progression of tamoxifen resistance. Primary resistance to tamoxifen occurs in breast cancers with high overexpression of the HER2 receptor. Acquired resistance develops as a response to a long-term block or impairment in DNA transcription and protein synthesis responsible for tumor progression. The cancer cell bypasses the tamoxifen-induced blockade and becomes hypersensitive to estrogens and tamoxifen. This causes even small doses of estrogen or tamoxifen to lead to transcription and tumor progression [13].

HER2 is a glycoprotein tyrosine kinase receptor belonging to the EGFR family. HER2 consists of three parts: an intracellular tyrosine kinase domain, a transmembrane lipophilic segment and an extracellular domain (ECD). According to the ASCO testing guideline, breast cancer is considered HER2 positive if the presence of transmembrane HER2 overexpression in the tumor tissue is confirmed by an immunohistochemistry assay or fluorescence in situ hybridization (FISH) [10]. HER2 is overexpressed in approximately 20% of breast cancers and it correlates with a poor clinical prognosis [17, 20, 21]. HER2 is important in choosing the right management in breast cancer patients. An overexpression of HER2 in breast cancer is a strong predictor of benefitting from treatment with trastuzumab (Herceptin) [22]. Trastuzumab is a monoclonal antibody against the extracellular domain of *HER2*, which, when used in adjuvant therapy, significantly extends overall survival in early breast cancer patients [23]. Except for breast cancer, *HER2* overexpression has been recognized in several different solid tumors such as lung, head and neck.

Ki-67 is an index providing the information about the proliferation of malignant tumors. High levels of Ki-67 are associated with poorer outcomes. According to St. Gallen's recommendation from 2015, a cut-off point of Ki-67 $\geq 20\%$ could be used to differentiate between low and high values [24]. Ki-67 has been shown to be prognostic of clinical outcomes in breast cancer as

well as a predictor of response to neoadjuvant chemotherapy or endocrine treatment. Expression of Ki-67 is often used to identify patients with a high risk of relapse.

Serum biomarkers

Serum biomarkers (so-called “wet biomarkers”) are easily accessible at any time and through any blood collection. They are minimally invasive, and therefore can be detected more often than tissue indicators [25]. Biomarkers can quickly provide additional information on patient prognosis and response to treatment. For breast cancer patients' prognosis and response to treatment, serum biomarkers are more convenient and cost-effective compared to mammograms and frequent tissue biopsies.

Among the standard serum tumor markers, CA-15-3 is dedicated to breast cancer. Due to the low diagnostic sensitivity, it is not used in the diagnosis of cancer, but may be important in monitoring treatment. Other recognized serum markers, such as CEA, CA-125 or CA-27-29, may be elevated in metastatic disease.

Increased expression of CA-15-3 in breast tumors is related to invasiveness and metastatic potential [26]. The main utility of CA-15-3 as a biomarker is monitoring therapy in patients with advanced breast cancer, because a relationship between in CA-15-3 levels and the response to chemotherapy has been observed [27]. CA-27-29 is clinically comparable to CA-15-3 due to lack of specificity. Higher serum levels of CA-27-29 may reflect an increased tumor burden [28, 29]. Persistently elevated CA-27-29 levels may indicate treatment failure or the progression of disease [30]. Increased levels of CA-125 have been observed in the majority of metastatic breast cancer patients [31]. The limitations of serum biomarkers such as CA-15-3 and CA-125 are that their temporary elevated levels in serum may occur after starting therapy, due to tumor lysis caused by chemotherapy. High levels of CEA in the blood are usually related to metastasis of breast cancer [32]. A combination of CA-15-3 and CEA is used as a diagnostic tool for relapse of breast cancer [33]. High levels of CA-15-3 together with CEA are associated with worse clinical outcomes since they indicate high tumor burden [34, 35].

In breast cancer, cytokeratins are applicable as serum biomarkers. The complex of cytokeratin fragments 8, 18 and 19 constitute a circulating polypeptide TPA (tissue polypeptide antigen). TPA indicates ongoing cell death and lysis [36]. TPS (tissue polypeptide specific antigen), an antigenic determinant associated with human cytokeratin 18, is released from proliferating cells during tumor development, when intensive multiplication and disintegration of cells may take place. The rate of concentration increase of TPS is correlated with the rate of progression of the neoplastic process. This increase provides information about the growth of the tumor before the clinical manifestations of the cancer. The level of TPS indicates the proliferative activity of neoplastic tissue regardless

of tumor size, and it is an independent prognostic factor for disease-free survival and overall survival [37, 38].

The use of the biomarkers listed above has some limitations in their use in diagnostic tests for breast cancer. Their main disadvantage is the lack of sensitivity and specificity, which makes them useless for screening purposes. At low stages of cancer, serum biomarkers have low diagnostic sensitivity [39]. The conventional serum biomarker testing is recommended but not mandatory. Their application plays an auxiliary role in the clinical management of breast cancer. Therefore, it is important to continue to search for new factors involved in tumor progression which can help to identify the risk groups, detect the disease at early stages and assess the risk of future relapse.

New biomarkers with a potential application in breast cancer

An example of a promising biomarker in breast cancer can be the extracellular domain (ECD) of *HER2*. The ECD *HER2* is released into the blood by means of proteolytic enzymes (shedding). The remaining shortened peptide in the cell membrane is more oncogenic than the full length receptor. The release of the extracellular domain into the serum is increased in metastases compared to primary breast cancer [40]. *HER2* is a risk factor of relapse, high-grade malignancy index and metastasis. Some studies suggest that the soluble *HER2* ECD is a better prognostic tool than tissue *HER2* and its prognostic value is independent of the *HER2* status of the tumor [41, 42].

Metalloproteinases are proteolytic enzymes that digest basement membrane and extracellular matrix (ECM) components, enabling metastasis and angiogenesis in breast cancer [43]. Some studies suggest the potential to use MMP-9 as a predictor of breast cancer progression, since there is a relationship between high MMP-9 expression and the occurrence of distant metastases in breast cancer patients and poor prognosis [44].

Another potential biomarker for breast cancer risk is leptin. Leptin is produced mainly by fat cells and is overexpressed in obese individuals. It is known as the “obesity hormone”, the blood level of which increases in proportion to the amount of body fat. In physiological conditions, leptin plays a crucial role in the regulation of energy balance by reducing appetite and increasing metabolism. Leptin has also been shown to promote cell proliferation and the development of breast cancer. Leptin and its receptors regulate progression, angiogenesis, metastasis and immunosuppression. Elevated serum leptin levels are associated with poor cancer prognosis, therefore it may be a potential biomarker of breast cancer risk, especially in overweight women or postmenopausal women [44, 45].

Biomarkers in liquid biopsy

Tumor biopsy is still the gold standard for diagnosis and classification of breast cancer, however, there is a growing need for personalized diagnostics based on tumor genome charac-

terization, relying on blood samples known as liquid biopsy. The liquid biopsy, similar to serum biomarkers, is non-invasive, enables frequent sampling and following patients over time. It can deliver information for understanding tumor characteristics and cell dissemination. Various components of tumor cells are released into the bloodstream: circulating tumor cells (CTC) and circulating DNA (ctDNA), cell-free RNA and exosomes. These elements can be used as potential biomarkers personalizing cancer treatment based on these real-time results.

Circulating tumor cells (CTCs) are malignant cells that following apoptosis, necrosis or active release are shed into the lymphatic or vascular system. CTCs in the bloodstream could be responsible for metastatic progression of breast cancer. The presence of CTCs indicates residual disease, increased risk of metastasis and poorer results for CTC-positive patients. Tracking the presence of ctDNA in serial postoperative serum samples may be used as a predictor of early relapse in ctDNA-positive patients [46]. Some researchers observed that breast cancer patients with levels of CTCs lower than 5 per 7.5 ml had a higher progression-free survival and overall survival in comparison with patients with higher levels of CTCs [47]. The strong correlation between CTCs results and radiographically confirmed progression of metastatic breast cancer indicates that CTCs numeration is useful in assessing the effectiveness of therapy [48]. Although it can be difficult to isolate CTCs from blood due to their short half-life, they have proven to be beneficial as a prognostic tool for cancer patients. CTCs circulating in the bloodstream can also be analyzed for their contents such as protein, DNA, messenger/matrix RNA (mRNA), mitochondrial RNA (miRNA). One of the protein biomarkers contained in CTCs is for example CA-15-3 [49]. CTCs markers often reflect the genetic profile of tumors because they represent a part of the patient's tumor that could be assessed for target antigens. However, some difficulties have been observed in differentiating between primary and metastatic tumors with CTC origin. Researchers found that CTCs represented metastatic tumors rather than primary tumors. There is some evidence that primary ER+/PR+ breast tumors have spread CTCs that are ER-/PR-, which have a significant importance in decisions regarding the choice of treatment [50]. Additionally, discrepancies between *HER2* level of expression in ductal breast tumors and plasma CTCs have been observed, confirming the difference in expression profiling between CTCs and primary tumors [51].

Circulating tumor DNA (ctDNA) is fragmented DNA derived directly from tumor cells or circulating tumor cells (CTC). Cell-free DNA can be detected in free form in sera or plasma [52]. In healthy individuals, ctDNA is present at low levels, whereas higher levels of ctDNA in cancer patients reflect progressive tumor sizes, nodal involvement and metastasis.

Determination of circulating tumor DNA may serve as a marker for the presence of disease and a tool for molecular tumor assessment at different time points in the disease.

It has been proven that analyses of mutations in ctDNA could detect tumors at early stages [53]. CtDNA compared with DNA isolated from primary tumors shows the presence of identical genetic changes that are specific to the tumor type. At present, the diagnosis and selection of breast cancer treatment is based on the analysis of tumor biopsy, but the information from the biopsy is not permanent due to changes in the tumor and its resistance to treatment. Examination of ctDNA overcomes tumor heterogeneity. Some researchers report on ctDNA's platform detecting genomic changes in breast cancer patients, showing its clinical utility for monitoring of disease [54]. In breast cancer, ctDNA enables monitoring the response to treatment and clinical prognosis. In tumors responding to treatment, a sharp decrease in ctDNA levels is observed [55, 56]. The levels of ctDNA are very high in advanced cancer, therefore it is possible to perform a liquid biopsy for molecular testing of ctDNA which may serve as a non-invasive tool for real-time monitoring of disease development [57].

Tumorigenesis is accompanied by high gene expression which leads to synthesis of large amounts of RNA shed from the tumor cells into the blood. The released RNA particles are called cell-free mRNA (cfRNA), and consist of mRNA and miRNA. In cancer patients the amount and composition of miRNA is modified. CfRNA analysis is useful due to its higher concentration in the blood compared to ctDNA in patients at an early stage of cancer. Analysis of cfRNA provides valuable information about tumor gene expression that could be used to monitor treatment and drug resistance of the tumor. For instance, miRNA was used to predict resistance to trastuzumab in HER2+ metastatic breast cancer patients. A several type of miRNA with distinct expression of HER2+ metastatic breast cancer patients with different sensitivities to trastuzumab have been found [58]. The prognostic and predictive value of a real-time PCR assay for cytokeratin-19 (CK-19) mRNA isolated from CTCs has been evaluated. The study suggested that detection of CK-19 mRNA expression may have a clinical impact on overall survival in patients with breast cancer, since they showed poor overall survival [59].

Despite numerous reports on the benefits of liquid biopsy, it has not yet been standardized as a routine diagnostic method in clinical settings of breast cancer. It is expected that the sequencing of the genetic material contained in ctDNA and cfRNA obtained from liquid biopsy will lead to the implementation of this diagnostic tool for routine diagnosis, early detection and follow-up of breast cancer patients.

Biomarkers as a target for anticancer therapy

An important potential application of biomarkers in breast cancer management is their use as a target for anticancer treatment.

Progranulin (PGRN) promotes tumorigenesis as a growth factor since it stimulates the proliferation and survival of several cancer cell types [60]. Progranulin and its receptor sortilin are

highly expressed in breast cancer and are associated with various clinical properties. PGRN is considered a poor prognostic factor because it inhibits tamoxifen-induced apoptosis [61]. The expression of progranulin in tumor and serum samples correlates with pathological grading, lymph node metastasis and angiogenesis [62]. Sortilin is linked to breast cancer progression and recurrence in advanced diseases [63]. High co-expression of progranulin and sortilin is associated with decreased breast cancer specific survival [64].

PGRN and sortilin targeting has potentials of application in novel targeted therapy of breast cancer consisting of blocking their tumor-promoting interplay. This offers a unique cancer treatment principle based on selectively targeting the microenvironment of the communication system. In vitro studies indicate that the use of PGRN-neutralizing antibodies and their receptors cause decreased expression of tyrosine-protein kinase and the tyrosine-protein kinase receptor involved in the metastasis of breast cancer [65]. Another in vitro study showed that inhibiting progranulin with the anti-progranulin antibody caused an inhibition of survival and a reduction in migration of TNBC cell lines. The decrease in Ki-67 expression and reduction in the expression of angiogenic proteins VEGF and HIF-1 α was also observed [66]. Blocking PGRN with antibody treatment may provide novel-targeted solutions in TNBC treatment resulting in the inhibition of breast cell tumor proliferation. An *in vivo* study proved that sortilin inhibition decreases progranulin-dependent breast cancer progression and the expansion of cancer stem cells [67]. These results suggest that targeting PGRN may be involved in optimizing treatment protocols for breast cancer patients, however further *in vivo* studies regarding serum PGRN should be conducted.

Another emerging potential therapeutic target for breast cancer treatment is the androgen receptor (AR). AR been detected in around 70–90% of breast cancers [68]. AR is considered as a good prognostic factor in ER- α positive breast cancer, since it interferes with the function of ER- α and suppresses tumor growth. However, in the case of ER- α negative breast cancer patients such as HER2+ and TNBC, the AR exhibits oncogenic properties contributing to cancer development. Androgen receptor-targeted therapies have demonstrated promising results in clinical trials in patients with breast cancer. A potential treatment for breast cancer cells is a selective AR modulator such as enobosarm. In vitro studies in the cell line of TMBC indicate that enobosarm inhibits the metastasis promoting factors (IL-6, MPO-13) and therefore blocks migration and invasion. Several AR antagonists have been examined as well. Bicalutamide interrupts the DNA-binding domain binding to the androgen related element. The outcome of the application of bicalutamide has achieved a 19% clinical benefit rate at 6 months and 12 weeks median progression-free survival (PFS) in patients with AR-negative and AR-positive advanced breast cancer. Other biomarkers of response to AR inhibitors should be established in the future [69].

Immune checkpoints play a very important role in the regulation of immune responses involved in cancer elimination. One of them is the programmed cell death-1 receptor (PD-1). PD-1 is expressed in immune effector system cells such as T cells, B cells, natural killer cells and dendritic cells. It is activated by PD-L1, expressed by the majority of human cells. The PD-1/PD-L1 pathway is crucial in maintaining immune tolerance, thus creating a mechanism of immune escape in response to cancer. Cancer cells are capable of activating PD-1 on T cells specific for the cancer antigen by abnormally expressing programmed death-ligand 1 (PD-L1) on their surface. The PD-1/PD-L1 inhibitory pathway is used by solid tumors to silence the immune system [70]. PD-L1 expression is correlated with large tumor size, high grade and high proliferation rate, as well as being inversely related to the survival of breast cancer patients [71]. It has been proven that the blockade of immune checkpoints anti-PD-1/PD-L1 using appropriate monoclonal antibodies triggers effective anticancer responses in many types of solid tumors, such as breast cancers. The inhibitors against PD-1/PD-L1 prevent the suppression of anti-cancer immune responses, allowing the immune system to attack and eliminate tumor cells by modulation T-cell activation and suppressing tumor growth. Immune checkpoint inhibitors (ICIs) are new immunotherapeutic agents that interrupt the interaction between PD-1 and PD-L1.

The application of ICIs against PD-1/PD-L1 is emerging as a new treatment option in breast cancer [72]. The expression of PD-L1 is higher in TNBC than in other molecular subtypes of breast cancer. There are 2 monoclonal antibodies approved by the FDA to treat breast cancer: pembrolizumab and atezolizumab [73]. It was shown *in vivo* that responses to antibody therapy were greater in tumors with high PD-L1 expression. The presence of PD-1 and PD-L1 have been proposed as biomarkers predictive of a response to PD-1/PD-L1 inhibition. The antagonists of the PD-1/PD-L1 pathway induce clinical responses in some patients with metastatic TNBC [74]. However, there are some patients positive for PD-L1 who do not respond to the treatment, while some patients negative for PD-L1 may respond [75]. This makes PD-L1 an imperfect predictive biomarker. Tumor responses with anti-PD-1 and PD-L1 antibodies are mediated by tumor antigen-specific T cells that were previously blocked by the PD-1/PD-L1 pathway.

Awareness of the presence or absence of T cells in breast cancer is crucial in understanding the mechanisms of cancer escape from immune surveillance and for response to anti-PD-1 and PD-L1 antibody therapy. Decisions on the use of anti-PD-1/PD-L1 antibody therapy should be based on the assessment of the presence or absence of T cells specific for the tumor antigen, which are inhibited by PD-L1 expression by tumor cells [76]. Tumor infiltrating lymphocytes (TILs) are an important biomarker in immunotherapy of breast cancer. The presence of tumor-infiltrating lymphocytes (TILs) is a favorable prognostic factor in breast cancer, since they interact

with ICI therapy to improve the clinical response. A higher density of TILs has been associated with favorable clinical outcomes in breast cancer: a significantly lower risk of relapse or death, metastasis and overall mortality. To date, the strongest relationship between TILs and treatment outcomes has been demonstrated for the TNBC type of breast cancer [77]. Another study in HER2+ breast cancer patients treated with adjuvant trastuzumab found that increased levels of TILs were correlated with decreased distant recurrence [78].

Biomarkers in adverse events in anti-cancer therapy

Another potential field of application of breast cancer biomarkers is their application in monitoring the side effects of treatment.

The most serious toxic effect of chemotherapy in breast cancer treatment is heart muscle failure, known as so-called "cardiotoxicity". The role of anti-breast cancer drugs such as trastuzumab and anthracyclines in determining cardiotoxicity has been demonstrated in numerous studies [79, 80]. It has been proven that tumor-related inflammation is an important factor in the development and progression of heart failure. Many studies point to biomarkers of inflammation for the risk assessment of breast cancer patients treated for cancer in early detection of cardiotoxicity.

These inflammatory biomarkers are high-sensitivity C-reactive protein (hsCRP), myeloperoxidase (MPO), soluble growth stimulation expressed gene 2 (sST2), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), growth differentiation factor-15 (GDF-15), endothelin-1 (ET-1) and galectin-3. Two of these factors, sST2 and galectin-3, were recommended in the latest ACC/AHA HF (American College of Cardiology and American Heart Association, guideline for management of heart failure) guidelines to be used as useful in risk of heart failure stratification in clinical settings, since they are able to track treatment responses [81]. Additionally, troponins and creatinine kinase have been identified as the serum cardiac biomarkers of choice for assessing myocardial injury. Various studies have evaluated the role of natriuretic peptides (NPs) in the diagnosis and prediction of anticancer drug-induced cardiotoxicity [82].

Immunotherapy has significantly improved the prognosis for many breast cancer patients, but it can also generate a wide range of serious immune-related adverse events (irAEs) which can be serious and even fatal. IrAEs are autoimmune conditions that can affect any organ. The most common are dermatitis, diarrhea/colitis and endocrinopathies such as thyroid disorders. IrAEs appear later and have a longer duration compared to chemotherapy-related adverse events. Since IrAEs can interfere with treatment management, it would be helpful to determine IrAE-related biomarkers.

In monitoring the ICI treatment of breast cancer thyroiditis, biomarker levels are useful. Thyroiditis following ICIs in breast cancer patients should be detected by routine blood tests

of TSH and FT4 and morning cortisol levels for concurrent adrenal insufficiency. Baseline TSH levels were observed to be significantly higher in patients who developed hypothyroidism as the initial thyroid irAE. The association of hypothyroidism with baseline TSH levels may suggest progression of pre-existing Hashimoto's subclinical thyroiditis accelerated by ICI treatment rather than ICI-induced thyroiditis [83]. ICI treatment may be continued if patients with asymptomatic and subclinical hypothyroidism have elevated TSH but normal T4 levels [84]. Moreover, additional testing for thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibody (TgAb) is recommended. Some studies show an association between TPOAb and TgAb positivity at baseline and the incidence of thyroid irAE associated with ICI. The presence of TPOAb and TgAb was evident in patients who developed thyroid dysfunction. The titers of these antibodies were higher in patients with overt thyroid irAEs than in patients with or without subclinical thyroid irAEs. These results suggest that pre-existing thyroid autoimmunity may be a strong risk factor for the future development of ICI-associated thyroid toxicity [83].

Neurological adverse events associated with ICI and chemotherapy are of particular interest. One of them is chemotherapy-induced peripheral neuropathy (CIPN). The occurrence of CIPN often forces clinicians to change the course of therapy which is associated with a decrease in anti-cancer effectiveness. Therefore, it is necessary to determine the biomarkers of neurotoxicity.

In the blood serum of patients with severe CIPN, researchers observed significantly higher concentrations of neurofilament light chains (NF-L). NF-Ls are part of the cytoskeleton of peripheral and central nervous system neurons. Due to the damage to the peripheral nervous system in chemotherapy-induced peripheral neuropathy, NF-L is released to the cerebrospinal fluid. Very low concentration of NF-Ls are also detected in serum of treated patients. Previous studies have confirmed the relationship between the degree of CIPN and the increase in NF-L concentration, underlining NF-L's potential as a translational biomarker [84, 85].

A potential biomarker for ICI-associated neurotoxicity is the monocyte chemotactic protein 1 (MCP-1). MCP-1 is a chemoattractant and activator of monocytes, promoting their infiltration into the tumor, it also causes the production of angiogenesis factors that promote angiogenesis and stimulate cell proliferation. MCP-1 is one of the chemokines with the highest expression during inflammation. There are studies indicating that patients with higher-grade neurotoxicity had significantly elevated serum MCP-1 levels at baseline compared to patients without neurological adverse events [86].

Conclusions

Since breast cancer is one of the most prevalent diagnosed cancers among women, there is an expectation for developing new prognostic and predictive biomarkers that would provide accurate and reliable information for clinical applica-

tions. In recent years, particular emphasis has been placed on the development of personalized breast cancer diagnosis with the use of the liquid biopsy, enabling accurate characterization of the tumor. Through the recognition of emerging biomarkers, it is possible to identify subgroups of patients who benefit from targeted therapies and manage treatment by monitoring side effects. There is still a huge clinical need for new objective prognostic biomarkers for adverse events in breast cancer therapies. However, these new biomarkers need to be validated and tested for their suitability before entering clinical use.

Article information and declarations

Author contributions

Agata Makówka – literature review and manuscript preparation.
Beata Kotowicz – conception and critical revision of the article.

Funding

None declared

Acknowledgments

The authors would like to thank Professor Maria Małgorzata Kowalska for her valuable comments.

Conflict of interest

None declared

Agata Makówka

*Maria Skłodowska-Curie National Research Institute of Oncology
Cancer Biomarker and Cytokines Laboratory Unit
ul. Roentgena 5
02-781 Warszawa, Poland
e-mail: Agata.Makowka@pib-nio.pl*

Received: 17 May 2023

Accepted: 1 Aug 2023

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021; 71(3): 209–249, doi: 10.3322/caac.21660, indexed in Pubmed: 33538338.
2. www.wcrf.org/cancer-trends/breast-cancer-statistics.
3. Wojciechowska U, Barańska K, Michałek I, et al. Cancer in Poland in 2020. National Cancer Registry. Ministry of Health, Warsaw 2022.
4. Youn HJo, Han W. A Review of the Epidemiology of Breast Cancer in Asia: Focus on Risk Factors. *Asian Pac J Cancer Prev.* 2020; 21(4): 867–880, doi: 10.31557/APJCP.2020.21.4.867, indexed in Pubmed: 32334446.
5. Sinn HP, Kreipe H. A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. *Breast Care (Basel).* 2013; 8(2): 149–154, doi: 10.1159/000350774, indexed in Pubmed: 24415964.
6. Goldhirsch A, Winer EP, Coates AS, et al. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol.* 2013; 24(9): 2206–2223, doi: 10.1093/annonc/mdt303, indexed in Pubmed: 23917950.
7. Denkert C, Liedtke C, Tutt A, et al. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. *Lancet.* 2017; 389(10087): 2430–2442, doi: 10.1016/S0140-6736(16)32454-0, indexed in Pubmed: 27939063.

8. Duffy MJ, Crown J. Precision treatment for cancer: role of prognostic and predictive markers. *Crit Rev Clin Lab Sci*. 2014; 51(1): 30–45, doi: 10.3109/10408363.2013.865700, indexed in Pubmed: 24432844.
9. BEST (Biomarkers, EndpointS and other Tools), FDA-NIH Biomarker Working Group. Last Updated: November 16, 2020.
10. Wolff AC, Hammond ME, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. *J Clin Oncol*. 2018; 36(20): 2105–2122, doi: 10.1200/JCO.2018.77.8738, indexed in Pubmed: 29846122.
11. Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: Past, present and future. *Semin Cancer Biol*. 2018; 52(Pt 1): 56–73, doi: 10.1016/j.semcancer.2017.08.010, indexed in Pubmed: 28882552.
12. Leclercq G. Molecular forms of the estrogen receptor in breast cancer. *J Steroid Biochem Mol Biol*. 2002; 80(3): 259–272, doi: 10.1016/S0960-0760(02)00026-2, indexed in Pubmed: 11948011.
13. Nawińska A, Litwiniuk M. Resistance to hormone therapy in patients with breast cancer – molecular mechanisms and clinical implications. *Contemporary Oncology/Współczesna Onkologia*. 2007; 11(10): 469–474.
14. Shen K, Yu H, Xie B, et al. Anticancer or carcinogenic? The role of estrogen receptor β in breast cancer progression. *Pharmacol Ther*. 2023; 242: 108350, doi: 10.1016/j.pharmthera.2023.108350, indexed in Pubmed: 36690079.
15. Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. *J Clin Oncol*. 2005; 23(30): 7721–7735, doi: 10.1200/JCO.2005.09.004, indexed in Pubmed: 16234531.
16. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. *J Natl Cancer Inst*. 2005; 97(17): 1254–1261, doi: 10.1093/jnci/dji249, indexed in Pubmed: 16145046.
17. Li Z, Wei H, Li S, et al. The Role of Progesterone Receptors in Breast Cancer. *Drug Des Devel Ther*. 2022; 16: 305–314, doi: 10.2147/DDDT.5336643, indexed in Pubmed: 35115765.
18. Keen JC, Davidson NE. The biology of breast carcinoma. *Cancer*. 2003; 97(3 Suppl): 825–833, doi: 10.1002/cncr.11126, indexed in Pubmed: 12548582.
19. Osborne CK, Schiff R, Arpino G, et al. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. *Breast*. 2005; 14(6): 458–465, doi: 10.1016/j.breast.2005.08.024, indexed in Pubmed: 16236516.
20. Perrier A, Gligorov J, Lefèvre G, et al. The extracellular domain of Her2 in serum as a biomarker of breast cancer. *Lab Invest*. 2018; 98(6): 696–707, doi: 10.1038/s41374-018-0033-8, indexed in Pubmed: 29491426.
21. Walaszczyk A, Gabryś D. Molecular markers used in breast cancer diagnosis — current practice and future perspectives. *Nowotwory. Journal of Oncology*. 2018; 68(5-6): 259–267, doi: 10.5603/2018.0041.
22. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. *Clin Breast Cancer*. 2005; 6(3): 240–246, doi: 10.3816/CBC.2005.n.026, indexed in Pubmed: 16137435.
23. Vici P, Pizzuti L, Natoli C, et al. Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. *Breast Cancer Res Treat*. 2014; 147(3): 599–607, doi: 10.1007/s10549-014-3133-1, indexed in Pubmed: 25234842.
24. Coates AS, Winer EP, Goldhirsch A, et al. Panel Members. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Ann Oncol*. 2015; 26(8): 1533–1546, doi: 10.1093/annonc/mdv221, indexed in Pubmed: 25939896.
25. Li J, Guan X, Fan Z, et al. Non-Invasive Biomarkers for Early Detection of Breast Cancer. *Cancers (Basel)*. 2020; 12(10), doi: 10.3390/cancers12102767, indexed in Pubmed: 32992445.
26. Ghosh SK, Pantazopoulos P, Medarova Z, et al. Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues. *Clin Breast Cancer*. 2013; 13(2): 109–118, doi: 10.1016/j.clbc.2012.09.016, indexed in Pubmed: 23122537.
27. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. *Clin Chim Acta*. 2010; 411(23-24): 1869–1874, doi: 10.1016/j.cca.2010.08.039, indexed in Pubmed: 20816948.
28. Lin DC, Genzen JR. Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing. *Breast Cancer Res Treat*. 2018; 167(1): 269–276, doi: 10.1007/s10549-017-4513-0, indexed in Pubmed: 28929449.
29. Rack B, Jückerstock J, Trapp E, et al. SUCCESS Study Group. CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients. *Tumour Biol*. 2016; 37(10): 13769–13775, doi: 10.1007/s13277-016-5171-2, indexed in Pubmed: 27481512.
30. Jeong S, Park MJ, Song W, et al. Current immunoassay methods and their applications to clinically used biomarkers of breast cancer. *Clin Biochem*. 2020; 78: 43–57, doi: 10.1016/j.clinbiochem.2020.01.009, indexed in Pubmed: 32007438.
31. Baskić D, Ristić P, Matić S, et al. Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer. *Biomarkers*. 2007; 12(6): 657–667, doi: 10.1080/13547500701520563, indexed in Pubmed: 17852076.
32. Uygun MM, Gümüş M. The utility of serum tumor markers CEA and CA 15-3 for breast cancer prognosis and their association with clinicopathological parameters. *Cancer Treat Res Commun*. 2021; 28: 100402, doi: 10.1016/j.ctarc.2021.100402, indexed in Pubmed: 34082362.
33. Shao Y, Sun X, He Y, et al. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer. *PLoS One*. 2015; 10(7): e0133830, doi: 10.1371/journal.pone.0133830, indexed in Pubmed: 26207909.
34. Li J, Liu L, Feng Z, et al. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. *Breast Cancer*. 2020; 27(4): 621–630, doi: 10.1007/s12282-020-01058-3, indexed in Pubmed: 32040723.
35. Li H, Chen K, Su F, et al. Preoperative CA 15-3 levels predict the prognosis of nonmetastatic luminal A breast cancer. *J Surg Res*. 2014; 189(1): 48–56, doi: 10.1016/j.jss.2014.02.048, indexed in Pubmed: 24680287.
36. Spiliotaki M, Mavroudis D, Kapranou K, et al. Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. *Breast Cancer Res*. 2014; 16(6): 485, doi: 10.1186/s13058-014-0485-8, indexed in Pubmed: 25432416.
37. Xie S, Ding X, Mo W, et al. Serum tissue polypeptide-specific antigen is an independent predictor in breast cancer. *Acta Histochem*. 2014; 116(2): 372–376, doi: 10.1016/j.acthis.2013.09.001, indexed in Pubmed: 24144486.
38. Barak V, Goike H, Panaretakis KW, et al. Clinical utility of cytokeratins as tumor markers. *Clin Biochem*. 2004; 37(7): 529–540, doi: 10.1016/j.clinbiochem.2004.05.009, indexed in Pubmed: 15234234.
39. Seale KN, Tkaczuk KHR. Circulating Biomarkers in Breast Cancer. *Clin Breast Cancer*. 2022; 22(3): e319–e331, doi: 10.1016/j.clbc.2021.09.006, indexed in Pubmed: 34756687.
40. Perrier A, Gligorov J, Lefèvre G, et al. The extracellular domain of Her2 in serum as a biomarker of breast cancer. *Lab Invest*. 2018; 98(6): 696–707, doi: 10.1038/s41374-018-0033-8, indexed in Pubmed: 29491426.
41. Di Gioia D, Dresse M, Mayr D, et al. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. *Clin Chim Acta*. 2015; 440: 16–22, doi: 10.1016/j.cca.2014.11.001, indexed in Pubmed: 25444743.
42. Darlix A, Lamy PJ, Lopez-Crapez E, et al. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases? *Int J Cancer*. 2016; 139(10): 2299–2311, doi: 10.1002/ijc.30290, indexed in Pubmed: 27464303.
43. Gonzalez-Avila G, Sommer B, Mendoza-Posada DA, et al. Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. *Crit Rev Oncol Hematol*. 2019; 137: 57–83, doi: 10.1016/j.critrevonc.2019.02.010, indexed in Pubmed: 31014516.
44. Habanjar O, Bingula R, Decombat C, et al. Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment. *Int J Mol Sci*. 2023; 24(4), doi: 10.3390/ijms24044002, indexed in Pubmed: 36835413.
45. Atoum MF, Alzoughool F, Al-Hourani H. Linkage Between Obesity Leptin and Breast Cancer. *Breast Cancer (Auckl)*. 2020; 14: 1178223419898458, doi: 10.1177/1178223419898458, indexed in Pubmed: 31975779.
46. Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. *Sci Transl Med*. 2015; 7(302): 302ra133, doi: 10.1126/scitranslmed.aab0021, indexed in Pubmed: 26311728.
47. Larsson AM, Jansson S, Bendahl PO, et al. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer

- in a prospective observational trial. *Breast Cancer Res.* 2018; 20(1): 48, doi: 10.1186/s13058-018-0976-0, indexed in Pubmed: 29884204.
48. Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. *J Clin Oncol.* 2009; 27(31): 5153–5159, doi: 10.1200/JCO.2008.20.6664, indexed in Pubmed: 19752342.
 49. Alimirzaie S, Bagherzadeh M, Akbari MR. Liquid biopsy in breast cancer: A comprehensive review. *Clin Genet.* 2019; 95(6): 643–660, doi: 10.1111/cge.13514, indexed in Pubmed: 30671931.
 50. Aktas B, Müller V, Tewes M, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. *Gynecol Oncol.* 2011; 122(2): 356–360, doi: 10.1016/j.ygyno.2011.04.039, indexed in Pubmed: 21605893.
 51. Sant M, Bernat-Peguera A, Felip E, et al. Role of ctDNA in Breast Cancer. *Cancers (Basel).* 2022; 14(2), doi: 10.3390/cancers14020310, indexed in Pubmed: 35053474.
 52. Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. *Sci Transl Med.* 2017; 9(403), doi: 10.1126/scitranslmed.aan2415, indexed in Pubmed: 28814544.
 53. Davis AA, Zhang Q, Gerratana L, et al. Association of a novel circulating tumor DNA next-generation sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. *Breast Cancer Res.* 2019; 21(1): 137, doi: 10.1186/s13058-019-1229-6, indexed in Pubmed: 31801599.
 54. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. *Nat Med.* 2008; 14(9): 985–990, doi: 10.1038/nm.1789, indexed in Pubmed: 18670422.
 55. Hrebien S, Citi V, Garcia-Murillas I, et al. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. *Ann Oncol.* 2019; 30(6): 945–952, doi: 10.1093/annonc/mdz085, indexed in Pubmed: 30860573.
 56. Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. *Hum Genomics.* 2019; 13(1): 34, doi: 10.1186/s40246-019-0220-8, indexed in Pubmed: 31370908.
 57. Li H, Liu J, Chen J, et al. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. *Nat Commun.* 2018; 9(1): 1614, doi: 10.1038/s41467-018-03537-w, indexed in Pubmed: 29691399.
 58. Park HS, Han HJu, Lee S, et al. Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR. *Yonsei Med J.* 2017; 58(1): 19–26, doi: 10.3349/ymj.2017.58.1.19, indexed in Pubmed: 27873491.
 59. He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. *J Mol Med (Berl).* 2003; 81(10): 600–612, doi: 10.1007/s00109-003-0474-3, indexed in Pubmed: 12928786.
 60. Koo DH, Park CY, Lee ES, et al. Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study. *PLoS One.* 2012; 7(6): e39880, doi: 10.1371/journal.pone.0039880, indexed in Pubmed: 22761921.
 61. Li Lq, Huang HI, Ping JI, et al. Clinicopathologic and prognostic implications of progranulin in breast carcinoma. *Chin Med J (Engl).* 2011; 124(13): 2045–2050, indexed in Pubmed: 22088468.
 62. Roselli S, Pundavela J, Demont Y, et al. Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion. *Oncotarget.* 2015; 6(12): 10473–10486, doi: 10.18632/oncotarget.3401, indexed in Pubmed: 25871389.
 63. Berger K, Rhost S, Rafnsdóttir S, et al. Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer. *BMC Cancer.* 2021; 21(1): 185, doi: 10.1186/s12885-021-07854-0, indexed in Pubmed: 33618683.
 64. Purrahman D, Mahmoudian-Sani MR, Saki N, et al. Involvement of progranulin (PGRN) in the pathogenesis and prognosis of breast cancer. *Cytokine.* 2022; 151: 155803, doi: 10.1016/j.cyto.2022.155803, indexed in Pubmed: 35066450.
 65. Guha R, Yue B, Dong J, et al. Anti-progranulin/GP88 antibody AG01 inhibits triple negative breast cancer cell proliferation and migration. *Breast Cancer Res Treat.* 2021; 186(3): 637–653, doi: 10.1007/s10549-021-06120-y, indexed in Pubmed: 33616772.
 66. Rhost S, Hughes É, Harrison H, et al. Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion. *Breast Cancer Res.* 2018; 20(1): 137, doi: 10.1186/s13058-018-1060-5, indexed in Pubmed: 30454027.
 67. Iacopetta D, Rechoum Y, Fuqua SA. The Role of Androgen Receptor in Breast Cancer. *Drug Discov Today Dis Mech.* 2012; 9(1-2): e19–e27, doi: 10.1016/j.ddmec.2012.11.003, indexed in Pubmed: 26568765.
 68. Kono M, Fujii T, Lim B, et al. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. *JAMA Oncol.* 2017; 3(9): 1266–1273, doi: 10.1001/jamaoncol.2016.4975, indexed in Pubmed: 28301631.
 69. Zatloukalová P, Pjehová M, Babčanová S, et al. [The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response]. *Klin Onkol.* 2016; 29 Suppl 4(Suppl 4): 72–77, indexed in Pubmed: 27846724.
 70. Schütz F, Stefanovic S, Mayer L, et al. PD-1/PD-L1 Pathway in Breast Cancer. *Oncol Res Treat.* 2017; 40(5): 294–297, doi: 10.1159/000464353, indexed in Pubmed: 28346916.
 71. Bou Zerdan M, Ghorayeb T, Saliba F, et al. Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. *Cancers (Basel).* 2022; 14(5), doi: 10.3390/cancers14051253, indexed in Pubmed: 35267561.
 72. Schick J, Ritchie RP, Restini C. Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. *Breast Cancer (Auckl).* 2021; 15: 1178223421995854, doi: 10.1177/1178223421995854, indexed in Pubmed: 33994789.
 73. Emens LA. Breast Cancer Immunotherapy: Facts and Hopes. *Clin Cancer Res.* 2018; 24(3): 511–520, doi: 10.1158/1078-0432.CCR-16-3001, indexed in Pubmed: 28801472.
 74. Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? *J Exp Med.* 2016; 213(13): 2835–2840, doi: 10.1084/jem.20161462, indexed in Pubmed: 27903604.
 75. Tavares DF, Chaves Ribeiro V, Andrade MA, et al. Immunotherapy using PD-1/PDL-1 inhibitors in metastatic triple-negative breast cancer: A systematic review. *Oncol Rev.* 2021; 15(2): 497, doi: 10.4081/oncol.2021.497, indexed in Pubmed: 35003528.
 76. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. *J Clin Oncol.* 2014; 32(27): 2959–2966, doi: 10.1200/JCO.2013.55.0491, indexed in Pubmed: 25071121.
 77. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. *Ann Oncol.* 2014; 25(8): 1544–1550, doi: 10.1093/annonc/mdl112, indexed in Pubmed: 24608200.
 78. Lenneman CG, Sawyer DB. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment. *Circ Res.* 2016; 118(6): 1008–1020, doi: 10.1161/CIRCRESAHA.115.303633, indexed in Pubmed: 26987914.
 79. Kufel-Grabowska J, Katarzyński S, Szmít S, et al. Cardiotoxicity in patients with early breast cancer treated with adjuvant trastuzumab. *Nowotwory. Journal of Oncology.* 2022; 72(5): 288–293, doi: 10.5603/njo.a2022.0047.
 80. Chaikijurajai T, Tang WH. Reappraisal of Inflammatory Biomarkers in Heart Failure. *Curr Heart Fail Rep.* 2020; 17(1): 9–19, doi: 10.1007/s11897-019-00450-1, indexed in Pubmed: 31916187.
 81. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. *Prog Cardiovasc Dis.* 2010; 53(2): 121–129, doi: 10.1016/j.pcad.2010.04.002, indexed in Pubmed: 20728699.
 82. Muir CA, Clifton-Bligh RJ, Long GV, et al. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. *J Clin Endocrinol Metab.* 2021; 106(9): e3704–e3713, doi: 10.1210/clinem/dgab263, indexed in Pubmed: 33878162.
 83. Gumusay O, Callan J, Rugo HS. Immunotherapy toxicity: identification and management. *Breast Cancer Res Treat.* 2022; 192(1): 1–17, doi: 10.1007/s10549-021-06480-5, indexed in Pubmed: 35015209.
 84. Huehnchen P, Schinke C, Bangemann N, et al. Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. *JCI Insight.* 2022; 7(6), doi: 10.1172/jci.insight.154395, indexed in Pubmed: 35133982.
 85. Burgess BL, Cho E, Honigberg L. Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin. *Sci Rep.* 2022; 12(1): 15593, doi: 10.1038/s41598-022-18716-5, indexed in Pubmed: 36114333.
 86. Möhn N, Mahjoub S, Duzzi L, et al. ICG-CCCH (Immune Cooperative Oncology Group; Comprehensive Cancer Center Hannover). Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity. *Cancer Med.* 2023; 12(8): 9373–9383, doi: 10.1002/cam4.5695, indexed in Pubmed: 36794673.

Have innovations in radiotherapy for head and neck cancer improved the curability of the disease?

Bogusław Maciejewski¹ , Dorota Gabryś² , Justyna Rembak-Szynkiewicz³ ,
Aleksandra Napieralska² , Małgorzata Stąpór-Fudzińska⁴ 

¹Div. Research Programmes, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

²Dept. Radiotherapy, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

³Dept. of Radiology and Diagnostic Imaging, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

⁴Dept. Radiotherapy Planning, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

In an era of distinct technological innovations in radiotherapy, a clinically important question has arisen: can the increase of radiotherapy (RT) effectiveness be attributed to these innovations, at least in the case of head and neck (H&N) cancers? In order to answer this question, 133 studies were published, including 21,058 patients who were selected for the present survey with H&N cancer treated within the period of 1970–2010. Three end-points, e.g. 5-year local tumor control (LTC), disease-free survival (DFS) and overall survival (OS) and their average values were evaluated over the consecutive decades. For cancer in the early stage, both LTC and DFS were constantly high (80–90%) through the analyzed decades. For locally advanced cancer, average rates of LTC and an DFS were also constant, but much lower than expected (40–45%). The OS had an increasing tendency: from 45–50% in 1980 to more than 70% in 2010. It may suggest that during the 5-year follow-up period, some proportion (~20%) of advanced tumors gradually progressed from local to chronic disease. Various technical and clinical problems influencing the results of the present review are discussed in detail. Some uncertainties and doubts regarding the RT trials may suggest that “evidence based” recommendations might not be satisfactory, as in the era of combined treatment modalities; it may seem reasonable to replace them with “individually personalized combined therapy”. However, nowadays the only plausible solution to improve H&N cancer curability is to intensify all efforts to detect it in the very early stages of the disease and to increase various activities to convince people to participate in regular prophylactic examinations.

Key words: head and neck cancers, local tumor control, disease-free survival, overall survival end-points, early cancer diagnosis, permanent curability

Technological revolution and innovations

The era of orthovoltage radiotherapy (RT) and the Ralston Paterson “school of radiation dose delivery” [1] lasted for over 60 years. During these years radiotherapy planning was relatively simple: based on X-ray radiographs and 2D-coplanar, geometrically regular, well-shaped 2–6 beams focused on

the tumor (fig. 1), whilst dose distribution was calculated based on diagrams of the percentage depth isodoses.

During the 1970s, cobalt units were gradually replaced by high-tech linear accelerators (Linacs), offering a wide range of MV energy (5–>20 MV) photon and electron beams. As opposed to Paterson’s principles, Fletcher’s rules were based

Jak cytować / How to cite:

Maciejewski B, Gabryś D, Rembak-Szynkiewicz J, Napieralska A, Stąpór-Fudzińska M. *Have innovations in radiotherapy for head and neck cancer improved the curability of the disease?* NOWOTWORY J Oncol 2023; 73: 286–293.




Figure 1. Schemes of three different techniques used in radiotherapy during <1970 and >2000 year with respective dose distribution within the tumor (T) and in the surrounding normal tissues (NT). 2D-RT – two dimensional nonconformal RT; 3D-IMRT – three dimensional dose intensity modulated conformal RT; SHRT – stereotactic hypofractionated multidimensional, conformal RT

on radiobiological principles, and have been universally accepted [2]. Linacs were gradually enriched with multileaf collimators (MLC), cone-beam CTs, real-time tumor tracking, fusion of the CT and Linacs (tomotherapy). Corollary to these technological innovations, RT planning has begun to use precise 3D-conformal IMRT, IGRT, IART, respiratory gating RT, biologically targeted IMRT [3–14], defined by Coleman et al. [12] as SMART radiotherapy. Irregular beam shapes made it possible to tailor the radiation dose which was focused both on the tumor and its margins, with a sharp decrease of radiation beyond this area (fig. 1). However, clinical practice has shown that this comprehensive and powerful solution is in fact a sword of Damocles. On the one hand, conformal techniques offer a substantial decrease in the dose deposited in the surrounding healthy tissues, and therefore reduce the risk of serious late complications, whilst on the other hand there is a risk of cold spot(s), even small ones, in the tumor volume, due to the dose within the tumor; this is likely to lower the preliminary predicted probability of local tumor control [14].

Such technological and systemic innovations [3–14] in three-dimensional RT has opened the possibility for various altered dose fractionation schedules used either alone or combined with other therapeutic modalities like surgery or chemotherapy [12, 15–17]. Moreover, proton and boron therapy have appeared, yet their set up is extremely expensive so the practical use is still somewhat limited. The next interesting option, increasingly growing in popularity, is stereotactic hypofractionated radiotherapy (radiosurgery, SHRT, SHRS) [18–20]. Although its principles were already defined

in 1948 by Takahaschi [8], SHRT has been widely used only since 2000, mainly due to special modifications of the Linacs (VMAT) and the new robotic CyberKnife. A key-principle of this method is the use of many (even more than 100) pencil beams focused on the tumor, with a sharp down dose gradient beyond its bounds (fig. 1). SHRT is an example of a “round game” in radiotherapy, meaning the return of RT to its roots, when in the 1900s, single or a very few large dose fractions were being used. This method was, however, quickly abandoned because of the very high incidence of lethal late complications. After more than 100 years, it came back to the RT arena, offering many pencil beams and robotic computerized 3D-dose planning systems instead of geometrically shaped single or two-dimensional field techniques and a low energy X-ray beam. Moreover, SHRT can be used as radical therapy or as a palliative treatment in the case of single or multiple distant metastases irradiated during a single set-up session. However, SHRT has one important limitation – it can only be used in the case of small and well-defined lesions.

This impressive progress in the use of radiation as one of the cancer treatment modalities provokes another important question: did all these achievements result in an increase of permanent curability of cancer patients, at least those with head and neck malignant tumors?

End-points of RT effectiveness

Since radiotherapy has been also used as a local treatment of malignant or some benign tumors or localized distant metastases, local tumor control (LTC) has been widely accepted.

That is why it is used as an appropriate end-point with a 5-year follow-up, at least for head and neck cancer, because about 80% of local recurrences occur within the first 3 years of completing the irradiation. However, when some cases are lost from observation and their follow-up is shorter than 5-years, then the actuarial LTC is limited, assuming the risk of recurrence which may occur if the follow-up lasts 5 years. The estimated date of an average limited LTC should therefore be interpreted with great caution because such averages might be underestimated.

Sometimes, LTC is erroneously identified with tumor cure probability (TCP), so it is misinterpreted as an indicator of tumor or even a patient's curability, which in fact is not. The TCP is only a preliminary predictor of local eradication of the tumor by the RT and individually estimated based on the tumor origin, type, stage (in fact a tumor volume rather than a stage), and the planned dose fractionation. The TCP is estimated based on radiobiological principles, but it is very often untrue and thus disappointing. If the dose is heterogeneously distributed within the tumor volume, and, for example, 50% of the planned dose is delivered to only 1% of the tumor (usually invisible on a tumor volume histogram [DVH]), then it completely ruins the predicted TCP, and its real value decreases close to zero. Therefore, the TCP has nothing to do with a patient's curability by RT.

Complete tumor regression (CR) is definitely unsuitable for an evaluation of RT effectiveness, although there are some suggestions that the CR might be a prerequisite for the LTC, but it rarely happens. One may believe that the CR is the clinical effect of radiation cell kill, but it is not, because it only indicates how fast and effectively dead cancer cells are removed out of the tumor mass by immunological and cellular homeostatic defensive processes.

Disease-free-survival (DFS) is a proper and representative end-point which is close to the chance of the permanent patient's curability, because it represents the LTC without local recurrence and/or distant metastases. However, real DFS which is the absolute number of patients who survived the outlined follow-up, must be distinguished from the censored DFS, for the same reasons as a real vs. actuarial LTC. The more cases are censored the lower reliability of the estimates. The 5-year DFS seems a reasonable time-limit for the H&N cancer, but for some other tumors (e.g. breast, lung cancers), this period is too short, and sometimes even 10 years are not enough.

Overall survival (OS) is usually reported as an additional end-point, however its validity in relation to permanent patient's curability remains uncertain since it does not inform how many patients are permanently cured and how many live with local recurrence and/or distant metastases.

LTC, DFS, OS results in the last four decades of RT

The present survey is the review of a large variety of retrospective prospective studies and clinical randomized trials, whose results were published in the literature between 1970 and 2010. Many studies reported incomplete results. The present review includes only complete rates of well documented three end-points, which are the LTC, DFS and the OS, although not all three end-points were reported in each study [10, 17, 23–35]. Furthermore, only studies on radiotherapy alone or as a primary treatment or sometimes combined with sequential or concurrent chemotherapy were selected. Four decades of treatment have been analyzed, and therefore the respective number of end-points differ. Altogether, 341 rates of the LTC, DFS and OS have been selected for the present analyses (tab. I). The rate of LTCs reported up to 1970 are lower than LTC rates in the following decades. In the remaining three decades, the LTC, DFS and OS rates did not differ very much. The LTC, DFS and OS were estimated for an overall number of 21,058 patients treated by RT using one of the four different dose fractionation schedules (tab. II). All the data are subdivided into two groups, i.e. tumors in the early stage T1–2N0M0 and advanced tumors in stage T2–4N+M0. Altered vs. conventional dose fractionations were used in the randomized trials and the number of patients recruited to each arm of these studies was more or less the same. Therefore, the overall number of patients treated with conventional fractionation was the largest and it includes 10,209 cases (48%).

Figure 2 illustrates the distribution of dots representing the LTC, DFS and OS rates documented in the studies selected for the present review. This figure shows a wide spread of black dots representing the 5-year LTC and DFS of patients with locally advanced head and neck cancer reported during 1980–2010, although its ranges were relatively narrow, not substantially changed over the last 30–40 years. It should be emphasized that during that extended period, tremendous high-tech progress in linacs and its tools and computerized 3D-dose planning systems have taken place; yet it has not really

Table I. Number of studies analyzing three RT end-points recruited to the present survey

End point	1970–1975	1980–1985	1990–1995	≥2010	Overall
local tumor control		32	40	36	108
disease-free-survival	6	37	35	37	115
overall survival	8	35	37	38	118
total	14	104	112	111	

Table II. Number of patients included in the selected studies presented in table I

Radiotherapy schedules	Number of patients	Percentage of patients
conventional	2638	12
altered vs. conventional	15,142	72
SHRT	1863	9
chemoradiation	1415	7
total	21,058	100

SHRT – stereotactic hypofractionated multidimensional

improved LTC and DFS results, with average rates invariably oscillating around 40–45%. Even the use of altered dose fractionation did not change these highly unsatisfactory, average rates of LTC and DFS [24, 25]. Promising results have been offered by concurrent chemoradiation which increased average LTC and DFS by 10–15%. There is a marked increase in LTC and DFS for patients with early stages (T1–2N0M0) of head and neck cancer to an average level of 80–≥90%, and also when the SHRS has been used. By contrast to the LTC and DFS end-points, OS significantly increased from about 40–45% in the 80s to >70% in the 2000s. The higher rates and prolonged OS over these 30 years do not necessarily suggest a benefit of RT but rather a gradual progression of the disease from local to chronic.

Comments

The curability of cancer patients means that an appropriate therapy (radiotherapy alone or combined modalities) will permanently and irreversibly eradicate all clonogenic cancer cells. Theoretically it should result in a 100% permanent cure rate. For radiotherapy (also for other therapeutic modalities in oncology) this might be an illusion because of the random

nature of radiation cell killing. Tumor stem cells are defined as clonogenic or colony forming cells, which may constitute only a small proportion of all tumor cells [36]. If only one stem cell survives irradiation, then it will be able to reconstruct the primary tumor as a local recurrence, although their genotype and phenotype may substantially differ from that in the primary tumor. Therefore, the key point of radiotherapy is to eradicate the last cancer stem cell, to ensure the tumor never regrows, but this is a theory only, and, moreover, it is impossible to recognize tumor stem cells in situ, and to establish their number and localization. Therefore, regarding a patient's curability, when estimating the LTC and DFS, the word "probability" instead of "certainty" is used.

Analyzing the results presented in the figure 2, two major questions arise. First, what is the reason for the small wide spread of dots representing the LTC, DFS and the OS, despite the outstanding technological and computerized 3D-RT planning advances during the last three decades; secondly, why during that period, did the RT efficacy represented by the LTC and DFS rates not increase? It seems that there are at least three important reasons. First of all, in clinical radiotherapy for H&N cancer clinical data, not only that recruited the present study, look like a "fruit basket". To a single study or two-three arms of the randomized trials were usually recruited H&N tumors with various sites and wide range stages (T2–4N+M0) [25, 26, 37]. Therefore, the range of initial tumor volumes (and respective initial number of cancer cells as well) was even wider. For such a diversity of parameters, a single and same 3D-dose fractionation was used within each arm of the study. The main aim was to estimate the most effective dose which would produce a significant increase in LTC and DFS. The use of the same dose fractionation for T2N0M0 as for T4N0M0 to achieve the highest therapeutic benefit is in fact ridiculous in the light of all radiobiological principles. Some years ago, L. Peters suggested that it is like searching for a single "Holy Grail", which could be




Figure 2. Distribution of the 5-year LTC, DFS and OS rates of (dost) during four decades of radiotherapy documented by the results of studical recruited to the present survey □ – average rates of the respective end-points for advanced H&N cancers; ■ – average rates representing concurrent chemo-radiation; open circles – early staged H&N cancers; △ – results of the SHRS




Figure 3. Schematic tumor volume (gross mass) with subclinical microscopic irregular cancer cell deposits

compared with a blind man looking for a needle in a haystack. The effect of the mixture of tumors in early and advanced stages is shown as a theoretical example in figure 3.

From a practical point of view, if the total dose of 70 Gy in 35 fractions is used to irradiate T1N0M0 H&N cancer, which contains about 10^9 clonogenic cancer cells then on average 0.1 cell/tumor should theoretically survive. It means that in a group of 100 such tumors, in 90 of them all the cells will die and in the remaining 10 tumors, 2, 4, 8 or more cells will survive, which gives on average 0.1 cell/tumors. Therefore, tumor cure probability ($TCP = e^{-0.1}$) will reach a level of 90%, which usually happens in RT practice. However, if the same dose is used to irradiate T3N0M0 tumor with 10^{11} clonogenic cells, then an average survival would be 1 cell/tumor, which as a consequence gives TCP of $e^{-1} = 37\%$, what also happens? This is not a theory but a real every day situation in radiotherapy.

One important point of view articulated 75 years ago in 1949 by Paterson [1], and 50 years later by Suit [38], is that a local success, important for patients, is to be free of local problems, but it does not affect the likelihood of the patient's curability.

An increase in the DFS seems to be realistic by effectively augmenting the LTC. Already Paterson in his textbook of radiotherapy published in 1949 (the first textbook in the world) strongly emphasized that "optimal tumor dose (TCD is actual term) must be assessed in terms of dose related to time, not as a dose alone. The dose/day of treatment is important from the beginning, because a low initial rate cannot be compensate by a high rate later, or vice versa. A most often forgotten corollary is that the treatment planned must be completed in the shortest time possible". It should lower a risk of local recurrences and/or distant metastases (the last failure type is not a key-problem in the case of the H&N squamous cell carcinomas, may be except nasopharyngeal cancer). It may seem surprising (fig. 2) that average rates of the LTC and DFS for advanced tumors have remained at a similar level during the last 30 years. One plausible explanation could be that LTC

rates shortly after completing RT were much higher, and they decreased during the follow-up, as the result of local recurrences. Finally, averages of both end-points reached similar levels at the 5-year follow-up. At first glance, a relatively wide spread of data dots representing the LTC and DFS rates may suggest differences in tumor radiosensitivity, but it is unrealistic to accept such wide variations in squamous cell carcinomas which are the subject of the present review. It could rather be the results of the pronounced variability in the initial tumor volume and the respective number of cancer cells (not TNM), which received a suboptimal radiation dosage. Falling into two major categories of H&N cancers, the LTC for tumors in the early stage treated adequately is very high, whereas for advanced tumors the LTC is usually low, and therefore the average rate is unexpectedly more or less moderate. In the present analysis we decided to separate these two categories.

High curability is a fundamental goal of radical RT, which can be attempted when the whole area containing cancer cells is covered homogeneously by respectively optimal dose delivered in the shortest overall time possible. Moreover, an important point is that cancer should be effectively controlled at the first attempt, because there is seldom a second chance. And this is the next important problem.

Generally, cancers usually have an irregular shape (except capsular or cystic tumors, very rare in the H&N) with the spread of subclinical cellular deposits beyond the bounds of the gross tumor mass (fig. 3). Gross mass is the only visible part of the tumor on the CT, MRI scans, and therefore the real tumor bounds cannot be precisely defined, since subclinical spread of tumor cell deposits are beyond the resolution of the CT or MRI and it is unable to determine the exact extent of the growing tumor. Spread of cellular deposits beyond the gross tumor mass is a major attribute of advanced rather than "early" tumors.

Currently, the aim of 3D conformal RT planning is to tailor irregularly shaped radiation beams within the CTV and PTV margins, and focus on the gross tumor mass, and with the dose gradient beyond, to spare the surrounding [fig. 3] normal tissue. Therefore, there is a risk of missing microscopic deposits of cancer cells aside individual volume. Regardless of that risk, collimator leaf(s) may sometimes cover even a very small part of the tumor volume (overconformality). Both events are a potential source of local recurrence of the tumor. If 10^3 – 10^6 clonogenic cancer cells were missed (even 1 stem cell is enough) beyond the irradiated volume, then local recurrence will likely occur clinically during 6–12 months after completing the treatment. To minimize that risk, the planned dose-volume-histograms (DVH) must be very carefully analyzed. It has to be emphasized that purely physical dose distributions might be misleading, and therefore the physical DVH should be converted into biologically normalized DVHs, where each pixel of dose becomes equivalent if it would be given in 2.0 Gy/fractions. Such a simple procedure discloses overdosage or underdosage

subregions of the whole tumor volume. It is a pity that such checking is often ignored in daily RT practice, and therefore, it could partially contribute in some way to the unsatisfactory average rates of LTC and DFS, shown in figure 2.

Dose cold and hot spots (the second one in the gross tumor volume can be ignored) are the third major problem, especially for heterogeneous dose distribution within the irradiated area. The UICC recommends using the D_{95} as a reference parameter and it was acceptable for 2D dose planning homogeneously distributed within the irradiated volume. When the 2D procedure was replaced by precise and highly sophisticated 3D–4D dose planning techniques, already more than 10 years ago, Jack Fowler strongly emphasized that D_{95} should, without doubt, be replaced by D_{100} as a reference factor, however the D_{95} still remains in daily practice. If preliminarily predicted TCP is 90% and dose planning is tailored to such prediction, that if even a small tumor subvolume will receive a few percent lower dose (cold spot), then in such an underdosed subvolume on average 1.0 instead of 0.1 cancer cell will survive, and therefore the TCP for that subvolume will be substantially lowered ($TCP = e^{-1} = 0.37$), and collorary overall LTC will lower to only 33% (0.90×0.37).

Withers [22] and Suit [38] pointed out that “the essential art of treatment planning is choosing where and how much of extra-tumoural radiation shall go”. However, this does not necessarily seem to be true after all, since once a tumor cold spot is underdosed, it will definitely ruin the expected high LTC, and any extra boost dose delivered thereafter will not neutralize such negative effect. Therefore this moves us to the beginning, that precise 3D-dose planning with the removal of any existing dose cold spots is a key point in achieving the LTC and DFS as high as predicted.

A final comment as regards overall survival (OS) in the present review shows an increasing tendency through the last 30 year period. The OS is not a proper and adequate end-point for an assessment of the patient’s permanent curability, although it is often used as an argument to express improvements of the efficacy of oncologic therapy as a whole. In the present review relatively moderate 5-year LTC and DFS of 45–50% compared with much higher average the OS may likely be interpreted as the gradual progress of a local cancer disease into its chronic phase (in about 20–25% in the present review), and the higher OS with prolonged survival can be a result of effective palliative therapy. SHRS has been found as a highly effective RT, not only radical but also local palliative therapy as well [19, 20]. Analyzing the OS as an end-point for prolonged survival, there is relatively small number of studies focused on the quality of life and what kind of price is paid for prolonged life. It does not look very optimistic. According to List and Bilir [39], about more than 50% of patients have difficulties in eating and swallowing, a decreased sense of taste, dry mouth (95%) and 30–35% reported sticky saliva, pain, unsatisfied appearance, which may recover is less than 35%

of patients. This is the price which patients with a chronic phase of H&N cancer may pay for prolonged survival, in other tumor types and origins as well.

To sum up, it is a pity that RT efficacy for locally advanced H&N cancer has not changed a lot during the last 3 decades and it still does not look overly optimistic, but it is not all bad news. Tumors in the early stage usually have well defined bounds as microscopic deposits of cancer cells have not had enough time to develop yet and therefore have not spread out of the tumor bounds. Radiation beams are precisely tailored to cover homogeneously whole PTV to eliminate overconformality, or dose cold spots. Therefore, the likelihood of a high LTC and DFS (~80–90%) by RT alone is not surprising. On the contrary, many studies including trials on various 3D-techniques and altered dose fractionation [15, 21, 23, 26, 28, 29] have convincingly shown that the effectiveness of RT alone for advanced H&N cancers is limited and generally disappointing. Ultimate proof of that comes from the four-arm RTOG-9003 trial [24]. Delivery of a total dose in the range of 67.2–81.6 Gy using altered fractionation to irradiate advanced H&N cancers resulted in similar LTC of 40–45%, in each arm of this trial. This became a strong argument for replacing RT alone by combined therapeutic strategy, which includes RT. Concurrent chemoradiation has been an attractive solution, although meta-analysis [26] showed a rather low (4%) average benefit of local tumor control. Combined therapy including various sequences of surgery, radiation and chemotherapy has been enriched by genomic, proteomic-molecular identifiers and modifiers (fig. 4), becoming promising options to improve cancer patient’s permanent curability. The point to be emphasized is the advertisement of a “quantum leap” in the improvement of the efficacy using 3D-IMRT in the local treatment of various tumor sites including the use of respiratory gating in the case of lung cancer. Glatstein [40, 41] pointed out that many investigators admit they are still uncertain, but suspect that some improvement could be expected. An objective evaluation of the benefits of IMRT has never been done and it still remains an open question. It is often suggested that high-tech RT has a high success rate but it is unclear as to what that success refers to, i.e., a permanent cure or local control only. Moreover about 80% patients are treated using RT beyond clinical trials.

Irrespective, of many uncertainties [44, 45], the “evidence based” RT is strongly forced and recommended as an obligatory guide and instruction for the RT planning and delivery based on the trial’s results. However, throughout all these efforts, spanning 30 years, of trying to improve RT efficacy, the recruitment of various, different tumor sites and sizes (although all being squamous cell cancers) to each arm of the trials to test one or two different RT schedules is an antimony of individual therapy, and in fact it fails. Some trials evaluating molecular agents combined with RT are restricted to the conclusion that the tested regimens are safe and fe-




Figure 4. Scheme of the elements of multimodality combined treatment: strategy as an instrument for improvement cancer curability

Table III. Local tumor control depending on ratio of early vs. advanced stage cancer treated by RT

Current and expected rate of early vs. advanced cases		Early	Advanced	Early and advanced
current rate	no. cases	40	60	100
	average LTC	80%	20%	44%
	no. with LTC	32	12	44
expected rate	no. cases	70	30	100
	average LTC	80%	20%	62%
	no. with LTC	56	6	62

LTC – local tumor control

asible – not one word regarding its efficacy is mentioned. Thus, it seems reasonable and reliable that “evidence based” cancer therapy (results are often biased and are not reliable facts) might be replaced in favor of “personalized combined therapy”, individually tailored to each single cancer patient. But this seems to be a promising future only, which we believe in or not. In conclusion, the only reasonable solution at the present moment, is to intensify all efforts to change the unsatisfactory ratio of early versus advanced tumors from 4:6 to 7:3, in favor of early stage tumors (tab. III B). Detection of cancers in the early stage of disease needs intensive and convincing efforts to increase access to early and fast diagnostics to effectively increase public awareness that till now early detection of cancer is reasonable solution to achieve the highest permanent curability for the patient.

Article information and declarations

Conflict of interest

None declared

Bogusław Maciejewski

Maria Skłodowska-Curie National Research Institute of Oncology
Gliwice Branch

Div. Research Programmes

Wybrzeże Armii Krajowej 15

44-102 Gliwice, Poland

e-mail: boguslaw.maciejewski@gliwice.nio.gov.pl

Received: 24 May 2023

Accepted: 18 Jul 2023

References

1. Paterson R. The treatment of malignant disease by radiation and X-rays being a practice of radiotherapy. Determination of treatment policy. Arnold RCO, London 1953: 19–52.
2. Fletcher GH. Textbook of radiotherapy. Lea & Febinger, Philadelphia 1966.
3. Le QT, Raben D. Integrating biologically targeted therapy in head and neck squamous cell carcinomas. Semin Radiat Oncol. 2009; 19(1): 53–62, doi: 10.1016/j.semradonc.2008.09.010, indexed in PubMed: 19028346.
4. Garden AS, Morrison WH, Rosenthal DI, et al. Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Semin Radiat Oncol. 2004; 14(2): 103–109, doi: 10.1053/j.semradonc.2003.12.004, indexed in PubMed: 15095256.
5. Hutcher GJ, Mohan R. Innovations in treatment delivery. Semin Radiat Oncol. 1995; 5(2): 75–76.

6. Green A. A Technical Advance in Irradiation Technique. *Proc R Soc Med*. 2016; 52(5): 344–346, doi: 10.1177/003591575905200506.
7. Simpson DR, Mell LK, Mundt AJ. Image-guided radiation therapy. In: Perez & Brady's Principles and Practice of Radiation Oncology VII ed. Wolters Kluwer, Philadelphia 2019: 288–307.
8. Takahashi S. Various types of rotation radiotherapy. *Jpn Med J*. 1949; 13: 1223–1249.
9. Koong AC. SBRT/ABR. *Semin Radiat Oncol*. 2017; 27(3): 189–288.
10. Cox JD, Ang KK. Radiation Oncology. VIII ed. Elsevier Sci, Mosby 2003: 178–281.
11. Wang TJC, Wu CS, Chao KSC. Intensity-Modulated radiation treatment techniques and clinical applications. In: Perez & Brady's Principles and Practice of Radiation Oncology VII ed. Wolters Kluwer, Philadelphia 2019: 260–287.
12. Coleman CN, Prasanna PG, Capala J. SMART radiotherapy. In: Perez & Brady's Principles and Practice of Radiation Oncology VII ed. Wolters Kluwer, Philadelphia 2019: 133–152.
13. Maciejewski B. Od Roentgena (120 lat) do stereotaktycznej radiochirurgii. Nowotwory. *Journal of Oncology*. 2016; 65(5): 373–382, doi: 10.5603/njo.2015.0074.
14. Goitein M, Niemierko A. Intensity modulated therapy and inhomogeneous dose to the tumor: a note of caution. *Int J Radiat Oncol Biol Phys*. 1996; 36(2): 519–522, doi: 10.1016/s0360-3016(96)00348-3, indexed in Pubmed: 8892479.
15. Rosenthal DI, Ang KK. Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma. *Semin Radiat Oncol*. 2004; 14(2): 153–166, doi: 10.1053/j.semradonc.2004.01.001, indexed in Pubmed: 15095261.
16. Bernier J. Current state-of-the-art for concurrent chemoradiation. *Semin Radiat Oncol*. 2009; 19(1): 3–10, doi: 10.1016/j.semradonc.2008.09.002, indexed in Pubmed: 19028339.
17. Mendenhall WA. Altered fractionation for squamous cell carcinoma of the head and neck. *Procc 5th International Conference on head and neck cancer*. Ommipress AHNS, Pittsburg USA 2000: 63–68.
18. Grégoire V, Maingon P. Intensity-modulated radiation therapy in head and neck squamous cell carcinoma: an adaptation of 2-dimensional concepts or a reconsideration of current clinical practice. *Semin Radiat Oncol*. 2004; 14(2): 110–120, doi: 10.1053/j.semradonc.2003.12.006, indexed in Pubmed: 15095257.
19. Webb S, Evans PM. Innovative techniques in radiation therapy: editorial, overview, and crystal ball gaze to the future. *Semin Radiat Oncol*. 2006; 16(4): 193–198, doi: 10.1016/j.semradonc.2006.04.001, indexed in Pubmed: 17010901.
20. Gorgulho AA, Agazaryan N, Slotman B. Shaped Beam Radiosurgery. *State of Art Springer-Verlag, Berlin Heidelberg* 2011: 3–61.
21. Ang KK, Garden AS. Radiotherapy for head and neck cancers. *Innovation and techniques*. II ed. Lippincott Williams & Williams, Philadelphia 2002: 3–41.
22. Withers HR, McBride WH. Biologic basis radiation therapy. In: Perez & Brady's Principles and Practice of Radiation Oncology III ed. Lippincott-Raven Press, Philadelphia 1998: 79–118.
23. Overgaard J, Hansen HS, Sapru W, et al. 110Conventional radiotherapy as the primary treatment of squamous cell carcinoma (SCC) of the head and neck. A randomized multicenter study of 5 versus 6 fractions per week — Preliminary report from the Dahanca 6 and 7 trial. *Radiation Oncol*. 1996; 40: 531, doi: 10.1016/s0167-8140(96)80119-8.
24. Fu K, Pajak T, Trotti A, et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. *Int J Radiat Oncol Biol Phys*. 2000; 48(1): 7–16, doi: 10.1016/s0360-3016(00)00663-5.
25. BOURHIS J, AUDRY H, OVERGAARD J, et al. Meta-analysis of conventional versus altered fractionated radiotherapy in head and neck squamous cell carcinoma (HNSCC): Final analysis. *Int J Radiat Oncol Biol Phys*. 2004; 60: S190–S191, doi: 10.1016/s0360-3016(04)01183-6.
26. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. *Lancet*. 2000; 355(9208): 949–955, doi: 10.1016/s0140-6736(00)90011-4.
27. Fein DA, Lee WR, Amos WR, et al. Oropharyngeal carcinoma treated with radiotherapy: a 30-year experience. *Int J Radiat Oncol Biol Phys*. 1996; 34(2): 289–296, doi: 10.1016/0360-3016(95)02028-4, indexed in Pubmed: 8567328.
28. And KK, Thames HD, Peters LJ. Altered fractionation schedules. In: Perez & Brady's Principles and Practice of Radiation Oncology III ed. Lippincott-Raven Press, Philadelphia 1998: 119–142.
29. Bernier J. Current state-of-the-art for concurrent chemoradiation. *Semin Radiat Oncol*. 2009; 19(1): 3–10, doi: 10.1016/j.semradonc.2008.09.002, indexed in Pubmed: 19028339.
30. Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. *Semin Radiat Oncol*. 2009; 19(1): 63–68, doi: 10.1016/j.semradonc.2008.09.009, indexed in Pubmed: 19028347.
31. Brizel DM, Geiger JL. Locally advanced squamous carcinoma of the head and neck. In: Perez & Brady's Principles and Practice of Radiation Oncology VII ed. Wolters Kluwer, Philadelphia 2019: 885–898.
32. Manon RR, Myers JN, Harari PM. Oral cavity. In: Perez & Brady's Principles and Practice of Radiation Oncology VII ed. Wolters Kluwer, Philadelphia 2019: 975–1004.
33. Salama JK, Brizel DM. Oropharynx. In: Perez & Brady's Principles and Practice of Radiation Oncology VII ed. Wolters Kluwer, Philadelphia 2019: 1005–1025.
34. Dragun A. Altered fractionation schedules. In: Perez & Brady's Principles and Practice of Radiation Oncology VII ed. Wolters Kluwer, Philadelphia 2019: 308–328.
35. Mendenhall WM, Mancuso AA, Amdur RJ, et al. Laryngeal cancer. In: Perez & Brady's Principles and Practice of Radiation Oncology VII ed. Wolters Kluwer, Philadelphia 2019: 1043–1062.
36. Joiner M, van der Kogel A. Clinical radiobiology. IV ed. Hodder Arnold ab Hachette UK Comp., London 2009: 1–55.
37. Brizel DM, Geiger JL. Locally advanced squamous carcinoma of the head and neck. In: Perez & Brady's Principles and Practice of Radiation Oncology VII ed. Wolters Kluwer, Philadelphia 2019: 885–898.
38. Suit H. The Gray Lecture 2001: coming technical advances in radiation oncology. *Int J Radiat Oncol Biol Phys*. 2002; 53(4): 798–809, doi: 10.1016/s0360-3016(02)02851-1.
39. List MA, Bilir SP. Functional outcomes in head and neck cancer. *Semin Radiat Oncol*. 2004; 14(2): 178–189, doi: 10.1053/j.semradonc.2003.12.008, indexed in Pubmed: 15095263.
40. Glatstein E. Personal thoughts on statistics, or lies, damn lies, and (oncologic) statistics. *Int J Radiat Oncol Biol Phys*. 2004; 58(5): 1329–1333, doi: 10.1016/j.ijrobp.2003.11.034, indexed in Pubmed: 15050306.
41. Glatstein E. The return of the snake oil salesmen. *Int J Radiat Oncol Biol Phys*. 2003; 55(3): 561–562, doi: 10.1016/s0360-3016(02)04204-9, indexed in Pubmed: 12573740.
42. Ho KF, Fowler JF, Sykes AJ, et al. IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult. *Acta Oncol*. 2009; 48(3): 431–439, doi: 10.1080/02841860802372272, indexed in Pubmed: 18781445.
43. Withers HR. Biological aspects of conformal therapy. *Acta Oncol*. 2000; 39(5): 569–577, doi: 10.1080/028418600750013258, indexed in Pubmed: 11093365.
44. Celejewska A, Maciejewski B, Wydmański J, et al. The efficacy of IORT (intraoperative radiotherapy) for early advanced breast cancer depending on the time delay of external beam irradiation (EXRT) post conservative breast surgery (CBS). *Nowotwory. Journal of Oncology*. 2021; 71(3): 133–138, doi: 10.5603/njo.a2021.0019.
45. Maciejewski B, Maciejczyk A. Individually personalized radiotherapy vs. evidence (trials) based standards – paradigms and dilemmas. *Nowotwory. Journal of Oncology*. 2021; 71(5): 296–302, doi: 10.5603/njo.a2021.0049.

Methotrexate-associated oral mucositis in children with acute lymphoblastic leukemia

Ewa Pustelnik¹ , Katarzyna Pikora¹ , Katarzyna Pawelec² 

¹Infant Jesus Clinical Hospital of the University Clinical Center, Medical University of Warsaw, Warsaw, Poland

²Department of Oncology, Pediatric Hematology, Clinical Transplantology and Pediatric, University Clinical Center, Medical University of Warsaw, Warsaw, Poland

Methotrexate is an antifolate widely used in oncology and rheumatology that plays an important role in the treatment of acute lymphoblastic leukemia in children. One of its most common side effects is oral mucositis, which is a general term for ulceration and inflammation of the mucous membrane of the mouth. It can severely affect a patient's quality of life, causes poor nutrition, and may lead to discontinuation of the next course of chemotherapy. Oral mucositis typically develops a few days after chemotherapy infusion. Due to this risk, it appears reasonable to use preventive agents against oral mucositis before the inclusion of methotrexate in therapy. To date, clinical trials have examined the effectiveness of medications such as glutamine, palifermin, chlorhexidine, amifostine, cyclooxygenase-1 inhibitor, leucovorin or other methods including laser therapy and oral cryotherapy. There are also several methods used to control already established inflammation and reduce pain more effectively: laser therapy, platelet-rich plasma and platelet gel, taxifolin, film-forming and coating agents. A crucial role is played by supportive interventions involving analgesic treatment, including topical morphine and benzydamine and a modern approach to pain management – for example, the use of virtual reality.

Key words: leukemia, methotrexate, chemotherapy, oral mucositis

Introduction

Acute lymphoblastic leukemia (ALL) is the most common malignant tumor in the pediatric population while it accounts for only 2% in adults [1]. Of all childhood cancers, leukemia accounts for about 26%, and ALL is the most common (about 85% of all leukemias) [2]. Intensive chemotherapy still regimens the first line of treatment of acute leukemia. However, it is not without adverse effects. The most frequent are pancytopenia, infectious disease and organ toxicity. Table I presents the side effects of frequently-used chemotherapy.

Methotrexate (MTX), an antifolate agent, is one of the most widely used and frequently studied drugs in various malignancies including leukemia and plays a crucial role in treating ALL in children. According to protocol AIEOP-BFM-2017, children

in low-risk and intermediate-risk groups receive four 24 h infusions of high-dose methotrexate (HD-MTX) during Protocole M. Children in the high-risk group receive HD-MTX during the first and second HR block. All of the children receive methotrexate at a dose 20 mg/m² once a week during maintenance therapy [11].

Pathogenesis of methotrexate toxicity

Methotrexate is a folate antagonist – it inhibits dihydrofolate reductase (DHFR). This enzyme reduces folic acid to tetrahydrofolic acid. Tetrahydrofolate has to be built up by a DHFR-catalyzed reaction. Inhibition of DHFR by methotrexate results in a deficiency of thymidylate and purines and then a decrease in nucleic acid synthesis, which leads to inhibited cells division.

Jak cytować / How to cite:

Pustelnik E, Pikora K, Pawelec K. *Methotrexate-associated oral mucositis in children with acute lymphoblastic leukemia*. NOWOTWORY J Oncol 2023; 73: 294–302.

Table I. Common side effects of widely used chemotherapeutic drugs

Medication	Adverse effect
vinca alkaloids (e.g. vincristine) [3]	neurotoxicity (peripheral neuropathy), constipation
cyclophosphamide [4, 5]	hemorrhagic cystitis, early-onset pneumonitis, pulmonary pneumonitis
methotrexate [6, 7]	hepatic toxicity, gastrointestinal toxicity, skin and mucosa toxicity, nephrotoxicity
cytarabine [8]	ocular toxicity (corneal pain, keratoconjunctivitis, blurred vision), maculopapular rash, bone pain
PEG-asparaginase [9]	thrombosis, pancreatitis, hyperglycemia, and hepatotoxicity
anthracyclines (e.g. doxorubicin, daunorubicin) [10]	cardiomyopathy

Methotrexate acts mainly in the “S” phase in a cell cycle, and is therefore appropriate for leukemias and lymphomas. Cytotoxic MTX occurs mainly in rapidly multiplying cells such as epithelial. These cells are susceptible to the effects of cytotoxic therapy because they undergo rapid turnover, usually every 7 to 14 days [13]. In addition, this effect can be exacerbated by bacterial or fungal infections, especially during neutropenia, which is relatively common in children with ALL.

For MTX, transport is essential to generate a sufficient quantity of intracellular drug to maximally inhibit DHFR and to provide a substrate for the synthesis of MTX polyglutamyl derivatives required for cellular drug retention as well as sustaining antitumor effects [14]. MTX enters cells through an active transporter called reduced folate carrier (RFC), a gene located on chromosome 21q22 [15]. In Down syndrome (DS), each somatic cell has an extra copy of this chromosome, resulting in an accumulation of MTX in the form of MTX polyglutamate [16]. This explains the severe toxicity of MTX in patients with DS, especially in the gastro-intestinal tract. After receiving a high-dose of 5 g/m² of MTX (HD-MTX), patients with DS showed significantly higher rates of severe leukopenia, thrombocytopenia, infections and oral mucositis compared to patients without DS, who received the same dose [17]. Knowing how the metabolism of MTX differs in children with DS, HD-MTX is administered differently in DS. According to the AIEOP-BFM-2017 protocol, children with DS receive a reduced dose of 0.5 g/m² of MTX, and then, if there is no severe toxicity, the dose is increased to 2 g/m² and finally 5 g/m² [10]. It is important to emphasize that children with DS who receive lower doses of MTX do not have a higher risk of relapse than children without DS who receive high-dose MTX. Moreover, among children with DS, there is no significant difference in the risk of relapse between children who received a first dose of MTX 0.5 g/m² and children who received MTX at a dose of 5 g/m² [18].

Methods of prevention

As mentioned, the use of methotrexate in treating ALL can cause a number of side effects, including oral mucositis with varying degrees of severity. This is a frequent complication, often contributing to a significant decrease in the patient's

quality of life due to pain and difficulties with oral intake of solid foods and liquids [19]. Considering the risk of its occurrence, it is already advisable to use preventive agents against stomatitis before including methotrexate in therapy. It is not possible to achieve one-hundred percent efficacy in preventing oral mucositis (OM), but there is a chance of decreasing its occurrence and alleviating its course in ALL patients.

Glutamine

Glutamine is one of a group of conditionally essential amino acids, especially under conditions of catabolic stress, when glutamine consumption by the kidney, gastrointestinal tract and immune system compartment increases rapidly. These observations reflect the dependence of growing cancer cells on glutamine, with some cancer cells dying promptly while being deprived of glutamine [20]. On the other hand, glutamine can regulate the inflammatory response and immune balance, reduce intestinal damage, maintain the intestinal mucosal barrier and reduce the translocation of the microbiota of the intestine [21]. From an analysis of the available literature, it was concluded that oral glutamine supplementation may be reasonable for the prevention of OM.

Gaurav et al. summarized the metabolism and therapeutic applicability of glutamine on animal models. They reported that this substance reduces the immunosuppressive effect of MTX, reducing the incidence of side effects including the inflammation of mucous membranes, especially the intestinal epithelium, as well as the oral cavity [22]. Another study compared the effectiveness of parenteral glutamine in patients with ALL receiving HD-MTX in consolidation therapy. In the study group, glutamine administration was initiated within 48 h of the start of chemotherapy and continued for 3 days. It was found that the incidence of OM was considerably lower in this group than in the control group, in which patients did not receive glutamine. There was no severe oral mucositis in any patient in the study group. Moreover, no severe adverse reactions related to glutamine administration were reported [23]. Widjaja et al. conducted a similar study, but in the study group, they included oral glutamine 24 h before HD-MTX administration and continued its administration for 14 days.

As a result, oral mucositis occurred in 4.2% in the glutamine group and 62.5% in the group receiving the placebo. Additionally, the duration of hospitalization of children taking glutamine was significantly shorter. That leads to the conclusion that glutamine may be an effective and safe adjunct in the future for preventing mucositis during MTX chemotherapy [24].

Palifermin

Palifermin is a recombinant human keratinocyte growth factor (KGF) with cytoprotective effects. It has been shown to stimulate epithelial cell proliferation in many tissues of the organism. It binds to specific receptors on the surface of cells that line the mouth, stomach and intestines. This potentially may help protect healthy tissues from certain side effects caused by certain types of cancer treatment [25].

One research study from 2016 investigated the efficacy of palifermin in preventing oral mucositis in children with ALL by intravenous administration 3 days before and 3 days after chemotherapy. Children in the study group had significantly less frequent and less severe mucositis (none had WHO grade III or IV mucositis) [26]. The clinical study by Schmidt et al. examined pediatric patients with ALL who developed severe oral mucositis (WHO grade III–IV) at the first stage of therapy. They were then administered palifermin with subsequent similar cycles of chemotherapy. The incidence of mucositis decreased significantly, and its duration shortened. This confirmed the hypothesis that palifermin could reduce the incidence, severity and duration of OM in HD-MTX-based chemotherapy and have a beneficial effect on patients' quality of life [27].

Laser therapy

Low-level laser therapy (LLLT), also known as photobiomodulation therapy (PBMT), is a non-invasive method of preventing and treating mucositis by applying a high-density monochromatic narrow-band light source of varying wavelengths (630–830 nm) to the mucosa. The proven clinical efficacy of PBMT in preventing mucositis has led to its increasing use in pediatric oncology [28]. Several studies have been published demonstrating the effectiveness of prophylactic laser therapy in children with ALL undergoing MTX treatment. One of them retrospectively examined the association of OM with PBMT in several pediatric oncology disease entities. MTX was the second most frequent cause of OM. PBMT significantly reduced the severity and incidence of OM in patients with ALL [29]. A study by de Castro et al. compared the course of chemotherapy treatment in patients using prophylactic oral laser therapy and laser therapy included only after the onset of OM symptoms. Summarizing the results, laser therapy has been proven effective in the treatment and prevention of OM, but prophylactic treatment resulted in better clinical outcomes at the end of treatment [30].

In contrast, another study compared the clinical outcomes of pediatric oncology patients receiving or not receiving pro-

phylactic lasotherapy. Tests on a group of 60 patients indicated no evidence of benefit from such treatment in children with chemotherapy-treated malignancy, especially when optimal dental and oral care was ensured [31].

Chlorhexidine

Chlorhexidine is an antiseptic solution used topically for various purposes, such as preoperative skin preparation, hand washing, vaginal antisepsis or treatment of gingivitis. It has broad spectrum activity against gram-positive and gram-negative bacteria, facultative anaerobes and aerobes, yeasts and certain lipid-bound viruses [32]. In view of this microbial-destroying effect, an attempt was made to implement chlorhexidine in the prevention of oral mucositis in oncology patients.

In the first trial, 0.12% chlorhexidine gluconate was administered to a study group of children with ALL for 10 days after each MTX infusion. Among these patients, a quarter developed grade I OM. In the control group, signs of inflammation appeared in 80% and were more severe [33]. A similar study was conducted among patients at a Brazilian Medical Center, with comparable results – a significant reduction in the incidence of OM was noted in children who received 0.12% chlorhexidine mouthwash during intensive chemotherapy [34]. Soares et al. conducted a study evaluating clinical and microbiological changes in the oral mucosa of children with ALL during chemotherapy and after prophylactic use of chlorhexidine. Only five children developed features of OM, and microbiological tests resulted in a reduced number of pathogenic microorganisms, including coagulase-negative staphylococci, *Candida albicans*, *E. coli* and *Stenotrophomonas maltophilia*. No control group was formed in the study [35]. The results presented above suggest that systematic prophylactic treatment with the chlorhexidine compound and careful attention to oral hygiene reduce the incidence of oral complications in children with ALL undergoing antineoplastic chemotherapy.

Other

A few single reports on other medical agents were also found, which may in future provide a basis for expanding research on their effectiveness in preventing OM.

Leucovorin is a derivative of folic acid used in the treatment of methotrexate toxicity and chemotherapy regimens [36]. The administration of leucovorin during MTX treatment increases cellular folate levels, so it has been hypothesized that this may further contribute to the reduced incidence of OM after subsequent courses of MTX [37].

In pathogenesis, methotrexate-induced oral mucositis is thought to develop through epithelial damage by reactive oxygen species, disruption of cell growth and apoptosis or necrosis. This exposes the mucous membranes to oral infections caused by bacteria and fungi. The administration of MTX leads to an increase in oxidative stress and, consequently, cytotoxicity [38]. A study by Maiguma et al.

examined the prophylactic use of a free radical scavenger (amifostine) and a cyclooxygenase-1 inhibitor as a disruptor of hydroxyl radical production. From an electron spin resonance study, it was found that methotrexate-induced cell damage was restored by amifostine and cyclooxygenase-1 inhibitor, and it was suggested that they may be useful protective agents against the chemotherapeutic toxicity of this drug [39].

The last preventive method suggested will be cryotherapy, which involves patients holding ice-chips in their mouths continuously during chemotherapy. No scientific studies have been found proving the efficacy of this method for MTX treatment, but several research papers have demonstrated its effectiveness against other chemotherapeutics, such as 5-FU or mephalan, and during conditioning before HSCT. It is assumed that ice causes local vasoconstriction, which reduces drug delivery to the oral mucosa tissues and therefore reduces the risk of OM. In the cited studies, patients in the study group developed severe OM less often, required less intensive and shorter analgesic treatment, and avoided the need for TPN. This leads to the hypothesis that it is advisable to conduct further randomized studies examining the beneficial effects

of cryotherapy on OM caused also by other medications, including MTX [40–43].

Clinical picture

MTX-associated oral mucositis typically develops a few days after chemotherapy. Symptoms are varied, ranging from mild soreness in the mouth to severe symptoms requiring total parenteral nutrition. The most common symptom is pain requiring analgesics. Other symptoms include: burning sensation in the mouth, difficulty swallowing leading to cessation of water and food intake. Changes in the oral mucosa develop from redness to ulcers. Due to pancytopenia after chemotherapy, bleeding from the ulcers may occur [44]. According to the WHO toxicity grading scale there are four grades of presence of oral mucositis:

- I. oral soreness, erythema,
- II. oral erythema, ulcers,
- III. oral ulcers, only liquids intake (due to the mucositis),
- IV. oral ulcers, oral alimentation impossible (due to the mucositis) [45].

In the next figures (fig. 1–8) four grades of MTX-oral mucositis in children with ALL are presented. The source of all the photographs is the authors



Figure 1. Oral mucositis grade I: erythema can be seen on the soft palate and upper labia; the patient complained of soreness on swallowing



Figure 2. Oral mucositis grade II: erythema and ulcers can be seen in the labias



Figure 3. Oral mucositis grade II: erythema and ulcers can be seen in the buccal mucosa



Figure 4. Oral mucositis grade III: ulcers with extensive erythema can be seen



Figure 5. Oral mucositis grade III: ulcers with extensive erythema can be seen. Only liquid food intake



Figure 6. Oral mucositis grade IV: generalized ulcers, erythema. Bleeding from the labias. Nourishing was no longer possible for this patient. Total parenteral nutrition was started



Figure 7. Oral mucositis grade IV: generalized ulcers, erythema, leukemia



Figure 8. Oral mucositis grade IV: generalized ulcers, erythema, leukemia. yellow coating after antifungals

Treatment of oral mucositis

A completely effective method of treating OM after chemotherapy has not been developed to date. There are several medications used to manage inflammation and reduce pain more quickly, as further described below. However, none provide certain efficacy and they are not widely published in treatment protocols. Therapeutic management is therefore based on agents that regenerate the oral mucosa and reduce inflammation. In addition, supportive treatment in the form of analgesics, antibacterials, antifungals, dietary modification, including total parenteral nutrition, and changes in oral hygiene are practiced.

Laser therapy

Different biological effects have been described to explain the mechanism of laser therapeutic efficacy: increased collagen production, the activation of energy production in the mitochondria, the detoxification of free radicals, the proliferation of fibroblast cells and stimulation of angiogenesis [28]. The literature examining the efficacy of LLLT in treating OM in a population of children with ALL was analyzed by the authors.

The first cited randomized clinical trial was conducted by Reyad et al. on a group of 14 patients. The study group was undergoing treatment with PBMT in addition to standard symptomatic therapy. There was a significant reduction in the severity of pain on the 10th day of treatment and a reduction in the degree of OM on the 14th day of treatment compared to the control group [46]. Another trial compared the use of LLLT or placebo in cancer patients receiving chemotherapy or hematopoietic stem cell transplantation; 86% of the participants were leukemia patients. In the laser-treated group, the average duration of OM to resolution of clinical symptoms was significantly shorter [47]. Other clinical studies by Cauwels et al., Karaman et al. and Fiwek et al. conducted similar clinical proceedings to those presented earlier. All obtained results confirmed that the use of PBMT reduces pain and discomfort in patients and has a positive effect on the severity and duration of OM [48–50].

Platelet-rich plasma and platelet gel

Platelet-rich plasma (PRP) contains a platelet concentration five times higher than the baseline, cytokines, growth factors,

adhesion molecules, a certain amount of red blood cells (RBCs) and white blood cells (WBCs) depending on the preparation method. It is obtained from fresh peripheral blood with a platelet concentration above the baseline value [51]. Platelet gel (PG) is derived from PRP and consists of platelet concentrate (PC) deposited in a semisolid network of polymerized fibrin. The biological reasoning behind the use of PRP and PG in regenerative medicine is related to the degranulation of platelets, allowing the release of growth factors, reducing the inflammatory response and promoting cell proliferation and differentiation in the targeted tissue. Use of PRP has broadened considerably to encompass many fields of medicine, including dermatology, orthopedics, surgery, sports medicine, aesthetic medicine and dentistry [52]. Some reports have also been published about the efficacy of these agents in reducing neuropathic and neurological pain associated with injuries. The use of platelet concentrates accelerates the healing of surgical wounds, skin ulcers, lesions typical of diabetic foot and chronic mucositis, as well as muscle and tendon repair [53].

Within the last few years, there has also been an attempt to use this agent in the field of oncology, including pediatrics. Piccin et al. examined the effectiveness of PG in treatment of severe oral and esophageal mucositis in an adult patient undergoing auto-HSCT for non-Hodgkin lymphoma. The patient self-administered the preparation in her oral cavity. A significant improvement in mucositis and pain was noted after only 3 days of consecutive use. On day 8, the inflammation was found to have regressed. No side effects of the preparation were observed [54]. Another study described a five-year-old girl with rhabdomyosarcoma undergoing intensive chemotherapy who developed stage IV OM with severe pain and fever during the second course of treatment. She was treated with antimicrobial drugs, analgesics, chlorhexidine and oral rinses, but no improvement was observed after three days of therapy. The decision was made to start a thrice-daily oral application of platelet gel. After just 12 h, significant improvement in mucosal condition was observed, and two days later the patient did not require analgesic treatment, was able to receive oral nutrition, continue chemotherapy treatment, and the oral ulcers were progressively improving [55].

Picardi et al. conducted a study on an Italian group of patients affected by hematologic malignancies and who after allo-HSCT developed cGvHD with oral involvement in the form of painful ulcers and impaired oral nutrition. Limited oral ulceration cGvHD was treated with PG alone, while the most extensive cGvHD received PG in combination with steroids. The results indicated that all patients treated with PG achieved rapid improvement in oral pain and food intake after just 2 applications of the gel. The absence of ulcer recurrence at the site of previous platelet gel application proves that its growth factor-rich content makes it a viable tool for maintaining long-term tissue repair [56]. The 2021 clinical trial studied the effectiveness of platelet gel in children with stage II and III OM

during chemotherapy. In the study group, PG was applied to mucosal lesions four times a day in addition to standard treatment including analgesics, antimicrobials, and oral rinses. In almost all patients, the application of PG provided relief, reduced pain and decreased any burning sensation after the first day of application. In addition, there was a significant improvement in the appearance of the mucous membranes and regression of the inflammatory lesions within 4–5 days [57].

Other

There are several other individual, insufficiently researched ideas and treatments for OM. Additional scientific studies reporting innovative treatment attempts are presented and summarized hereafter.

Taxifolin is a bioactive flavonoid found commonly in grapes or olive oil, among others, with well-established pharmacological effects, including having anti-inflammatory, antioxidant properties, and also antimicrobial and anticancer potential. It reduces oxidative stress, modulates signaling pathways to prevent apoptosis and decreases the expression of pro-inflammatory cytokines [58, 59]. Bayramoglu et al. conducted a study on MTX-treated rats, administering taxifolin by gavage. The oral mucosa was subsequently analyzed macroscopically, histopathologically and biochemically. It was found that taxifolin antagonized the MTX-induced increase in oxidative and pro-inflammatory factors and decrease in antioxidant properties in the internal tissues of the cheek and tongue. Taxifolin also significantly reduced histopathological damage induced by MTX administration. The results suggest that taxifolin may be useful in the treatment of MTX-induced oral mucositis [60].

Film-forming or coating agents might also be useful for the treatment of established mucositis. These include sucralfate and hydroxypropyl cellulose, whose efficacy in reducing OM has been clinically studied. An initial randomized clinical trial reported good outcomes in reducing the severity of OM in a patient population treated with chemotherapy (5-fluorouracil) after treatment with sucralfate. However, a subsequent double-blind phase III study did not support the hypothesis from the initial study, as there were no differences in the severity or duration of inflammation between the study and placebo group [61]. Hydroxypropyl cellulose is a bioadhesive substance that can function as a protective barrier over mucosal ulceration enabling pain relief and improved healing. The study group included chemotherapy-treated patients with symptoms of OM. After application of the gel with hydroxypropyl cellulose and benzocaine hydrochloride, oral pain and discomfort were assessed using a visual analog scale (VAS) and visual assessments of the amount of drug that remained on the mucosal lesions. Benzocaine hydrochloride, combined with a protective, mucoadhesive film coating, alleviated discomfort even with exposure to an irritating beverage. This indicates that the administered treatment may enable patients with OM to drink and eat with significantly reduced

or no pain. However, the results are difficult to interpret due to the use of a gel combining two active substances in the study group [13, 62].

Pain management

Pain may be the only symptom of OM, although it is usually the first of many. The crucial issue remains to control it effectively, as severe pain impairs food and drink intake, which may result in malnutrition and mineral deficiencies. In addition to the classic analgesic ladder approach in children, additional less-known pain management methods are presented, including topical analgesics and the use of virtual reality.

Topical morphine

The use of non-opioid topical analgesics can reduce the dose of systemic opioids. Compared to their administration, topical morphine has been shown to have even more beneficial effects. These include simplicity of use, low cost and minimal systemic side effects. The benefits are not only related to pain relief. There is also some evidence that opioid receptors are expressed on oral epithelial cells and morphine may accelerate cell migration, which in turn can enhance the wound healing process. Topical morphine is applied as a solution to swish and spit. There have been studies on the selection of the most effective percentage solution. Sarvizadeh et al. reported that 2% morphine was effective in reducing the severity of OM. However, its use with a pediatric population suffering from ALL is unknown. MASCC/ISOO suggest 0.2% topical morphine mouthwash for the treatment of OM-associated pain in head and neck cancer patients treated with RTX/CTX [63, 64].

Benzydamine

Benzydamine is a local anti-inflammatory drug that also has analgesic properties. It is an inhibitor of leukocyte-endothelial interactions, neutrophil degranulation, vasodilation and vascular permeability. It also reduces the synthesis of TNF- α , IL-1 β and prostaglandins [65]. Although it is widely used in radiotherapy-induced OM, there is still no strong evidence for its use in hematologic malignancies. However, given that it is feasible, inexpensive and frequently administered in pediatrics, more studies are needed in children with ALL [66].

Virtual reality

Virtual reality (VR) is a feasible, non-pharmacological method of distraction and adjustment to conventional pain management. VR is a digital simulation. It can be either immersive (IVR) or non-immersive, depending on the patient's point of view and the experience created during use. Non-immersive VR allows content to be viewed through traditional graphical displays, such as a TV or smartphone, while IVR includes head-mounted glasses and motion tracking systems. This allows full immersion to be attained. VR distraction has the potential to manage pain and anxiety in children with hematological cancers [67].

Virtual reality can be used for more than just the management of chronic pain associated with malignant disease. It has been tested in patients undergoing painful procedures, such as burn wound care, with the following results: reduced pain scores and decreased use of opioids [68]. The aforementioned results indicate that this use of virtual reality may prove helpful during the treatment of children with oral mucositis. This distraction and diversion may be particularly important during procedures that increase a child's pain sensation associated with oral interventions, which include physical examination, mouth rinsing or application of topical medications.

Conclusions

Methotrexate, an antifolate agent, is one of the most widely used drugs in various malignancies and plays a crucial role in treating ALL in children. Patients with Down syndrome have an extra copy of the gene responsible for encoding the transporter for methotrexate, resulting in a significant increase in the toxicity of the drug in this group. One of the most frequent side effects following its administration is inflammation of the mucosa, including the oral cavity. Clinical trials have evaluated the effectiveness of medications such as glutamine, palifermin, chlorhexidine, amifostine, cyclooxygenase-1 inhibitors, leucovorin, or other methods including laser therapy and oral cryotherapy in preventing OM. Typically, oral mucositis develops a few days after chemotherapy. Symptoms are varied, ranging from mild soreness in the mouth to erythema, ulcers and severe pain. There are several methods used to control established inflammation and reduce pain more effectively: laser therapy, platelet-rich plasma and platelet gel, taxifolin, film-forming and coating agents. Crucial support is offered by interventions involving analgesic treatment, including topical morphine and benzydamine and a more recent approach based on virtual reality, for example.

Article information and declarations

Author contributions

Katarzyna Pawelec – conceptualization, review and editing. Ewa Pustelnik, Katarzyna Pikora – methodology, formal analysis, investigation, original draft preparation.

Funding

None declared

Conflict of interest

None declared

Ewa Pustelnik

*Medical University of Warsaw
Infant Jesus Clinical Hospital of the University Clinical Center
ul. Lindleya 4
02-005 Warszawa, Poland
e-mail: ewa.pustelnik1994@gmail.com*

References

- Wojciechowska U, Barańska K, Miklewska M, et al. Cancer incidence and mortality in Poland in 2020. *Nowotwory. Journal of Oncology*. 2023; 73(3): 129–145, doi: 10.5603/njo.2023.0026.
- Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. *CA Cancer J Clin*. 2014; 64(2): 83–103, doi: 10.3322/caac.21219, indexed in Pubmed: 24488779.
- Brigo F, Balter R, Marradi P, et al. Vincristine-related neuropathy versus acute inflammatory demyelinating polyradiculoneuropathy in children with acute lymphoblastic leukemia. *J Child Neurol*. 2012; 27(7): 867–874, doi: 10.1177/0883073811428379, indexed in Pubmed: 22241706.
- Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. *Arthritis Rheum*. 2010; 62(1): 9–21, doi: 10.1002/art.25061, indexed in Pubmed: 20039416.
- Malik SW, Myers JL, DeRemee RA, et al. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. *Am J Respir Crit Care Med*. 1996; 154(6 Pt 1): 1851–1856, doi: 10.1164/ajrccm.154.6.8970380, indexed in Pubmed: 8970380.
- Campbell JM, Bateman E, Stephenson MD, et al. Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. *Cancer Chemother Pharmacol*. 2016; 78(1): 27–39, doi: 10.1007/s00280-016-3043-5, indexed in Pubmed: 27142726.
- Wiczter T, Dotson E, Tuten A, et al. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. *J Oncol Pharm Pract*. 2016; 22(3): 430–436, doi: 10.1177/1078155215594417, indexed in Pubmed: 26152702.
- Di Francia R, Crisci S, De Monaco A, et al. Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers. *Cancers (Basel)*. 2021; 13(5), doi: 10.3390/cancers13050966, indexed in Pubmed: 33669053.
- Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. *Clin Adv Hematol Oncol*. 2009; 7(9): 600–606, indexed in Pubmed: 20020672.
- Mancilla TR, Iskra B, Aune GJ. Doxorubicin-Induced Cardiomyopathy in Children. *Compr Physiol*. 2019; 9(3): 905–931, doi: 10.1002/cphy.c180017, indexed in Pubmed: 31187890.
- AIEOP-BFM ALL 2017 International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia. A randomized phase III study conducted by the AIEOP-BFM study group. Protocol version 1.3 (date 01.02.2018).
- Naidu MU, Ramana GV, Rani PU, et al. Chemotherapy-induced and/or radiation therapy-induced oral mucositis—complicating the treatment of cancer. *Neoplasia*. 2004; 6(5): 423–431, doi: 10.1593/neo.04169, indexed in Pubmed: 15548350.
- Adam de Beaumais T, Jacqz-Aigrain E. Pharmacogenetics: Applications to Pediatric Patients. *Adv Pharmacol*. 2018; 83: 191–215, doi: 10.1016/b.s.apha.2018.04.006, indexed in Pubmed: 29801575.
- Mattherly LH, Wilson MR, Hou Z. The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer. *Drug Metab Dispos*. 2014; 42(4): 632–649, doi: 10.1124/dmd.113.055723, indexed in Pubmed: 24396145.
- Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. *Pediatr Blood Cancer*. 2005; 44(1): 33–39, doi: 10.1002/pbc.20092, indexed in Pubmed: 15390307.
- Kroll M, Kaupat-Bleckmann K, Mörickel A, et al. Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen. *Haematologica*. 2020; 105(4): 1013–1020, doi: 10.3324/haematol.2019.224774, indexed in Pubmed: 31371414.
- Alaama J, Ahmad M, Ahmad S, et al. Altered Metabolism in Down Syndrome. *Health Problems in Down Syndrome*. 2015, doi: 10.5772/60638.
- Sun Q, Xie Y, Zhao WH, et al. [Adverse effects of high-dose methotrexate therapy]. *Zhongguo Dang Dai Er Ke Za Zhi*. 2017; 19(7): 781–785, doi: 10.7499/j.issn.1008-8830.2017.07.010, indexed in Pubmed: 28697831.
- Altman BJ, Stine ZE, Dang CV, et al. From Krebs to clinic: glutamine metabolism to cancer therapy. *Nat Rev Cancer*. 2016; 16(10): 619–634, doi: 10.1038/nrc.2016.71, indexed in Pubmed: 27492215.
- Tang G, Pi F, Qiu YH, et al. Postoperative parenteral glutamine supplementation improves the short-term outcomes in patients undergoing colorectal cancer surgery: A propensity score matching study. *Front Nutr*. 2023; 10: 1040893, doi: 10.3389/fnut.2023.1040893, indexed in Pubmed: 37006941.
- Gaurav K, Goel RK, Shukla M, et al. Glutamine: A novel approach to chemotherapy-induced toxicity. *Indian J Med Paediatr Oncol*. 2012; 33(1): 13–20, doi: 10.4103/0971-5851.96962, indexed in Pubmed: 22754203.
- Chang YH, Yu MS, Wu KH, et al. Effectiveness of Parenteral Glutamine on Methotrexate-induced Oral Mucositis in Children with Acute Lymphoblastic Leukemia. *Nutr Cancer*. 2017; 69(5): 746–751, doi: 10.1080/01635581.2017.1324995, indexed in Pubmed: 28569624.
- Widjaja NA, Pratama A, Prihaningtyas R, et al. Efficacy Oral Glutamine to Prevent Oral Mucositis and Reduce Hospital Costs During Chemotherapy in Children with Acute Lymphoblastic Leukemia. *Asian Pac J Cancer Prev*. 2020; 21(7): 2117–2121, doi: 10.31557/APJCP.2020.21.7.2117, indexed in Pubmed: 32711440.
- Coutsouvelis J, Corallo C, Spencer A, et al. A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancy. *Crit Rev Oncol Hematol*. 2022; 172: 103606, doi: 10.1016/j.critrevonc.2022.103606, indexed in Pubmed: 35101586.
- Gholizadeh N, Mehdipoor M, Sajadi H, et al. Palifermin and Chlorhexidine Mouthwashes in Prevention of Chemotherapy-Induced Mucositis in Children with Acute Lymphocytic Leukemia: A Randomized Controlled Trial. *J Dent (Shiraz)*. 2016; 17(4): 343–347, indexed in Pubmed: 27942550.
- Schmidt E, Thoenissen NH, Rudat A, et al. Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. *Ann Oncol*. 2008; 19(9): 1644–1649, doi: 10.1093/annonc/mdn179, indexed in Pubmed: 18453519.
- Legouté F, Bensadoun RJ, Seegers V, et al. Low-level laser therapy in treatment of chemoradiotherapy-induced mucositis in head and neck cancer: results of a randomised, triple blind, multicentre phase III trial. *Radiat Oncol*. 2019; 14(1): 83, doi: 10.1186/s13014-019-1292-2, indexed in Pubmed: 31118057.
- Nunes LF, de Arruda JA, Souza AF, et al. Prophylactic photobiomodulation therapy using 660 nm diode laser for oral mucositis in paediatric patients under chemotherapy: 5-year experience from a Brazilian referral service. *Lasers Med Sci*. 2020; 35(8): 1857–1866, doi: 10.1007/s10103-020-03060-9, indexed in Pubmed: 32535807.
- de Castro JF, Abreu EG, Correia AV, et al. Low-level laser in prevention and treatment of oral mucositis in pediatric patients with acute lymphoblastic leukemia. *Photomed Laser Surg*. 2013; 31(12): 613–618, doi: 10.1089/pho.2012.3327, indexed in Pubmed: 24261310.
- Cruz LB, Ribeiro AS, Rech A, et al. Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy. *Pediatr Blood Cancer*. 2007; 48(4): 435–440, doi: 10.1002/pbc.20943, indexed in Pubmed: 16862549.
- Milstone AM, Passaretti CL, Perl TM. Chlorhexidine: expanding the armamentarium for infection control and prevention. *Clin Infect Dis*. 2008; 46(2): 274–281, doi: 10.1086/524736, indexed in Pubmed: 18171263.
- Pereira Pinto L, de Souza LB, Gordón-Núñez MA, et al. Prevention of oral lesions in children with acute lymphoblastic leukemia. *Int J Pediatr Otorhinolaryngol*. 2006; 70(11): 1847–1851, doi: 10.1016/j.ijporl.2006.04.016, indexed in Pubmed: 16914211.
- Costa EM, Fernandes MZ, Quinder LB, et al. Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. *Pesqui Odontol Bras*. 2003; 17(2): 147–150, doi: 10.1590/s1517-74912003000200009, indexed in Pubmed: 14569357.
- Soares AF, Aquino AR, Carvalho CH, et al. Frequency of oral mucositis and microbiological analysis in children with acute lymphoblastic leukemia treated with 0.12% chlorhexidine gluconate. *Braz Dent J*. 2011; 22(4): 312–316, doi: 10.1590/s0103-64402011000400009, indexed in Pubmed: 21861031.
- Rider B. Leucovorin. *xPharm: The Comprehensive Pharmacology Reference*. 2007; 1–4, doi: 10.1016/b978-008055232-3.62968-x.
- den Hoed MAH, Lopez-Lopez E, Winkel ML, et al. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. *Pharmacogenomics J*. 2015; 15(3): 248–254, doi: 10.1038/tpj.2014.63, indexed in Pubmed: 25348617.
- Babiak R, Campello A, Carnieri E, et al. Methotrexate: pentose cycle and oxidative stress. *Cell Biochemistry and Function*. 1998; 16(4): 283–293, doi: 10.1002/(sici)1099-0844(1998120)16:4<283::aid-cbf801>3.0.co;2-e.
- Maiguma T, Kaji H, Makino K, et al. Protective effects of amifostine and cyclooxygenase-1 inhibitor against normal human epidermal

- keratinocyte toxicity induced by methotrexate and 5-fluorouracil. *Basic Clin Pharmacol Toxicol*. 2009; 105(1): 1–9, doi: 10.1111/j.1742-7843.2009.00400.x, indexed in Pubmed: 19371262.
39. Lilleby K, Garcia P, Gooley T, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant*. 2006; 37(11): 1031–1035, doi: 10.1038/sj.bmt.1705384, indexed in Pubmed: 16633359.
 40. Aisa Y, Mori T, Kudo M, et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. *Support Care Cancer*. 2005; 13(4): 266–269, doi: 10.1007/s00520-004-0726-y, indexed in Pubmed: 15668755.
 41. Cascinu S, Fedeli A, Fedeli SL, et al. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. *Eur J Cancer B Oral Oncol*. 1994; 30B(4): 234–236, doi: 10.1016/0964-1955(94)90003-5, indexed in Pubmed: 7950836.
 42. Rocke L, Loprinzi C, Lee J, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. *Cancer*. 1993; 72(7): 2234–2238, doi: 10.1002/1097-0142(19931001)72:7<2234::aid-cnrcr2820720728>3.0.co;2-n.
 43. Bruya MA, Madeira NP. Stomatitis after chemotherapy. *Am J Nurs*. 1975; 75(8): 1349–1352, indexed in Pubmed: 1041191.
 44. World Health Organization: WHO Offset Publication. World Health Organization (1979).
 45. Reyad FA, Elsayed NM, El Chazli Y. Photobiomodulation for chemotherapy-induced oral mucositis in leukemic children: A randomized controlled clinical trial. *Oral Dis*. 2023; 29(5): 2239–2247, doi: 10.1111/odi.14217, indexed in Pubmed: 35460304.
 46. Kuhn A, Porto FA, Miraglia P, et al. Low-level infrared laser therapy in chemotherapy-induced oral mucositis: a randomized placebo-controlled trial in children. *J Pediatr Hematol Oncol*. 2009; 31(1): 33–37, doi: 10.1097/MPH.0b013e318192cb8e, indexed in Pubmed: 19125084.
 47. Cauwels RG, Martens LC. Low level laser therapy in oral mucositis: a pilot study. *Eur Arch Paediatr Dent*. 2011; 12(2): 118–123, doi: 10.1007/BF03262791, indexed in Pubmed: 21473845.
 48. Karaman K, Sarica A, Tunc SK, et al. Is Low-level Laser Therapy a Candidate to Be a Good Alternative in the Treatment of Mucositis in Childhood Leukemia? *J Pediatr Hematol Oncol*. 2022; 44(1): e199–e203, doi: 10.1097/MPH.0000000000002306, indexed in Pubmed: 34986132.
 49. Fiwek P, Emerich K, Irga-Jaworska N, et al. Photobiomodulation Treatment in Chemotherapy-Induced Oral Mucositis in Young Haematological Patients-A Pilot Study. *Medicina (Kaunas)*. 2022; 58(8), doi: 10.3390/medicina58081023, indexed in Pubmed: 36013491.
 50. Ban Y, Yang X, Xing Y, et al. Intrauterine Infusion of Leukocyte-Poor Platelet-Rich Plasma Is an Effective Therapeutic Protocol for Patients with Recurrent Implantation Failure: A Retrospective Cohort Study. *J Clin Med*. 2023; 12(8), doi: 10.3390/jcm12082823, indexed in Pubmed: 37109159.
 51. Sriram S, Hasan S, Alqarni A, et al. Efficacy of Platelet-Rich Plasma Therapy in Oral Lichen Planus: A Systematic Review. *Medicina (Kaunas)*. 2023; 59(4), doi: 10.3390/medicina59040746, indexed in Pubmed: 37109704.
 52. Piccin A, Di Pierro AM, Canzian L, et al. Platelet gel: a new therapeutic tool with great potential. *Blood Transfus*. 2017; 15(4): 333–340, doi: 10.2450/2016.0038-16, indexed in Pubmed: 27483482.
 53. Piccin A, Rebulli P, Pupella S, et al. Impressive tissue regeneration of severe oral mucositis post stem cell transplantation using cord blood platelet gel. *Transfusion*. 2017; 57(9): 2220–2224, doi: 10.1111/trf.14205, indexed in Pubmed: 28656652.
 54. Aielli F, Giusti R, Rugghetti A, et al. Rapid resolution of refractory chemotherapy-induced oral mucositis with platelet gel-released supernatant in a pediatric cancer patient: a case report. *J Pain Symptom Manage*. 2014; 48(5): e2–e4, doi: 10.1016/j.jpainsymman.2014.06.015, indexed in Pubmed: 25131890.
 55. Picardi A, Ferraro AS, Miranda M, et al. Therapeutic efficiency of platelet gel for the treatment of oral ulcers related to chronic graft versus host disease after allogeneic haematopoietic stem cell transplantation. *Oral Implantol (Rome)*. 2017; 10(4): 398–405, doi: 10.11138/orl/2017.10.4.398, indexed in Pubmed: 29682257.
 56. Albrecht K, Laguna P, Lachert E, et al. Efficacy of Platelet Gel in Children with Stomatitis during Chemotherapy. *Postepy Hig Med Dosw*. 2021; 75(1): 720–723, doi: 10.2478/ahem-2021-0019.
 57. Althunibat OY, Abukhalil MH, Jghaf MM, et al. Hepatoprotective effect of taxifolin on cyclophosphamide-induced oxidative stress, inflammation, and apoptosis in mice: Involvement of Nrf2/HO-1 signaling. *Biomol Biomed*. 2023; 23(4): 649–660, doi: 10.17305/bb.2022.8743, indexed in Pubmed: 36762432.
 58. Alaswad HA, Mahbub AA, Le Maitre CL, et al. Molecular Action of Polyphenols in Leukaemia and Their Therapeutic Potential. *Int J Mol Sci*. 2021; 22(6), doi: 10.3390/ijms22063085, indexed in Pubmed: 33802972.
 59. Bayramoglu Z, Mokhtare B, Mendil AS, et al. Effect of taxifolin on methotrexate-induced oxidative and inflammatory oral mucositis in rats: biochemical and histopathological evaluation. *J Appl Oral Sci*. 2022; 30: e20220115, doi: 10.1590/1678-7757-2022-0115, indexed in Pubmed: 36134855.
 60. Loprinzi CL, Ghosh C, Camoriano J, et al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. *J Clin Oncol*. 1997; 15(3): 1235–1238, doi: 10.1200/JCO.1997.15.3.1235, indexed in Pubmed: 9060567.
 61. LeVeque FG, Parzuchowski JB, Farinacci GC, et al. Clinical evaluation of MGI 209, an anesthetic, film-forming agent for relief from painful oral ulcers associated with chemotherapy. *J Clin Oncol*. 1992; 10(12): 1963–1968, doi: 10.1200/JCO.1992.10.12.1963, indexed in Pubmed: 1453210.
 62. Saunders DP, Rouleau T, Cheng K, et al. Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients and clinical practice guidelines. *Support Care Cancer*. 2020; 28(5): 2473–2484, doi: 10.1007/s00520-019-05181-6, indexed in Pubmed: 32052137.
 63. Sarvizadeh M, Hemati S, Meidani M, et al. Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer. *Adv Biomed Res*. 2015; 4: 44, doi: 10.4103/2277-9175.151254, indexed in Pubmed: 25789270.
 64. Nicolatou-Galitis O, Bossi P, Orlandi E, et al. The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis. *Support Care Cancer*. 2021; 29(10): 5701–5709, doi: 10.1007/s00520-021-06048-5, indexed in Pubmed: 33649918.
 65. Epstein J, Silverman S, Paggiarino D, et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis. *Cancer*. 2001; 92(4): 875–885, doi: 10.1002/1097-0142(20010815)92:4<875::aid-cnrcr1396>3.0.co;2-1.
 66. Comparcini D, Simonetti V, Galli F, et al. Immersive and Non-Immersive Virtual Reality for Pain and Anxiety Management in Pediatric Patients with Hematological or Solid Cancer: A Systematic Review. *Cancers (Basel)*. 2023; 15(3), doi: 10.3390/cancers15030985, indexed in Pubmed: 36765945.
 67. Hoffman HG, Richards TL, Van Oostrom T, et al. The analgesic effects of opioids and immersive virtual reality distraction: evidence from subjective and functional brain imaging assessments. *Anesth Analg*. 2007; 105(6): 1776–83, table of contents, doi: 10.1213/01.ane.0000270205.45146.db, indexed in Pubmed: 18042882.

The influence of fluid therapy on short- and long-term outcomes in patients undergoing liver resection for malignant indications

Marta Dec¹, Wojciech Figiel² , Paweł Andruszkiewicz¹, Michał Grąt²

¹2nd Department of Anaesthesiology and Intensive Care, Medical University of Warsaw, Warsaw, Poland

²Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland

Although fluid therapy in hepatic surgery affects the postoperative course and morbidity, there is a paucity of unequivocal guidelines in the literature as to which of three fluid strategies to use: liberal, restrictive or goal-directed. We performed a review of literature regarding fluid management strategies in major abdominal procedures, focusing on hepatic surgery. The quantity and quality of fluids infused perioperatively is often dependent on the preference of the physician, institutional experience and practices. A liberal fluid regimen carries the risk of impaired wound healing and prolonged ileus, furthermore in liver surgery it may increase blood loss. Restrictive fluid therapy is the mainstay of the anesthetic management in hepatic resections, keeping the central venous pressure low controls outflow from the liver and results in a decrease in intraoperative blood loss. In recent years, goal-directed fluid therapy (GDFT), as a component of enhanced recovery pathways after surgery (ERAS) programs, has gained in popularity. It is based on the concept of hemodynamic optimization in order to ensure optimal tissue perfusion and oxygen delivery. Furthermore, a fluid infusion strategy should be individualized in terms of the unique pathophysiology of the patient (e.g. cirrhosis) and the specific requirements of the surgical technique (laparoscopic procedures). Controversy regarding often contradictory data, leaves the clinician at a loss as to which fluid strategy will best serve the patient. Therefore, it is imperative to design and conduct clinical trials in a homogenous group of patients to define the optimal type and amount of fluid for patients undergoing hepatic surgery.

Key words: liver resection, fluid management, goal-directed therapy, restrictive therapy, enhanced recovery pathways after surgery

Fluid regimes in major abdominal surgery

Relevant articles were searched for using the Pubmed database with the following terms: “liver resection”, “liver surgery”, “goal-directed therapy”, “fluid management” and “enhanced recovery after surgery”. The results were independently assessed by the authors for scope and relevance.

Many factors influence the normal postoperative course of patients undergoing extensive liver surgery. One of those

is a fluid infusion strategy; preoperatively – in urgent cases – intraoperatively and in the postoperative period. Transfusion of the optimal fluid volume during surgical procedures and in the postoperative period affects the course of the operation, as well as postoperative morbidity. Both excessive and insufficient fluid intake can be harmful [1, 2]. The main goal is to restore and maintain fluid volume to ensure homeostasis in terms of euolemia, electrolyte balance and tissue perfusion.

Jak cytować / How to cite:

Dec M, Figiel W, Andruszkiewicz P, Grąt M. *The influence of fluid therapy on short- and long-term outcomes in patients undergoing liver resection for malignant indications.* NOWOTWORY J Oncol 2023; 73: 303–308.

[3]. Intra- and postoperative fluid transfusion strategies have been the subject of numerous studies. Both surgeons and anesthesiologists have different approaches to fluid management. The confirmation of the thesis that fluid therapy depends mainly on individual preferences of the physician is a study by Lilot et al., which included a group of 5,912 patients undergoing various abdominal procedures. The authors concluded that a patient weighing 75 kg can receive from 500 to 5400 ml of crystalloids depending on the physician's preference [4]. There are generally three main strategies of perioperative fluid therapy: "liberal", "restrictive" and "goal-directed". Each of these strategies has its supporters and opponents, and each has been the subject of randomized trials. After years of a "liberal" approach, a paper by Brandstrup et al. was published comparing "liberal" and "restrictive" strategies. The results of the study clearly indicated a statistically significant increase in the number of complications in the patients from the "liberal" group [5]. Over the following years, the "restrictive strategy" has gained popularity, as one of the components of the "enhanced recovery after surgery" (ERAS) protocols. In 2018, a multicenter study was published comparing the two strategies. The study included a group of 3,000 patients. One of the key results of the study was the finding of a statistically higher incidence of acute kidney injury in patients who received fluids according to restriction protocol [6].

The adopted perioperative fluid therapy strategies have been extensively studied especially in patients undergoing gastrointestinal procedures. Some researchers believe that excessive fluid loading impairs the healing of intestinal anastomoses, delays the return of gastrointestinal motility, increases the overall incidence of complications, increases the length of hospital stay and the cost of treatment [7–9]. While this is true in patients undergoing procedures on the large intestine [10], it has been shown that the use of restrictive fluid therapy does not bring such benefits in cases of pancreatoduodenectomy [11, 12]. With regards to abdominal surgery, it should be noted that the specificity of individual procedures (the number of intestinal anastomoses, the need to open the retroperitoneal space, the presence of vascular anastomoses) affects the movement of fluids between compartments. In order to recommend a "surgery specific" fluid strategy, studies should be carried out in homogeneous groups.

Evolution of aim-directed fluid protocols. Optimization of oxygen delivery to tissues

In addition to the restrictive and liberal strategies discussed so far, or rather, as a result of the inconclusive results of conducted studies, a third strategy named goal-directed therapy (GDT) was introduced.

This strategy was created not only in response to the contradictory results of studies on the previously mentioned liberal and restrictive strategies, but also stemmed from in-depth analysis of the pathophysiology of the phenomena leading to

increased number of complications, prolonged hospitalization and postoperative deaths in patients undergoing non-cardiac surgery. It was proven that intraoperative tissue perfusion (tissue blood flow), arterial oxygen saturation, hemoglobin concentration and cardiac output – components of the parameter referred to as oxygen tissue delivery (DO_2) – affect mortality and morbidity. The conducted studies have shown that perioperative fluid therapy, optimized on the basis of hemodynamic parameters significantly reduces the number of postoperative complications and the risk of death. At the same time, it has been shown that traditional parameters monitored intra- and postoperatively, i.e., blood pressure and heart rate, are not sensitive enough to detect moderate hypovolemia, which may cause inadequate tissue perfusion, especially in the visceral bed [13–15]. Goal-directed therapy is based on the premise that perioperative fluid administration is essential to maximizing DO_2 . Therefore, it should be based on dynamic flow-dependent parameters, i.e., stroke volume (SV) and its variability in response to fluid bolus (stroke volume variation – SVV) [16, 17]. The results of randomized trials, where the primary endpoint was the occurrence of postoperative complications (as in other studies evaluating the liberal and restrictive strategy) are contradictory. The FEDORA study showed a statistically significant lower complication rate in patients from the GDT group who underwent abdominal procedures [15]. However, the work of Pestania et al. (POEMAS study) showed no such relationship [18].

Concept of perioperative euvolemia

Most studies refer to intraoperative fluid administration. Some papers treat this topic more broadly and include the preoperative and postoperative period as well. The protocols regarding the intake of fluids before abdominal surgery clearly indicate the benefits of the lack of restrictions in oral administration up to 2 hours before the induction of anesthesia [19]. Postoperative fluid therapy should continue as long as the patient is unable to tolerate oral intake. Its primary goal is to maintain intravascular volume while avoiding a positive fluid balance which, among others, leads to delayed healing of the wounds and anastomoses, consequently leading to a longer hospital stay, prolonged ileus and other complications [20]. In recent years the term "goal-directed therapy" has been introduced in literature in relation to intraoperative infusions, and "zero balance" – in relation to postoperative management.

Fluid therapy in liver surgery

The incidence of liver tumors is on the rise [21]. Indications to liver resections are mainly oncological, with the majority of cases being hepatocellular carcinoma and metastatic tumors. The basic differences in the approach to intraoperative and postoperative fluid therapy in patients undergoing liver surgery will be presented below. Clinical situations related to patients who are hemodynamically unstable prior

to emergency surgery will be intentionally omitted. Septic patients, as well as those receiving total parenteral nutrition will not be discussed either. Thus, we will concentrate on fluid therapy in ASA ≤ 3 patients undergoing elective liver procedures.

Liver surgery can be divided into hepatic parenchymal surgery, biliary tract surgery and cholecystectomy. The aim is to discuss the strategy of intra- and postoperative fluid therapy in large (including excision of more than 3 segments) liver resections.

Limitation of blood loss in liver surgery

One of the key aspects of liver surgery is the bloodless surgical field. The inflow to the liver may be controlled, e.g. by the Pringle maneuver (a temporary tightening of the hepatoduodenal ligament). Back bleeding from valveless hepatic veins is prevented by low central venous pressure. CVP of 5 mmHg is recommended to provide unobstructed outflow and limit blood loss. It has been shown that maintaining low central venous pressure effectively reduces bleeding, limiting the need for blood product transfusions, morbidity and postoperative mortality. At the same time, it has been shown that it does not significantly affect the incidence of postoperative acute kidney injury [22–27].

Looking for a silver bullet in fluid management

Recently, the role of central venous pressure (CVP) as a reliable parameter for assessing volemia has been increasingly questioned. Hemodynamic parameters as guides to volume management have gained popularity, although analysis of the literature reveals that these methods also have limitations. Problematic situations include mechanical ventilation and cardiac arrhythmias to name a few [28].

Regardless of the monitoring methods used, the aim of the anesthetic technique is to maintain the free outflow of the blood through the hepatic veins. This is achieved by simultaneously employing several methods: fluid restriction, head-elevated patient positioning and ventilation techniques with pressure limitation in airways. Vasodilators (nitroglycerin) sublingually or intravenously are also used. It should be emphasized that these strategies are limited to the stage of parenchymal transection. Fluid infusion is being restricted to 1 ml/kg/h of buffered crystalloid plus additional volume to make up for the ongoing blood loss at a ratio 1:1. Intraoperative fluid therapy strategies are the subject of randomized trials. Correa-Galle et al. compared a conventional strategy with “goal-directed fluid therapy”. Randomization was performed after the resection stage. The “conventional” group received an infusion of crystalloid at a dose of 6 ml/kg/h. The “goal-directed” group received infusion at a rate of 1 ml/kg/h with the simultaneous supplementation of albumin solution with an aim to restore stroke volume variation (SVV) to the level measured at the induction of anesthesia. In both groups, additional fluid volume was administered to main-

tain systolic blood pressure ≥ 90 mmHg or diuresis > 25 ml/h. Red blood cell concentrate was also given to ensure hemoglobin concentration ≥ 7 g/dl. In the postoperative period, conventional fluid therapy of 1.2 ml/kg/h was used with additional infusion in order to maintain the above-mentioned targets. There was no statistically significant difference in terms of the incidence of postoperative complications, the length of hospital stay or other variables specified in the study. A statistically significant difference was observed in the total volume of fluids infused during the post-hepatectomy phase. In the “goal-directed” group it was lower by an average of 900 ml [29]. Another study by Weinberg et al. compared the addition of a fluid restrictive intraoperative cardiac output-guided algorithm to standard fluid protocol. The “conventional care” group consisted of patients in whom the amount of fluid and catecholamines administration were at the discretion of the anesthesiologist. In both groups a higher incidence of postoperative complications was found, compared to the previously cited study, and these were mainly grade I and II complications according to the Clavien-Dindo classification. This trial showed a statistically significant lower fluid balance in the study group compared to the control group. There were no differences in the incidence of acute kidney injury between the groups [30].

Studies conducted by Kim Y. et al. [31] and Lilot M. et al. [32] showed that despite the recommendations regarding intraoperative fluid therapy in patients undergoing abdominal procedures, including liver resections, there is a very large discrepancy regarding the amount of fluids administered between individual centers and even physicians. Hepatic resections are procedures that can significantly affect hemodynamics, e.g. by compressing the inferior vena cava during surgical maneuvers, which causes a decrease in venous return and consequently cardiac output. In addition, the liver because of its metabolic function, i.e., contributing to lactate clearance, affects the acid-base balance.

Taking into account these facts and the protocols of enhanced recovery after surgery (ERAS) [33], which recommend intraoperative fluid restriction but not at the cost of organ hypoperfusion, the following can be suggested: the most appropriate approach to perioperative fluid therapy in liver resections should be goal-directed therapy with fluid restriction until transection completion (low central venous pressure) with subsequent volemia restoration under SVV guidance. Indicators of organ perfusion, e.g. serum lactate concentration should be monitored and included in decision-making regarding fluid therapy in the postoperative period with the aim to stabilize hemodynamic parameters, maintain diuresis and improve metabolic hemostasis [34, 35].

In the postoperative period, methods based on techniques that assess the diameter of the inferior vena cava, its collapsibility, extensibility and the Doppler spectrum of the portal vein and hepatic veins can be used to guide fluid therapy [36, 37]. To date, there are no reports on the effectiveness of these methods in liver surgery.

There are no data concerning the impact of the applied fluid strategy on early and long-term prognosis in resections performed for oncological reasons. Restrictive and goal-oriented therapy facilitates visualization in the operating field, which may improve the radicality of the procedure. No studies have investigated the relation between the type of perioperative fluid regimen used as regards tumor recurrence risk. Further research in this direction is warranted.

Laparoscopic techniques

Laparoscopic liver resections have been gaining popularity. There are no randomized prospective studies comparing different strategies (liberal, restrictive and goal-directed) in resections performed laparoscopically. Nevertheless, in the published trials, the technique of maintaining low central venous pressure in the transection phase was adopted as a standard, with the aim of reducing bleeding. However, low central venous pressure together with increased intra-abdominal pressure increases the risk of gas embolism (carbon dioxide) [38, 39]. It seems prudent to use SVV rather than CVP monitoring as an indicator of vascular bed filling and use it as a guide to fluid therapy during the transection phase. In laparoscopic procedures, central venous pressure is notoriously unreliable due to the influence of the pneumoperitoneum on the inferior vena cava pressure [40, 41].

Challenges in cirrhosis

Data on fluid therapy in extensive resections in patients with cirrhosis is lacking. Published trials describe anesthesia complexity in this population, including strategies of fluid therapy [42, 43]. Taking into account the detailed data on the multi-organ consequences of cirrhosis and liver failure, it can be assumed that goal-directed therapy should be adopted.

Depending on the severity of cirrhosis and abnormal liver function (assessed according to the MELD or Child–Pugh scale), organ dysfunctions will vary, e.g. the presence of hepatorenal syndrome or the severity of hyperkinetic circulation with a relative or absolute intravascular volume deficit. Portal hypertension with collateral circulation, independently of other causes of coagulopathies, may increase the risk of bleeding at the stage of abdominal cavity incision. Multifactorial coagulopathy complicates anesthesia management. Vigilance over blood loss is essential with thresholds for red blood cells, platelets and plasma transfusions to maintain homeostasis. Fluid strategy, other than goal-directed, may exacerbate pathologies present in cirrhosis. The restrictive strategy may lead to hypoperfusion of vital organs, including the liver, intestines and kidneys, and as a result, lead to their failure. The liberal strategy, in addition to preexisting hypoalbuminemia, may lead to edema of the liver and the intestinal wall. Removal of the excess fluid may prove difficult, and, in some cases, impossible without implementing renal replacement therapy.

Performing major abdominal surgeries in patients with hepatic insufficiency, requires balancing the risk of exacerbation

of liver failure and its organ consequences with expected benefits. Mortality in cirrhotic patients decreased due to advances in surgical techniques, anesthesia and postoperative care. In group C according to the Child–Pugh scale, it is expected to be 12%, in comparison to previous years, when it was estimated at 82% [44, 45]. However, these estimates do not refer to hepatic surgeries. Scheduled liver resections in C group are contraindicated.

Types of fluids

An increase in lactate concentration in patients undergoing liver resection is a common phenomenon. This is due to impaired lactate liver clearance but can also be caused by increased anaerobic metabolism associated with maintaining low central venous pressure and subsequent organ hypoperfusion. It is widely accepted to use balanced crystalloid solutions. A study by Weinberg et al. showed that acetate buffered crystalloids are recommended. Better biochemical and hematological indices are obtained in terms of electrolyte balance, acid-base balance and coagulation parameters compared to solutions buffered with lactates [46]. Data on the safety of hydroxyethyl starch solutions are conflicting and mainly drawn from studies of intensive care patients. However, most authors indicate a potentially higher risk of acute kidney injury and coagulation disorders in patients receiving these solutions [47–49]. No definitive conclusions can be drawn on gelatin solution use. Conclusive data from randomized trials is lacking. Acute kidney injury, coagulation disorders and remnant failure may complicate liver resection. Thus, in the author's opinion, the use of the above-mentioned solutions should not be encouraged during liver resection and in the postoperative period. Postoperative fluid therapy in patients undergoing laparoscopic liver resections does not differ significantly from what has been discussed previously. This technique results in fewer complications, faster recovery of gastrointestinal function, which encourages earlier oral fluid intake and a shorter hospital stay. The published results of studies on the safety of using albumin solutions cover mainly critically ill patients and patients undergoing abdominal surgery, not specifically liver resection [50, 51]. Although there are no studies on this group of patients, being aware of the possibility of liver failure after the procedure (sometimes before) and the physiological role of albumin i.e. in maintaining oncotic pressure, preventing the occurrence of edema, it can be assumed that their administration both intra- and postoperatively is beneficial – especially when large volumes of crystalloids would have to be used otherwise.

Conclusions

Fluid transfusion in the perioperative period in major liver resections is a complex topic. The chosen fluid strategy has an impact on morbidity and the length of hospital stay. It is of the utmost importance to detect features of cirrhosis

and its complications which may largely determine the type of strategy adopted. In extensive liver resections without cirrhosis, restrictive fluid therapy is most often used. During liver resection in cirrhotic livers, goal-directed therapy is preferred. It should be emphasized that only close cooperation between the surgeon and the anesthesiologist during the procedure enables the rational implementation of the adopted strategy, depending on the progress of surgery and clinical situation. The type of fluid is equally as important as the volume. The use of balanced crystalloid solutions is recommended with the exception of lactate-buffered solutions. In cirrhotic liver resection, it is important to maintain an adequate concentration of albumin in the serum, which is justified by the pathophysiology of cirrhosis and its consequences.

Article information and declarations

Author contributions

Marta Dec, Wojciech Figiel – writing of the manuscript.

Paweł Andruszkiewicz, Michał Grąt – review of the manuscript.

Funding

None declared

Conflict of interest

None declared

Wojciech Figiel

Medical University of Warsaw

Department of General, Transplant and Liver Surgery

ul. Banacha 1a

02-097 Warszawa

e-mail: wojciech.figiel@wum.edu.pl

Received: 19 Jul 2023

Accepted: 25 Sep 2023

References

- Bellamy MC. Wet, dry or something else? *Br J Anaesth.* 2006; 97(6): 755–757, doi: 10.1093/bja/ael290, indexed in Pubmed: 17098724.
- Minto G, Mythen MG. Perioperative fluid management: science, art or random chaos? *Br J Anaesth.* 2015; 114(5): 717–721, doi: 10.1093/bja/aev067, indexed in Pubmed: 25794505.
- Miller TE, Myles PS. Perioperative Fluid Therapy for Major Surgery. *Anesthesiology.* 2019; 130(5): 825–832, doi: 10.1097/ALN.0000000000002603, indexed in Pubmed: 30789364.
- Lilot M, Ehrenfeld JM, Lee C, et al. Variability in practice and factors predictive of total crystalloid administration during abdominal surgery: retrospective two-centre analysis. *Br J Anaesth.* 2015; 114(5): 767–776, doi: 10.1093/bja/aev452, indexed in Pubmed: 25586725.
- Brandstrup B, Tønnesen H, Beier-Holgersen R, et al. Danish Study Group on Perioperative Fluid Therapy. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. *Ann Surg.* 2003; 238(5): 641–648, doi: 10.1097/01.sla.0000094387.50865.23, indexed in Pubmed: 14578723.
- Myles PS, McIlroy DR, Bellomo R, et al. Australian and New Zealand College of Anaesthetists Clinical Trials Network and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery. *N Engl J Med.* 2018; 378(24): 2263–2274, doi: 10.1056/NEJMoa1801601, indexed in Pubmed: 29742967.
- Marjanovic G, Villain C, Juettner E, et al. Impact of different crystalloid volume regimes on intestinal anastomotic stability. *Ann Surg.* 2009; 249(2): 181–185, doi: 10.1097/SLA.0b013e31818b73dc, indexed in Pubmed: 19212167.
- Kulemann B, Timme S, Seifert G, et al. Intraoperative crystalloid overload leads to substantial inflammatory infiltration of intestinal anastomoses—a histomorphological analysis. *Surgery.* 2013; 154(3): 596–603, doi: 10.1016/j.surg.2013.04.010, indexed in Pubmed: 23876362.
- Holte K, Sharrock NE, Kehlet H. Pathophysiology and clinical implications of perioperative fluid excess. *Br J Anaesth.* 2002; 89(4): 622–632, doi: 10.1093/bja/aef220, indexed in Pubmed: 12393365.
- Irish Surgical Research Collaborative. PERioperative Fluid Management in Elective Colectomy (PERFECT)—a national prospective cohort study. *Ir J Med Sci.* 2019; 188(4): 1363–1371, doi: 10.1007/s11845-019-02003-w, indexed in Pubmed: 30982155.
- Martin D, Lykoudis PM, Jones G, et al. Impact of postoperative intravenous fluid administration on complications following elective hepato-pancreato-biliary surgery. *Hepatobiliary Pancreat Dis Int.* 2018; 17(5): 402–407, doi: 10.1016/j.hbpd.2018.09.001, indexed in Pubmed: 30243876.
- Chen BP, Chen M, Bennett S, et al. Systematic Review and Meta-analysis of Restrictive Perioperative Fluid Management in Pancreaticoduodenectomy. *World J Surg.* 2018; 42(9): 2938–2950, doi: 10.1007/s00268-018-4545-6, indexed in Pubmed: 29464346.
- Bundgaard-Nielsen M, Holte K, Secher NH, et al. Monitoring of perioperative fluid administration by individualized goal-directed therapy. *Acta Anaesthesiol Scand.* 2007; 51(3): 331–340, doi: 10.1111/j.1399-6576.2006.01221.x, indexed in Pubmed: 17390421.
- Lobo SM, de Oliveira NE. Clinical review: What are the best hemodynamic targets for noncardiac surgical patients? *Crit Care.* 2013; 17(2): 210, doi: 10.1186/cc11861, indexed in Pubmed: 23672840.
- Calvo-Vecino JM, Ripollés-Melchor J, Mythen MG, et al. FEDORA Trial Investigators Group. Effect of goal-directed haemodynamic therapy on postoperative complications in low-moderate risk surgical patients: a multicentre randomised controlled trial (FEDORA trial). *Br J Anaesth.* 2018; 120(4): 734–744, doi: 10.1016/j.bja.2017.12.018, indexed in Pubmed: 29576114.
- Grocott MPW, Mythen MG, Gan TJ. Perioperative fluid management and clinical outcomes in adults. *Anesth Analg.* 2005; 100(4): 1093–1106, doi: 10.1213/01.ANE.00000148691.33690.AC, indexed in Pubmed: 15781528.
- Price HL, Deutsch S, Marshall BE, et al. Hemodynamic and metabolic effects of hemorrhage in man, with particular reference to the splanchnic circulation. *Circ Res.* 1966; 18(5): 469–474, doi: 10.1161/01.res.18.5.469, indexed in Pubmed: 5937539.
- Pestaña D, Espinosa E, Eden A, et al. Perioperative goal-directed hemodynamic optimization using noninvasive cardiac output monitoring in major abdominal surgery: a prospective, randomized, multicenter, pragmatic trial: POEMAS Study (PeriOperative goal-directed tHERapy in Major Abdominal Surgery). *Anesth Analg.* 2014; 119(3): 579–587, doi: 10.1213/ANE.0000000000000295, indexed in Pubmed: 25010820.
- Pędziwiatr M, Mavrikis J, Witowski J, et al. Current status of enhanced recovery after surgery (ERAS) protocol in gastrointestinal surgery. *Med Oncol.* 2018; 35(6): 95, doi: 10.1007/s12032-018-1153-0, indexed in Pubmed: 29744679.
- Malbrain ML, Langer T, Annane D, et al. Intravenous fluid therapy in the perioperative and critical care setting: Executive summary of the International Fluid Academy (IFA). *Ann Intensive Care.* 2020; 10(1): 64, doi: 10.1186/s13613-020-00679-3, indexed in Pubmed: 32449147.
- Wojciechowska U, Barańska K, Miklewska M, et al. Cancer incidence and mortality in Poland in 2020. *Nowotwory. Journal of Oncology.* 2023; 73(3): 129–145, doi: 10.5603/NJO.2023.0026.
- Cunningham JD, Fong Y, Shriver C, et al. One hundred consecutive hepatic resections. Blood loss, transfusion, and operative technique. *Arch Surg.* 1994; 129(10): 1050–1056, doi: 10.1001/archsurg.1994.01420340064011, indexed in Pubmed: 7944934.
- Melendez JA, Arslan V, Fischer ME, et al. Perioperative outcomes of major hepatic resections under low central venous pressure anesthesia: blood loss, blood transfusion, and the risk of postoperative renal dysfunction. *J Am Coll Surg.* 1998; 187(6): 620–625, doi: 10.1016/s1072-7515(98)00240-3, indexed in Pubmed: 9849736.
- Jones RM, Moulton CE, Hardy KJ. Central venous pressure and its effect on blood loss during liver resection. *Br J Surg.* 1998; 85(8): 1058–1060, doi: 10.1046/j.1365-2168.1998.00795.x, indexed in Pubmed: 9717995.
- Chen H, Merchant NB, Didolkar MS. Hepatic resection using intermittent vascular inflow occlusion and low central venous pressure anesthesia improves morbidity and mortality. *J Gastrointest Surg.*

- 2000; 4(2): 162–167, doi: 10.1016/s1091-255x(00)80052-9, indexed in Pubmed: 10675239.
26. Smyrniotis V, Kostopanagiotou G, Theodoraki K, et al. The role of central venous pressure and type of vascular control in blood loss during major liver resections. *Am J Surg.* 2004; 187(3): 398–402, doi: 10.1016/j.amjsurg.2003.12.001, indexed in Pubmed: 15006570.
27. Eid EA, Sheta SA, Mansour E. Low central venous pressure anesthesia in major hepatic resection. *Middle East J Anaesthesiol.* 2005; 18(2): 367–377, indexed in Pubmed: 16438011.
28. Huntington JT, Royall NA, Schmidt CR. Minimizing blood loss during hepatectomy: a literature review. *J Surg Oncol.* 2014; 109(2): 81–88, doi: 10.1002/jso.23455, indexed in Pubmed: 24449171.
29. Marik PE, Monnet X, Teboul JL. Hemodynamic parameters to guide fluid therapy. *Ann Intensive Care.* 2011; 1(1): 1, doi: 10.1186/2110-5820-1-1, indexed in Pubmed: 21906322.
30. Correa-Gallego C, Tan KS, Arslan-Carlson V, et al. Goal-Directed Fluid Therapy Using Stroke Volume Variation for Resuscitation after Low Central Venous Pressure-Assisted Liver Resection: A Randomized Clinical Trial. *J Am Coll Surg.* 2015; 221(2): 591–601, doi: 10.1016/j.jamcollsurg.2015.03.050, indexed in Pubmed: 26206652.
31. Weinberg L, Ianno D, Churilov L, et al. Goal directed fluid therapy for major liver resection: A multicentre randomized controlled trial. *Ann Med Surg (Lond).* 2019; 45: 45–53, doi: 10.1016/j.amsu.2019.07.003, indexed in Pubmed: 26263833.
32. Kim Y, Ejaz A, Gani F, et al. Crystalloid administration among patients undergoing liver surgery: Defining patient- and provider-level variation. *Surgery.* 2016; 159(2): 389–398, doi: 10.1016/j.surg.2015.06.037, indexed in Pubmed: 26263833.
33. Lilot M, Ehrenfeld JM, Lee C, et al. Variability in practice and factors predictive of total crystalloid administration during abdominal surgery: retrospective two-centre analysis. *Br J Anaesth.* 2015; 114(5): 767–776, doi: 10.1093/bja/aeu452, indexed in Pubmed: 25586725.
34. Warner SG, Jutric Z, Nisimova L, et al. Early recovery pathway for hepatectomy: data-driven liver resection care and recovery. *Hepatobiliary Surg Nutr.* 2017; 6(5): 297–311, doi: 10.21037/hbsn.2017.01.18, indexed in Pubmed: 29152476.
35. Giustiniano E, Nisi F, Rocchi L, et al. Perioperative Management of Complex Hepatectomy for Colorectal Liver Metastases: The Alliance between the Surgeon and the Anesthetist. *Cancers (Basel).* 2021; 13(9), doi: 10.3390/cancers13092203, indexed in Pubmed: 34063684.
36. Yoshino O, Perini MV, Christophi C, et al. Perioperative fluid management in major hepatic resection: an integrative review. *Hepatobiliary Pancreat Dis Int.* 2017; 16(5): 458–469, doi: 10.1016/S1499-3872(17)60055-9, indexed in Pubmed: 28992877.
37. Charbonneau H, Riu B, Faron M, et al. Predicting preload responsiveness using simultaneous recordings of inferior and superior vena cavae diameters. *Crit Care.* 2014; 18(5): 473, doi: 10.1186/s13054-014-0473-5, indexed in Pubmed: 25189403.
38. Rola P, Miralles-Aguilar F, Argaz E, et al. Clinical applications of the venous excess ultrasound (VExUS) score: conceptual review and case series. *Ultrasound J.* 2021; 13(1): 32, doi: 10.1186/s13089-021-00232-8, indexed in Pubmed: 34146184.
39. Jin D, Liu M, Huang J, et al. Gas embolism under standard versus low pneumoperitoneum pressure during laparoscopic liver resection (GASES): study protocol for a randomized controlled trial. *Trials.* 2021; 22(1): 807, doi: 10.1186/s13063-021-05678-8, indexed in Pubmed: 34781988.
40. Dunki-Jacobs EM, Philips P, Scoggins CR, et al. Stroke volume variation in hepatic resection: a replacement for standard central venous pressure monitoring. *Ann Surg Oncol.* 2014; 21(2): 473–478, doi: 10.1245/s10434-013-3323-9, indexed in Pubmed: 24150192.
41. Tranchart H, Dagher I. Laparoscopic liver resection: A review. *Journal of Visceral Surgery.* 2014; 151(2): 107–115, doi: 10.1016/j.jvisc-surg.2013.10.003.
42. Abbas N, Makker J, Abbas H, et al. Perioperative Care of Patients With Liver Cirrhosis: A Review. *Health Serv Insights.* 2017; 10: 1178632917691270, doi: 10.1177/1178632917691270, indexed in Pubmed: 28469455.
43. Kiamanesh D, Rumley J, Moitra VK. Monitoring and managing hepatic disease in anaesthesia. *Br J Anaesth.* 2013; 111 Suppl 1: i50–i61, doi: 10.1093/bja/aet378, indexed in Pubmed: 24335399.
44. Mansour A, Watson W, Shayani V, et al. Abdominal operations in patients with cirrhosis: still a major surgical challenge. *Surgery.* 1997; 122(4): 730–5; discussion 735, doi: 10.1016/s0039-6060(97)90080-5, indexed in Pubmed: 9347849.
45. Telem DA, Schiano T, Goldstone R, et al. Factors that predict outcome of abdominal operations in patients with advanced cirrhosis. *Clin Gastroenterol Hepatol.* 2010; 8(5): 451–7, quiz e58, doi: 10.1016/j.cgh.2009.12.015, indexed in Pubmed: 20036761.
46. Weinberg L, Pearce B, Sullivan R, et al. The effects of plasmalyte-148 vs. Hartmann's solution during major liver resection: a multicentre, double-blind, randomized controlled trial. *Minerva Anesthesiol.* 2015; 81(12): 1288–1297, indexed in Pubmed: 25407026.
47. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. *Cochrane Database Syst Rev.* 2013(2): CD000567, doi: 10.1002/14651858.CD000567.pub6, indexed in Pubmed: 23450531.
48. Bagshaw SM, Chawla LS. Hydroxyethyl starch for fluid resuscitation in critically ill patients. *Can J Anaesth.* 2013; 60(7): 709–713, doi: 10.1007/s12630-013-9936-4, indexed in Pubmed: 23604905.
49. Mutter TC, Ruth CA, Dart AB, et al. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. *Cochrane Database Syst Rev.* 2010(1): CD007594, doi: 10.1002/14651858.CD007594.pub2, indexed in Pubmed: 20091640.
50. Roberts I, Blackhall K, Alderson P, et al. Albumin Reviewers (Alderson P, Bunn F, Li Wan Po A, Li L, Blackhall K, Roberts I, Schierhout G), Albumin Reviewers, Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. *BMJ.* 1998; 317(7153): 235–240, doi: 10.1136/bmj.317.7153.235, indexed in Pubmed: 9677209.
51. Finfer S, Bellomo R, Boyce N, et al. SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med.* 2004; 350(22): 2247–2256, doi: 10.1056/NEJMoa040232, indexed in Pubmed: 15163774.

Anemia in cancer patients: addressing a neglected issue – diagnostics and therapeutic algorithm

Konrad Tałasiewicz¹ , Aleksandra Kapała^{1,2} 
¹Department of Oncology Diagnostics, Cardio-Oncology and Palliative Medicine,
Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

²Department of Clinical Nutrition, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Cancer-related anemia (CRA) continues to be a critical concern despite advancements in oncology treatments. The prevalence of anemia varies from 30% to 90%, impacting the quality of life and prognosis of cancer patients. While CRA is often attributed to antineoplastic therapies, it can also result from the disease itself. Inflammation and the iron regulatory hormone hepcidin play significant roles in CRA pathogenesis. Treatment-induced anemia caused by chemotherapy, tyrosine kinase inhibitors (TKIs) and immunotherapy, pose additional challenges. Intravenous (IV) iron has emerged as an effective treatment option for CRA, overcoming limitations associated with oral iron supplementation. Combining IV iron and ESAs enhances treatment outcomes. Future directions involve exploring ESA safety and their immunomodulatory effects. Transfusions provide quick relief but might impact prognosis and immune response. Other considerations include incorporating physical activity and exploring hepcidin-directed therapy. In conclusion, CRA management necessitates a multifaceted approach to address deficiencies, optimize therapies and improve patient outcomes.

Key words: anemia, cancer, hepcidin, erythropoiesis-stimulating agents, blood transfusions

Introduction

Although modern oncology drugs employ mechanisms distinct from classical 20th-century cytotoxic therapies, cancer-related anemia (CRA) remains an underestimated issue. It is not always solely a consequence of antineoplastic treatments. The prevalence of anemia, varying from 30% to 90%, depends on factors such as neoplasm type, disease progression, or treatment method [1–4]. Anemia ranges from causing mild, persistent symptoms like fatigue to life-threatening conditions, especially for individuals with concurrent chronic diseases. Without a doubt, it significantly impairs quality of life (QOL) for cancer patients [5–6].

General definitions

According to the World Health Organization (WHO), anemia is a state where hemoglobin levels or red blood cell counts fall below the lower limits of normal (women <12 g/dl, men <13 g/dl) [7]. Cancer-related anemia (CRA) can result from cancer treatment (chemotherapy-induced anemia [CIA]) or the disease itself. Neoplasms can affect red blood cell (RBC) production (erythropoiesis), RBC breakdown (hemolysis), and blood loss (bleeding). For anemia resulting from oncological therapy, the Common Terminology Criteria for Adverse Events (CTCAE) grading system is used [8]. However, there are inconsistencies between WHO values and those of CTCAE (tab. I).

Jak cytować / How to cite:

Tałasiewicz K, Kapała A. *Anemia in cancer patients: addressing a neglected issue – diagnostics and therapeutic algorithm*. NOWOTWORY J Oncol 2023; 73: 309–316.

Table I. Comparison of the values proposed by the World Health Organization and adapted by the Common Terminology Criteria for Adverse Events (CTCAE)

Severity of anemia	Hb		CTCAE	CTCAE level
	women	men		
normal level	≥12 g/dl	≥13 g/dl	up to lower limit of normal (LLN)	0
mild	10–11.9 g/dl	10–12.9 g/dl	10 g/dl – LLN	1
moderate	8–9.9 g/dl	8–9.9 g/dl	8–9.9 g/dl	2
severe	6.5–7.9 g/dl	6.5–7.9 g/dl	<8 g/dl	3
life-threatening	<6.5 g/dl	<6.5 g/dl	life-threatening consequences	4

Pathogenesis and diagnostic approach

Anemia diagnosis must consider the intricate interplay of RBC production and usage across various organs (the intestines, liver, spleen, kidney, bone marrow) [9]. In most cases, CRA is primarily attributed to two causes – iron deficiency and concurrent antineoplastic therapy. Key indicators in CRA diagnosis are serum ferritin (SF) and transferrin saturation (TSAT; serum iron/total iron binding capacity x 100). Other iron-related parameters are often influenced by external factors and are unreliable predictors (e.g., MCV, soluble transferrin receptor) or are not routinely available (e.g., zinc protoporphyrin or hepcidin levels).

Functional and absolute iron deficiency

Typically, CRA patients exhibit normocytic anemia accompanied by iron deficiency (TSAT < 20%) and normal or elevated SF > 100 ng/ml [10–13]. This condition is referred to as functional iron deficiency anemia (FIDA). Another situation arises when TSAT is <20% and ferritin is <100 ng/ml, leading to absolute iron deficiency anemia (AIDA) [14]. These two clinical scenarios have distinct underlying causes. AIDA is usually linked to blood loss or inadequate iron intake/malabsorption. FIDA, on the other hand, arises due to iron sequestration driven by chronic inflammation (involving hepcidin) [15], and/or iron-restricted erythropoiesis prompted by endogenous erythropoietin production or erythropoiesis-stimulating agents [16].

Role of inflammation and hepcidin

Inflammation is a hallmark of cancer [17], impacting erythropoiesis *via* cytokines like IL-1, IL-6, IL-10, IFN- γ , TNF- α , and raising reactive oxygen species (ROS) levels. The levels of these cytokines can predict hemoglobin concentrations [18]. Hepcidin, a liver-produced iron regulatory hormone, is affected by both inflammatory cytokines and ROS. Hepcidin inhibits iron release to erythropoiesis from macrophages and hepatocytes, and also influences iron absorption in enterocytes. This hormone binds to ferroportin, an iron exporter, causing its degradation [19–20]. Consequently, oral iron absorption is limited in cancer patients, reducing its availability for dietary supplementation.

Treatment-induced anemia

In the past five years, over 200 cancer drugs have been approved, with 14% surpassing the prior standard of care [21]. Chemotherapy-induced anemia remains a significant concern, as it is still widely used, especially in neoadjuvant and adjuvant settings for solid tumors. Up to 90% of solid tumor patients experience anemia during chemotherapy [22], with incidence varying by regimen, tumor type and stage.

New agents like tyrosine kinase inhibitors (TKIs), small molecules and immunotherapy (ICI) can induce or exacerbate preexisting anemia differently from traditional cytotoxic agents. TKIs often lead to hematological toxicities [23], with mechanisms varying. Some TKIs, such as sunitinib, imatinib and pazopanib, can cause macrocytosis, which may serve as a predictor of patient survival [24–26]. The mechanism might relate to c-KIT inhibition [26]. Rarely do drugs like alectinib induce hemolytic anemia [27].

Immunotherapy can also lead to anemia via autoantibody-induced hemolysis, requiring treatment with steroids and rituximab [28]. In extremely rare cases, lethal aplastic anemia has been described [29].

CRA treatment

Three main strategies address CRA, either individually or in combination. Correcting deficiencies (iron, vitamin B₁₂, folate) is paramount. Erythropoiesis-stimulating agents (ESAs) and red blood cell concentrates (transfusions) follow.

Iron treatment

While oral iron is standard for general iron deficiency anemia treatment, it has limitations in cancer patients due to gastrointestinal (GI) intolerance. GI symptoms often accompany cancer treatments, making oral supplementation difficult [30]. Moreover, heightened hepcidin levels impair proper iron utilization. Studies suggest alternating dosing schedules could decrease hepcidin levels and enhance iron absorption [31–32]. Intravenous (iv) iron is preferred for CRA patients due to its more direct delivery and bypassing GI issues [33–34]. Intravenous iron, alone or with ESA, effectively treats chemotherapy-induced anemia, saves costs and improves QOL [35–38]. Intravenous iron suits both functional and absolute iron deficiency scenarios.

Intravenous iron treatment

Intravenous iron formulations have been utilized in human medicine for nearly a century; however, some physicians continue to harbor unnecessary concerns reminiscent of the early days of its introduction [39]. The prospective European ECAS study, conducted at the beginning of the 21st century to gather data on the prevalence and treatment of anemia, revealed that only 6.5% of patients received iron treatment [40]. These concerns likely stem from apprehensions about potential side effects.

Safety and side effects of intravenous iron supplementation

Contemporary iron products (as outlined in table II) all possess an iron core enveloped by a carbohydrate shell, a feature that distinguishes them from one another. Intravenous iron infusions seldom lead to hypersensitivity reactions, and although such reactions can be life-threatening, severe anaphylactic-type reactions are exceedingly rare [41]. High molecular weight iron dextrans, previously used, had significantly higher rates of serious adverse drug events, leading to their discontinuation. The new formulations are designed to be safer. A comprehensive systemic review that evaluated the safety of intravenous iron across randomized clinical trials established that intravenous iron is not correlated with an increased risk of serious adverse events [42]. The European Medical Agency has issued recommendations for managing allergic reactions associated with intravenous iron-containing medications, concluding that the benefits of these medications outweigh the associated risks [43]. As a result, administering a test dose with these new formulations is no longer advised.

Prevention and management protocols for infusion reactions have been well-delineated and align with approaches used in managing other infusion-related reactions observed in the field of oncology [44, 45]. There is contradictory data concerning cardiotoxicity and the risk of exacerbating infections when using intravenous iron [42, 46, 47]. Consequently, intravenous iron administration should be avoided in patients

with active infections and on the same day as cardiotoxic chemotherapy administration.

In conclusion, the use of more recent intravenous iron formulations is regarded as safer compared to other commonly used methods in addressing anemia among cancer patients [42]. Nonetheless, determining the optimal dosing and treatment schedule for intravenous iron remains an ongoing effort, with variations among the different available products.

Erythropoiesis-stimulating agents

Erythropoietin (EPO), a hormone produced in the kidneys and liver, increases red blood cell production in response to hypoxia. Recombinant EPO was synthesized in the 1980s, revolutionizing chronic kidney disease treatment [48]. ESAs entered oncology in the 1990s, gaining popularity but later encountering safety concerns [49]. Modern erythropoiesis-stimulating agents (ESAs) (tab. III) are indicated for adult cancer patients with non-myeloid malignancies receiving chemotherapy, aiming to raise hemoglobin from 8–10 g/dl to no more than 12 g/dl. ESA treatment necessitates reevaluation after 4–6 weeks, adjusting doses based on response or cessation if no response is observed.

ESAs concerns

The most common side effects include allergic reactions and cardiovascular complications. Allergic reactions range from more commonly occurring mild local injection site reactions to rare but serious reactions that require prompt attention. Early reports regarding thrombotic risk [50] led to concerns about the safety of ESAs and their potential impact on the survival of cancer patients. A recent systematic review of randomized controlled trials revealed that although this type of therapy is associated with adverse cardiovascular effects, including venous thromboembolism (VTE), it does not affect patients' overall survival, and ESAs can be used safely [51]. Due to the lack of prospective trials, neither the National

Table II. Intravenous iron formulations: characteristics, dosing and comments. The information based on the summaries of product characteristics approved by the EMA and/or FDA

Preparation	Dosing	Comments
ferric carboximaltose	20 mg/kg up to 750–1000 mg intravenous infusion or single injection up to minimum 15 mins. Second dose might be administered after ≥7 days	may cause transient hypophosphataemia
derisomaltoze	500–2000 mg depending on the weight, infusion over 15 mins. (up to 1000 mg) and over 30 mins. (>1000 mg) or 500 mg bolus at a speed of 250 mg/min.	relatively a new product
iron sucrose	200 mg maximum dose in injection, 500 mg infusion of at least 3.5 h	commonly used in the USA
LMWID	depending on the preparation – 240–360 mins. infusion – complicated dosing (test dose recommended)	complicated dosing
ferric gluconate	125 mg in 60 mins., repeat in 2–3 weeks until a total dose of 1000 mg is obtained	associated with serious infusion reactions
ferumoxytol	510 mg in 15 mins. not available in the European Union	might influence MR results up to 3 months

LMWID – low molecular weight iron dextran; MR – magnetic resonance

Table III. Erythropoiesis-stimulating agents. The information is based on the summaries of product characteristics approved by the EMA and/or FDA

Erythropoiesis-stimulating agent (ESA)	Dosing	Dose escalation possibility
epoetin alfa	150 units/kg 3x/week or 30 000 units/week	300 units/kg 3x/week or 60 000 units/week
epoetin beta	30 000 units (450 units/kg)	60 000 units (900 units/kg/week)
epoetin theta	20 000 units/week	40 000 units/week (max. 60 000 units/week)
darbepoetin alpha	2.25 µg/kg/week or 500 µg/3 weeks	4.5 µg/kg/week

Comprehensive Cancer Network® (NCCN®) nor the European Society of Medical Oncology recommends the routine use of standard prophylactic anticoagulation in the absence of other risk factors [33, 52]. The use of validated scales predicting VTE events, such as the KHORANA scale, is strongly encouraged for patients receiving chemotherapy [53]. Another significant cardiovascular effect is arterial hypertension, which typically manifests at the beginning of therapy. The exact mechanism of this complication is not well understood. An important subgroup of patients includes those with chronic kidney disease or preexisting arterial hypertension. For these individuals, the introduction of ESAs should be cautious, and a gradual correction of anemia is advised [54].

ESAs and possible stimulation of cancer growth

Increased EPO signaling has been observed on cancer cells, particularly in the hypoxic regions of various tumors [55]. This observation led to the hypothesis of potential cancer growth stimulation. Early trials suggested inferior overall survival among patients receiving ESA during chemotherapy [56–57]. However, all trials that raised such concerns targeted hemoglobin levels above 12 g/dl. When ESAs are used within registered indications among patients receiving chemotherapy for non-myeloid cancers with hemoglobin levels below 10 g/dl and a target range up to 12 g/dl, no impact on overall survival was confirmed [51, 58–61]. Recent randomized, double-blinded, placebo-controlled studies focusing on this strategy appear to confirm the safety of ESAs and their lack of impact on overall survival (OS) and progression-free survival (PFS) for patients with solid tumors [62].

Combining intravenous iron and ESAs

Given the recommendation for correcting all deficiencies prior to initiating ESA treatment, a question arises about the combination of *iv* iron formulations and ESAs. This treatment approach should be administered on a regular daily basis, as demonstrated in a randomized controlled trial that showed significant improvements in both quality of life (QoL) and hemoglobin levels [16]. This combination also leads to a reduction in the need for transfusions when compared to the use of ESAs alone [63].

ESA future directions

Further research, particularly randomized controlled trials focused on the safety of ESAs, is necessary. With the growing interest in the potential immunomodulatory effects of erythropoietin (EPO) and its derivatives (given that ESAs might exhibit anti-inflammatory effects) [64], additional studies are required to determine the viability of their use in conjunction with modern treatment modalities like immunotherapy.

Transfusions

RBC transfusions are commonly used, because they provide quick relief, but come with risks like immune modulation [65, 66]. Transfusions negatively impact cancer patients, affecting progression-free and overall survival, recurrence and perioperative morbidity [67–74]. Some negative effects stem from immune activation, impacting oncology treatments [75–76]. Recent trials found decreased immunotherapy response rates with transfusions [77].

Considerations for optimizing RBC use in cancer patients

Although the precise hemoglobin (Hb) level or timing for blood transfusions in relation to the type of cancer treatment or disease stage has yet to be definitively established, there is existing data regarding different approaches to red blood cell (RBC) utilization.

Recognizing the adverse effects of transfusions on cancer patients at various stages of therapy, many healthcare professionals underscore the importance of adopting a more cautious approach to RBC transfusions. This approach is founded on the use of a lower Hb concentration as the threshold for initiating transfusions (typically around 7–8 g/dl), in contrast to a more liberal threshold (around 9–10 g/dl). Restrictive RBC transfusion strategies (Hb < 7–8 g/dl) align with reduced morbidity and mortality [78–79].

Folate and vitamin B₁₂ deficiency

Megaloblastic anemia stemming from deficiencies in vitamin B₁₂ and folate is less frequent among cancer patients compared to iron deficiency. Such deficiencies may be linked to

disease progression and malnutrition, as well as increased cellular turnover, particularly in cases of lymphomas and leukemias. Individuals who have undergone gastrectomy or have experienced significant infiltration of the intestine may also experience such deficiencies due to the altered absorption of these vitamins in these parts of the digestive system. Certain cytotoxic drugs, commonly employed in cancer treatment such as 5-fluorouracyl, methotrexate and hydroxycarbamide, can induce megaloblastic anemia by interfering with DNA synthesis [80].

Additional considerations for the treatment of cancer-related anemia

While the primary modalities of addressing cancer-related anemia (ESA, iron supplementation and transfusions) form the foundation of management, there are several other noteworthy aspects to be taken into account. These encompass lifestyle interventions and a range of supplementary approaches.

Physical activity

Compelling evidence underscores the pivotal role of exercise and various forms of physical activity in cancer prevention and treatment, notably in enhancing patients' quality of life (primarily alleviating fatigue). Of all cancer-related fatalities worldwide, approximately 35% can be attributed to environmental factors, including sedentary lifestyles [81]. Different types of exercise have proven highly effective in mitigating cancer-related fatigue during treatment [82], as well as potentially improving overall cancer survival rates [83]. Given the key role inflammation plays in the development of cancer-related anemia, the potential anti-inflammatory effects of physical activity are noteworthy. Moreover, physical activity may influence hepcidin levels. Emerging data suggests that engaging in exercise can lead to improvements in hemoglobin levels in patients undergoing chemotherapy while using ESAs [84], in breast cancer patients during radiotherapy [85], and in breast cancer patients undergoing chemotherapy [86–87]. Nonetheless, an optimal type and intensity of physical activity has yet to be definitively established.

Hepcidin-directed therapy

Given the often-elevated levels of hepcidin in cancer patients, therapeutic approaches involving monoclonal antibodies that neutralize these proteins have gained attention. This form of treatment holds the potential to enhance ferroportin expression in enterocytes and macrophages, thereby facilitating the release of stored iron and promoting effective erythropoiesis. Initial clinical trials assessing the safety of such antibodies in addressing cancer-related anemia have yielded promising results [88]. Subsequent research in this domain is warranted, as it could potentially introduce another avenue for targeted treatment of cancer-related anemia.

Zinc deficiency

Zinc deficiency is prevalent in many countries and frequently coexists with iron deficiency. Among adults afflicted with chronic diseases, zinc deficiency has been associated with anemia [89]. While some recent analyses among non-cancer anemic patients have suggested a correlation between zinc levels and hemoglobin concentration [90], evidence in the context of cancer patients remains limited.

Conclusions

CRA's impact is significant, but awareness and treatment approach vary. There are three main pillars guide treatment: correcting deficiencies, using ESAs and transfusions. Intravenous iron addresses iron deficiency more effectively. ESAs have associated concerns but remain valuable. Transfusions provide relief but may affect prognosis. Future research focuses on enhancing interventions and combining treatments to optimize CRA management.

Article information and declarations

Author contributions

Konrad Tałasiewicz – conceptualization, visualization, writing – original draft, writing – reviewing and editing.

Aleksandra Kapała – conceptualization, supervision, writing – reviewing and editing.

All authors discussed and commented on the manuscript.

Funding

None declared

Conflict of interest

None declared

Konrad Tałasiewicz

*Maria Skłodowska-Curie National Research Institute of Oncology
Department of Oncology Diagnostics, Cardio-Oncology and Palliative Medicine
ul. Roentgena 5
02-781 Warszawa, Poland
e-mail: konrad.talasiewicz@nio.gov.pl*

Received: 12 Aug 2023

Accepted: 6 Sep 2023

References

1. Wojtukiewicz MZ, Sierko E, Rybaltowski M, et al. The Polish Cancer Anemia Survey (POLCAS): a retrospective multicenter study of 999 cases. *Int J Hematol.* 2009; 89(3): 276–284, doi: 10.1007/s12185-009-0273-x, indexed in Pubmed: 19343481.
2. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. *Am J Med.* 2004; 116 Suppl 7A: 11S–26S, doi: 10.1016/j.amjmed.2003.12.008, indexed in Pubmed: 15050883.
3. Harrison L, Shasha D, Shiao L, et al. Prevalence of anemia in cancer patients undergoing radiation therapy. *Semin Oncol.* 2001; 28(2 Suppl 8): 54–59, doi: 10.1016/s0093-7754(01)90214-3, indexed in Pubmed: 11395854.
4. Xu H, Xu L, Page JH, et al. Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010–2013. *Clin Epidemiol.* 2016; 8: 61–71, doi: 10.2147/CLEP.S89480, indexed in Pubmed: 27186078.

5. Cella D, Kallich J, McDermott A, et al. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. *Ann Oncol.* 2004; 15(6): 979–986, doi: 10.1093/annonc/mdh235, indexed in Pubmed: 15151958.
6. Barca-Hernando M, Muñoz-Martin AJ, Rios-Herranz E, et al. Case-Control Analysis of the Impact of Anemia on Quality of Life in Patients with Cancer: A Qca Study Analysis. *Cancers (Basel).* 2021; 13(11), doi: 10.3390/cancers13112517, indexed in Pubmed: 34063886.
7. Cappellini MD, Motta I. Anemia in Clinical Practice-Definition and Classification: Does Hemoglobin Change With Aging? *Semin Hematol.* 2015; 52(4): 261–269, doi: 10.1053/j.seminhematol.2015.07.006, indexed in Pubmed: 26404438.
8. National Cancer Institute, Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50 (24.07.2023).
9. Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. *Blood.* 2020; 136(7): 801–813, doi: 10.1182/blood.2019004017, indexed in Pubmed: 32556170.
10. Ludwig H, Müldür E, Endler G, et al. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. *Ann Oncol.* 2013; 24(7): 1886–1892, doi: 10.1093/annonc/mdt118, indexed in Pubmed: 23567147.
11. Park S, Jung CW, Kim K, et al. Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. *Oncotarget.* 2015; 6(40): 42803–42812, doi: 10.18632/oncotarget.5658, indexed in Pubmed: 26517509.
12. Naoum FA. Iron deficiency in cancer patients. *Rev Bras Hematol Hemoter.* 2016; 38(4): 325–330, doi: 10.1016/j.bjhh.2016.05.009, indexed in Pubmed: 27863761.
13. Gluszk C, de Vries-Brilland M, Seegers V, et al. Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study). *Oncologist.* 2022; 27(4): 328–333, doi: 10.1093/oncolo/oyac005, indexed in Pubmed: 35380718.
14. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. *Blood.* 2010; 116(23): 4754–4761, doi: 10.1182/blood-2010-05-286260, indexed in Pubmed: 20826717.
15. Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia. *Am J Hematol.* 2014; 89(2): 203–212, doi: 10.1002/ajh.23628, indexed in Pubmed: 24532336.
16. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. *J Clin Oncol.* 2004; 22(7): 1301–1307, doi: 10.1200/JCO.2004.08.119, indexed in Pubmed: 15051778.
17. Hanahan D. Hallmarks of Cancer: New Dimensions. *Cancer Discov.* 2022; 12(1): 31–46, doi: 10.1158/2159-8290.CD-21-1059, indexed in Pubmed: 35022204.
18. Macciò A, Madeddu C, Gramignano G, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. *Haematologica.* 2015; 100(1): 124–132, doi: 10.3324/haematol.2014.112813, indexed in Pubmed: 25239265.
19. Goodnough LT. Iron deficiency syndromes and iron-restricted erythropoiesis (CME). *Transfusion.* 2012; 52(7): 1584–1592, doi: 10.1111/j.1537-2995.2011.03495.x, indexed in Pubmed: 22211566.
20. Ganz T. Anemia of Inflammation. *N Engl J Med.* 2019; 381(12): 1148–1157, doi: 10.1056/nejmra1804281.
21. Benjamin DJ, Xu A, Lythgoe MP, et al. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016–2021. *JAMA Netw Open.* 2022; 5(3): e222265, doi: 10.1001/jamanetworkopen.2022.2265, indexed in Pubmed: 35289858.
22. Xu H, Xu L, Page JH, et al. Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010–2013. *Clin Epidemiol.* 2016; 8: 61–71, doi: 10.2147/CLEP.S89480, indexed in Pubmed: 27186078.
23. Barber NA, Afzal W, Akhtari M. Hematologic toxicities of small molecule tyrosine kinase inhibitors. *Target Oncol.* 2011; 6(4): 203–215, doi: 10.1007/s11523-011-0202-9, indexed in Pubmed: 22127751.
24. Kucharz J, Giza A, Dumnicka P, et al. Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma. *Med Oncol.* 2016; 33(10): 109, doi: 10.1007/s12032-016-0818-9, indexed in Pubmed: 27573381.
25. Schallier D, Trullemans F, Fontaine C, et al. Tyrosine kinase inhibitor-induced macrocytosis. *Anticancer Res.* 2009; 29(12): 5225–5228, indexed in Pubmed: 20044640.
26. Kloth JSL, Hamberg P, Mendelaar PAJ, et al. Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment. *Eur J Cancer.* 2016; 56: 101–106, doi: 10.1016/j.ejca.2015.12.019, indexed in Pubmed: 26841094.
27. Dore GM, Nayernama A, Cheng C, et al. Hemolytic anemia following alectinib reported to the U.S. Food and Drug Administration Adverse Event Reporting System. *Am J Hematol.* 2022; 97(4): E129–E132, doi: 10.1002/ajh.26454, indexed in Pubmed: 34985778.
28. Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors. *Blood.* 2022; 139(25): 3594–3604, doi: 10.1182/blood.2020009016, indexed in Pubmed: 34610113.
29. Guo Q, Zhao JN, Liu T, et al. Immune checkpoint inhibitor-induced aplastic anaemia: Case series and large-scale pharmacovigilance analysis. *Front Pharmacol.* 2023; 14: 1057134, doi: 10.3389/fphar.2023.1057134, indexed in Pubmed: 36778017.
30. Rund D. Intravenous iron: do we adequately understand the short- and long-term risks in clinical practice? *Br J Haematol.* 2021; 193(3): 466–480, doi: 10.1111/bjh.17202, indexed in Pubmed: 33216989.
31. Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. *Blood.* 2015; 126(17): 1981–1989, doi: 10.1182/blood-2015-05-642223, indexed in Pubmed: 26289639.
32. Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. *Lancet Haematol.* 2017; 4(11): e524–e533, doi: 10.1016/S2352-3026(17)30182-5, indexed in Pubmed: 29032957.
33. Aapro M, Beguin Y, Bokemeyer C, et al. ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. *Ann Oncol.* 2018; 29(Suppl 4): iv96–iv91v110, doi: 10.1093/annonc/mdx758, indexed in Pubmed: 29471514.
34. Radziwon P, Krzakowski M, Kalinka-Warchoła E, et al. Anemia in cancer patients — Expert Group recommendations. *Oncol Clin Pract.* 2017; 13: 202–210, doi: 10.5603/OCP.2017.0023.
35. Makharadze T, Boccia R, Krupa A, et al. Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo-controlled study (IRON-CLAD). *Am J Hematol.* 2021; 96(12): 1639–1646, doi: 10.1002/ajh.26376, indexed in Pubmed: 34653287.
36. Jang JHo, Kim Y, Park S, et al. Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. *PLoS Med.* 2020; 17(6): e1003091, doi: 10.1371/journal.pmed.1003091, indexed in Pubmed: 32511251.
37. Luporsi E, Mahi L, Morre C, et al. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective. *J Med Econ.* 2012; 15(2): 225–232, doi: 10.3111/13696998.2011.639823, indexed in Pubmed: 22077267.
38. Gluszk C, de Vries-Brilland M, Seegers V, et al. Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study). *Oncologist.* 2022; 27(4): 328–333, doi: 10.1093/oncolo/oyac005, indexed in Pubmed: 35380718.
39. GOETSCH A, MOORE C, MINNICH V. OBSERVATIONS ON THE EFFECT OF MASSIVE DOSES OF IRON GIVEN INTRAVENOUSLY TO PATIENTS WITH HYPOCHROMIC ANEMIA. *Blood.* 1946; 1(2): 129–142, doi: 10.1182/blood.v1.2.129.129.
40. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. *Eur J Cancer.* 2004; 40(15): 2293–2306, doi: 10.1016/j.ejca.2004.06.019, indexed in Pubmed: 15454256.
41. Wysowski DK, Swartz L, Borders-Hemphill BV, et al. Use of parenteral iron products and serious anaphylactic-type reactions. *Am J Hematol.* 2010; 85(9): 650–654, doi: 10.1002/ajh.21794, indexed in Pubmed: 20661919.
42. Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. *Mayo Clin Proc.* 2015; 90(1): 12–23, doi: 10.1016/j.mayocp.2014.10.007, indexed in Pubmed: 25572192.
43. European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144874.pdf (27.07.2023).
44. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management.

- Haematologica. 2014; 99(11): 1671–1676, doi: 10.3324/haematol.2014.111492, indexed in Pubmed: 25420283.
45. Lim W, Afif W, Knowles S, et al. Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults. *Vox Sang.* 2019; 114(4): 363–373, doi: 10.1111/vox.12773, indexed in Pubmed: 30937914.
46. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. *BMJ.* 2013; 347: f4822, doi: 10.1136/bmj.f4822, indexed in Pubmed: 23950195.
47. Shah A, Fisher SA, Wong H, et al. Safety and efficacy of iron therapy on reducing red blood cell transfusion requirements and treating anaemia in critically ill adults: a systematic review with meta-analysis and trial sequential analysis. *J Crit Care.* 2019; 49: 162–171.
48. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. *Proc Natl Acad Sci U S A.* 1985; 82(22): 7580–7584, doi: 10.1073/pnas.82.22.7580, indexed in Pubmed: 3865178.
49. Schoen MW, Hoque S, Witherspoon BJ, et al. End of an era for erythropoiesis-stimulating agents in oncology. *Int J Cancer.* 2020; 146(10): 2829–2835, doi: 10.1002/ijc.32917, indexed in Pubmed: 32037527.
50. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. *JAMA.* 2008; 299(8): 914–924, doi: 10.1001/jama.299.8.914, indexed in Pubmed: 18314434.
51. Gergal Gopalkrishna Rao SR, Bugazia S, Dhandapani TP, et al. Efficacy and Cardiovascular Adverse Effects of Erythropoiesis Stimulating Agents in the Treatment of Cancer-Related Anemia: A Systematic Review of Randomized Controlled Trials. *Cureus.* 2021; 13(9): e17835, doi: 10.7759/cureus.17835, indexed in Pubmed: 34527499.
52. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Growth Factors Version 2.2023 — March 6, 2023. © National Comprehensive CancerNetwork, Inc. 2023. All rights reserved. Accessed 27 July 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.
53. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. *Blood.* 2008; 111(10): 4902–4907, doi: 10.1182/blood-2007-10-116327, indexed in Pubmed: 18216292.
54. Brar SK, Perveen S, Chaudhry MR, et al. Erythropoietin-Induced Hypertension: A Review of Pathogenesis, Treatment, and Role of Blood Viscosity. *Cureus.* 2021; 13(1): e12804, doi: 10.7759/cureus.12804, indexed in Pubmed: 33628672.
55. Kumar SM, Zhang G, Bastian BC, et al. Erythropoietin and erythropoietin receptor expression in human cancer. *Cancer Res.* 2001; 61(9): 3561–3565, indexed in Pubmed: 11325818.
56. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. *J Clin Oncol.* 2007; 25(9): 1027–1032, doi: 10.1200/JCO.2006.07.1514, indexed in Pubmed: 17312332.
57. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. *J Clin Oncol.* 2005; 23(25): 5960–5972, doi: 10.1200/JCO.2005.06.150, indexed in Pubmed: 16087945.
58. Aapro M, Moebus V, Nitz U, et al. Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis. *Ann Oncol.* 2015; 26(4): 688–695, doi: 10.1093/annonc/mdl579, indexed in Pubmed: 25542926.
59. Vansteenkiste J, Glaspy J, Henry D, et al. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. *Lung Cancer.* 2012; 76(3): 478–485, doi: 10.1016/j.lungcan.2011.12.015, indexed in Pubmed: 22277104.
60. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. *Br J Cancer.* 2010; 102(2): 301–315, doi: 10.1038/sj.bjc.6605498, indexed in Pubmed: 20051958.
61. Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. *J Clin Oncol.* 2009; 27(17): 2838–2847, doi: 10.1200/JCO.2008.19.1130, indexed in Pubmed: 19380447.
62. Gascón P, Nagarkar R, Šmakal M, et al. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC. *J Thorac Oncol.* 2020; 15(2): 190–202, doi: 10.1016/j.jtho.2019.10.005, indexed in Pubmed: 31629060.
63. Bastit L, Vandebroek An, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. *J Clin Oncol.* 2008; 26(10): 1611–1618, doi: 10.1200/JCO.2006.10.4620, indexed in Pubmed: 18375890.
64. Silva I, Alipio C, Pinto R, et al. Potential anti-inflammatory effect of erythropoietin in non-clinical studies in vivo: A systematic review. *Biomed Pharmacother.* 2021; 139: 111558, doi: 10.1016/j.biopha.2021.111558, indexed in Pubmed: 33894624.
65. Ludwig H, Aapro M, Bokemeyer C, et al. A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. *Support Care Cancer.* 2014; 22(8): 2197–2206, doi: 10.1007/s00520-014-2189-0, indexed in Pubmed: 24659244.
66. Schrijvers D. Management of anemia in cancer patients: transfusions. *Oncologist.* 2011; 16 Suppl 3: 12–18, doi: 10.1634/theoncologist.2011-53-12, indexed in Pubmed: 21930830.
67. Chau JKM, Harris JR, Seikaly HR. Transfusion as a predictor of recurrence and survival in head and neck cancer surgery patients. *J Otolaryngol Head Neck Surg.* 2010; 39(5): 516–522, indexed in Pubmed: 20828514.
68. Anic K, Schmidt MW, Schmidt M, et al. Impact of perioperative red blood cell transfusion, anemia of cancer and global health status on the prognosis of elderly patients with endometrial and ovarian cancer. *Front Oncol.* 2022; 12: 967421, doi: 10.3389/fonc.2022.967421.
69. Al-Refaie WB, Parsons HM, Markin A, et al. Blood transfusion and cancer surgery outcomes: a continued reason for concern. *Surgery.* 2012; 152(3): 344–354, doi: 10.1016/j.surg.2012.06.008, indexed in Pubmed: 22938895.
70. Busch OR, Hop WC, Hoynck van Papendrecht MA, et al. Blood transfusions and prognosis in colorectal cancer. *N Engl J Med.* 1993; 328(19): 1372–1376, doi: 10.1056/NEJM199305133281902, indexed in Pubmed: 8292113.
71. Squires MH, Kooby DA, Poultsides GA, et al. Effect of Perioperative Transfusion on Recurrence and Survival after Gastric Cancer Resection: A T-Institution Analysis of 765 Patients from the US Gastric Cancer Collaborative. *J Am Coll Surg.* 2015; 221(3): 767–777, doi: 10.1016/j.jamcollsurg.2015.06.012, indexed in Pubmed: 26228017.
72. Kooby DA, Stockman J, Ben-Porat L, et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. *Ann Surg.* 2003; 237(6): 860–9; discussion 869, doi: 10.1097/01.SLA.0000072371.95588.DA, indexed in Pubmed: 12796583.
73. Khorana AA, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. *Arch Intern Med.* 2008; 168(21): 2377–2381, doi: 10.1001/archinte.168.21.2377, indexed in Pubmed: 19029504.
74. Xenos ES, Vargas HD, Davenport DL. Association of blood transfusion and venous thromboembolism after colorectal cancer resection. *Thromb Res.* 2012; 129(5): 568–572, doi: 10.1016/j.thromres.2011.07.047, indexed in Pubmed: 21872295.
75. Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? *Blood.* 2001; 97(5): 1180–1195, doi: 10.1182/blood.v97.5.1180, indexed in Pubmed: 11222359.
76. Cata JP, Wang H, Gottumukkala V, et al. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. *Br J Anaesth.* 2013; 110(5): 690–701, doi: 10.1093/bja/aet068, indexed in Pubmed: 23599512.
77. Mispelbaum R, Hattenhauer ST, Brossart P, et al. Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors. *Front Immunol.* 2022; 13: 976011, doi: 10.3389/fimmu.2022.976011, indexed in Pubmed: 36159812.
78. Carson JL, Stanworth SJ, Dennis JA, et al. Transfusion thresholds for guiding red blood cell transfusion. *Cochrane Database Syst Rev.* 2021; 12(12): CD002042, doi: 10.1002/14651858.CD002042.pub5.
79. Watkins T, Surowiecka MK, McCullough J. Transfusion indications for patients with cancer. *Cancer Control.* 2015; 22(1): 38–46, doi: 10.1177/107327481502200106, indexed in Pubmed: 25504277.
80. Scott JM, Weir DG. Drug-induced megaloblastic change. *Clin Haematol.* 1980; 9(3): 587–606, indexed in Pubmed: 6450011.
81. Danaei G, Vander Hoorn S, Lopez AD, et al. Comparative Risk Assessment collaborating group (Cancers). Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. *Lancet.* 2005; 366(9499): 1784–1793, doi: 10.1016/S0140-6736(05)67725-2, indexed in Pubmed: 16298215.

82. Dong B, Qi Y, Lin Lu, et al. Which Exercise Approaches Work for Relieving Cancer-Related Fatigue? A Network Meta-analysis. *J Orthop Sports Phys Ther.* 2023; 0(6): 1–10, doi: 10.2519/jospt.2023.11251, indexed in Pubmed: 36947532.
83. Brown JC, Ma C, Shi Q, et al. Association between physical activity and the time course of cancer recurrence in stage III colon cancer. *Br J Sports Med.* 2023; 57(15): 965–971, doi: 10.1136/bjsports-2022-106445, indexed in Pubmed: 36878665.
84. Rørth M, Madsen KR, Burmølle SH, et al. Effects of Darbepoetin Alfa with exercise in cancer patients undergoing chemotherapy: an explorative study. *Scand J Med Sci Sports.* 2011; 21(3): 369–377, doi: 10.1111/j.1600-0838.2009.01066.x, indexed in Pubmed: 20136754.
85. Drouin JS, Young TJ, Beeler J, et al. Random control clinical trial on the effects of aerobic exercise training on erythrocyte levels during radiation treatment for breast cancer. *Cancer.* 2006; 107(10): 2490–2495, doi: 10.1002/cncr.22267, indexed in Pubmed: 17031805.
86. Mohamady HM, Elsis HF, Aneis YM. Impact of moderate intensity aerobic exercise on chemotherapy-induced anemia in elderly women with breast cancer: A randomized controlled clinical trial. *J Adv Res.* 2017; 8(1): 7–12, doi: 10.1016/j.jare.2016.10.005, indexed in Pubmed: 27872759.
87. Ashem HN, Hamada HA, Abbas RL. Effect of aerobic exercise on immunoglobulins and anemia after chemotherapy in breast cancer patients. *J Bodyw Mov Ther.* 2020; 24(3): 137–140, doi: 10.1016/j.jbmt.2020.01.001, indexed in Pubmed: 32825979.
88. Vadhan-Raj S, Abonour R, Goldman JW, et al. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. *J Hematol Oncol.* 2017; 10(1): 73, doi: 10.1186/s13045-017-0427-x, indexed in Pubmed: 28327200.
89. Jeng SS, Chen YH. Association of Zinc with Anemia. *Nutrients.* 2022; 14(22), doi: 10.3390/nu14224918, indexed in Pubmed: 36432604.
90. Greffeuille V, Fortin S, Gibson R, et al. Associations between Zinc and Hemoglobin Concentrations in Preschool Children and Women of Reproductive Age: An Analysis of Representative Survey Data from the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) Project. *J Nutr.* 2021; 151(5): 1277–1285, doi: 10.1093/jn/nxaa444, indexed in Pubmed: 33693923.

The European Code Against Cancer – new evidence and recommendations

Ariadna Feliu , David Ritchie , Joachim Schüz , Carolina Espina 

Environment and Lifestyle Epidemiology Branch, International Agency for Research on Cancer, Lyon, France

Cancer is a major public health concern in the European Union (EU). There were 2.7 million new cancer cases and 1.3 million deaths in 2020 in the EU; of them, around 40% could have been prevented. Primary prevention is the most cost-effective long-term strategy for cancer control. The European Code Against Cancer (ECAC, 4th edition) is a health education tool aimed at raising awareness about evidence-based cancer prevention actions among EU citizens. The ECAC describes 12 ways individuals can reduce their cancer risk. Awareness of the ECAC (4th ed.) has been low (2–21%) and, therefore, efforts are needed to improve cancer prevention awareness throughout the region. Civil society and other stakeholders' engagement is key to improving cancer prevention in the region. Our aim is to propose recommendations to improve future ECAC editions to ensure an increase in cancer prevention literacy in the EU.

Key words: European Code Against Cancer, cancer prevention, health literacy

Introduction

Cancer is a major public health concern in the European Union (EU) since it is the second leading cause of mortality after cardiovascular diseases [1]. Europe accounts for approximately 10% of the global population but yet has 25% of the world's registered cancer cases [2]. In 2020, there were 2.7 million new cancer cases and 1.3 million deaths in the EU. Four cancer types were responsible for almost 50% of all cancer diagnoses. Breast cancer is the most commonly diagnosed cancer accounting for 13.3% of all cancer diagnoses (355,500 cases; females only), followed by colorectal (341,400; 12.7%), prostate (335,500; 12.5%) and lung (318,300; 11.9%) cancers.

In Poland, specifically, there were 204,575 new cancer cases and 119,319 deaths. Breast cancer is the most common cause of cancer death (11.8%), followed by lung cancer (11.4%) and colorectal cancer (10.4%) [3]. Poland has 8.7% lower age-adjusted incidence rate for all cancer types (excluding non-melanoma skin cancer) than the average in the EU. Highest

differences in age-adjusted incidence rates were observed for skin melanoma (5.1 vs. 13.4), liver (3.5 vs. 5.8) and non-Hodgkin lymphoma (6.1 vs. 9.4) (figure 1; illustrated for all cancer types with an age-adjusted incidence rate of 5 per 100,000 persons per year or larger in the EU27) [1]. Given the significant risk-modifying effect of modifiable factors [4], it has been estimated that around 40% of all cancer cases in Europe could be prevented and mortality reduced [5].

Primary prevention, or the avoidance of cancer, is the most cost-effective long-term strategy for cancer control [6]; yet further comprehensive efforts are needed to address cancer burden, including secondary prevention interventions, such as screening programs followed by effective and early diagnoses and treatment [7]. Successful cancer prevention requires evidence-based effective preventive measures at the individual-level, to avoid or reduce certain exposures or unhealthy behaviours, as well as governmental policies and programmes at the population-level, to create the healthy environments

Jak cytować / How to cite:

Feliu A, Ritchie D, Schüz J, Espina C. *The European Code Against Cancer – new evidence and recommendations*. NOWOTWORY J Oncol 2023; 73: 317–322.




Figure 1. Difference in the age-adjusted incidence rates (expressed in %) between Poland and the EU27 in 2020; the figure shows the difference in cancer types with age-adjusted incidence rates of 5 per 100,000 persons per year or more [1]

and health care infrastructures needed to prevent cancer. However, significant investment is still required by EU Member states (MS) to raise awareness on major risk factors and available interventions, to implement and endorse policies that would support people in making healthier choices by default, and to encourage participation in cancer screening and immunization programmes. Without these actions in place, according to Europe's Beating Cancer Plan, cancer mortality within the EU is expected to increase by more than 24% by 2035 [5], making it the region's leading cause of death.

Improved cancer prevention in Europe requires both, addressing modifiable risk factors of cancer such as tobacco and alcohol consumption, lack of physical activity, being overweight, an unhealthy diet, exposure to ultraviolet radiation and air pollution, as well as strengthening cancer screening and vaccination programs. For individuals to engage in such preventive actions, they first need to be informed about those evidence-based actions and interventions that can reduce their risk of cancer. However, in today's media landscape, the amount of confusing, ambiguous, overwhelming, or even contradictory messages is escalating [8], making suitable advice based on the most up to date evidence and developed by authoritative organizations a key tool for cancer prevention. Offering information that is consistent with the best scientific evidence available at the time and providing access to high-quality health information that is relevant, trustworthy, and accessible [9, 10], is crucial for individuals to be able to make informed decisions on cancer prevention.

Yet knowledge alone will not suffice when it comes to promoting a change in unhealthy behaviours or engaging in healthy actions and interventions [11]. Indeed, behavioural change theories, such as the Integrated Theory of Health Behavior Change (ITHBC) [12] or the Behaviour Change Wheel

[13], argue that healthy behaviours can be enhanced by fostering knowledge and understanding, since individuals are more likely to engage in recommended healthy actions and interventions if they have information about them. For example, understanding the health risks associated with smoking is essential in making a decision about quitting [14]. Similarly, evidence shows that providing information about established risk factors of cancer to individuals can improve the accuracy of risk perception, enhance response efficacy and increase intention to take action [15].

The European Code Against Cancer (ECAC) is an educational tool from credible authoritative sources, aimed at providing high-quality evidence-based information to the public, about cancer prevention actions that can be followed without specialised skills or advice. The aim of this work is to present the ECAC, assess the level of cancer prevention awareness among the European population, describe the role of civil society and other stakeholders' engagement in improving cancer prevention in the region, and propose recommendations for future interventions designed to boost cancer prevention literacy across the region.

The European Code Against Cancer

The ECAC is a health education tool aimed at raising awareness about evidence-based cancer prevention actions among EU citizens. The ECAC consists of a set of cancer prevention recommendations for the individuals to avoid or reduce exposures to established causes of cancer, adopt healthy behaviours to reduce cancer risk, and to participate in vaccination and screening programs under the appropriate national guidelines [8]. The ECAC has succeeded to inform policymakers and other stakeholders to develop national health policies in cancer prevention [16, 17].

The ECAC, 4th edition, describes “12 ways to reduce your cancer risk”, including avoiding or reducing unhealthy behaviours, such as:

- tobacco smoking and use of other forms of tobacco,
- exposure to second-hand smoke,
- drinking alcohol,
- exposure to ultraviolet radiation, high levels of radon and occupational carcinogens,
- limiting the use of hormone replacement therapy.

And protecting measures, such as:

- maintaining a healthy body weight,
- being physically active,
- eating a healthy diet,
- breastfeeding,
- participating in human papilloma virus (HPV) and hepatitis B virus (HBV) vaccination programmes, and bowel, breast, and cervical cancer screening.

The 4th edition also included a website, with over 200 questions and answers aimed at the public, explaining and providing additional information on the recommendations as well as cancer prevention topics not covered in the ECAC [8].

The ECAC is originally an initiative of the European Commission (EC) that provides a comprehensive synthesis of the available current evidence on cancer prevention and translates this into recommendations in an understandable way to the public following a standardized methodology developed to guide scientific assessments [18]. The International Agency for Research on Cancer (IARC), specialized cancer agency of the WHO, was mandated by the EC to produce the current 4th edition of the ECAC, introducing the objective to formulate the recommendations in clear, straightforward, and actionable language that can be understood by the general public without requiring specialised skills, knowledge, or training [8]. With the publication of Europe's Beating Cancer Plan [5], the IARC's mandate to provide the scientific coordination to update the ECAC was renewed, with the target of producing the 5th edition of ECAC by 2025.

In addition, the Innovative Partnership for Action Against Cancer (iPAAC) Joint Action (JA), commissioned to develop recommendations to ensure sustainability and monitoring of the ECAC [19], concluded that ongoing monitoring and evaluation of the ECAC are needed to ensure that the ECAC reaches its target population(s), as well as measure the impact of its use and inform routine updates [20]. In 2017, Ritchie et al. [16] evaluated for the first time the impact of the ECAC (4th ed.) at the EU level and found that, although the awareness of the ECAC was low – 2% in the United Kingdom (UK) to 21% in Hungary and Poland – willingness to make behavioural changes towards cancer prevention after reading the recommendations reached over 60%. These results highlight that we are still far from achieving Europe's Beating Cancer Plan's goal to making at least 80% of the population aware of the ECAC by 2025 [5].

The ECAC, 4th edition, provided an inspiring model to IARC for scaling up this tool to other regions of the world under the umbrella of a World Code Against Cancer Framework [21] to promote cancer prevention globally [22]. Despite disparities between regions, the experience of developing the ECAC 4th ed. provided the strategy, methodology and tools to expand these guidelines to other regions of the world. The European model has been recently adapted to the Latin America and the Caribbean (LAC) region [23]. The LAC Code Against Cancer will be launch during the second half of 2023.

Cancer prevention awareness in Europe

Currently, there is no psychometric instrument available based on the last edition of the ECAC; however, other surveys have been developed in relation to cancer and its risk factors, uptake of cancer screening and cancer prevention in general among the general population. Some examples include the Cancer Awareness Measure (CAM) [24], Attitudes and Beliefs about Cancer (ABC) [25] and national Cancer Barometers (France, Spain, or Belgium) [26–28].

Previous studies in European countries based on population-based surveys have assessed the public's knowledge of cancer risk factors and perceptions of symptoms, behaviours, and risks. Findings from Denmark, France, Ireland, Spain, Sweden and the UK reveal modest to low levels of public awareness of cancer risk factors [29–32]. Although most individuals perceived tobacco smoking as a main risk factor for cancer, they failed to identify other well-established modifiable risk factors, such as sexually transmitted viruses, alcohol, being overweight or environmental factors [29, 33]. Lifestyle determinants were commonly thought to be associated with cancer since the majority of French and Spanish respondents thought that physical inactivity, being overweight and having unhealthy diets played an important role; however, the protective association of breastfeeding with cancer was mostly unknown [33, 34]. Levels of awareness of modifiable risk factors of cancer demonstrated a sociodemographic gradient. Perceptions of the impact of these factors on the onset of cancer were lower among men, the elderly and those with a lower socio-economic status or education level [29, 31, 34]. Awareness was, therefore, lowest among those demographic groups at higher risk of developing cancer.

Health literacy (HL) is defined as “the ability to obtain, understand, process and apply health information to health decision-making” [35] and it is directly linked to engagement in cancer prevention behaviours. Previous studies have shown that limited levels of HL lead to lower adherence to risk-reducing behaviours and are related to smoking, a sedentary lifestyle and low fruit and vegetable consumption [36]. Low HL also contributes to a false perception of low risk from cancer and, therefore, lower adoption of cancer prevention actions and interventions, since perceived risk is a key component in behavioural change theoretical models [37]. Finally,

low HL has also been associated with cancer misconceptions and myths, less information-seeking and reduced perceived control over cancer risks [38]. All in all, despite the fact that individuals' knowledge and perceptions may not always match their actions [11], awareness of cancer risk factors is still essential for cancer prevention.

Efforts are needed to improve cancer prevention awareness throughout the EU. Policies and interventions within a universalism framework should be designed to reach all social segments of the population. In other words, due to the importance of sociodemographic factors on individuals' knowledge and perceptions, community-wide and tailored health education interventions on cancer prevention are needed to reduce socioeconomic disparities in cancer incidence and mortality [39], and to ensure that no country is left behind in the EU. The ECAC serves as a "toolbox" for policymakers, civil society and other stakeholders to prioritize the policies and strategies that will allow improving EU citizens' adherence to cancer prevention.

Civil society and cancer prevention

Civil society is a widely used term to denote the field of activity that is independent of both governmental and for-profit interests. Civil society organizations (CSOs) have, therefore, been defined as non-state, not-for-profit, voluntary organizations formed by people in a social sphere that is separate from both the state and the market [40]. Standing aside from the economic imperative to deliver a profit, and outside of the direct influence of governments, civil society is placed in a position of unique responsibility to act solely for social good.

CSOs have been instrumental in advancing cancer prevention, as recommended by the ECAC, through various means. As service providers, CSOs deliver programs and provide vital resources that are neglected or absent from governmental provision, particularly in resource-limited settings [41]. This work takes place at the grassroots level, whereby CSOs can enhance resilience in those communities by catalysing the implementation of, for instance, organized cancer screening programs [42], or by extending the scope of primary and secondary cancer prevention services to better address the needs of vulnerable or marginalized sections of society [43].

A further approach by which CSOs contribute towards cancer prevention is via the dissemination of evidence-based cancer prevention guidance to the general population as laid out by the ECAC. CSOs have been instrumental knowledge brokers for cancer prevention by developing understandable materials to heighten awareness of health determinants and cancer risk factors [16]. This capacity has proven to be an especially valuable asset when mitigating the effects of inaccurate information or the vested interests of stakeholders, which can be opposed to the objectives of cancer prevention [40]. For instance, in countries which have experienced a loss of confidence in the HPV vaccination programmes, CSOs have

demonstrated success in developing campaigns that promote honest and reliable scientific information to the concerned public, which has resulted in regained trust and improved uptake of the HPV vaccination program [44].

CSOs not only provide information to the public but play a vital role in conveying the concerns and interest of wide sections of society to policymakers. Becoming advocates and enablers of change for the public good, further demonstrates how CSOs contribute to cancer prevention [45]. In recognition of the contribution of CSOs, the 2017 World Health Assembly resolution on "cancer prevention and control in the context of an integrated approach" calls upon member states of the WHO to foster partnerships with CSOs to improve the provision of services for cancer prevention and control [46]. This underscores the essential role CSOs have in promoting and sustaining cancer prevention as part of a "Whole of Society" approach [47].

Case-study in Poland

Cancer prevention advocates in Poland have had a long and proud history of disseminating the ECAC from its very beginnings – since the 1980s. Even before Poland became an EU member state in 2004, the ECAC was actively and widely disseminated across the country, with a special emphasis on communicating to children, adolescents and young adults. For the 3rd edition of ECAC, published in 2003, the programme "Schools promoting the recommendations of the European Code Against Cancer" was an especially successful initiative, which in the Małopolska voivodship reached approximately 80% of schools, 20,000 teachers, 300,000 students and 20,000 members of the local community [48]. Activities to promote the ECAC continued following the publication of the 4th edition in 2014. Of note was the informational brochure developed by experts in conjunction with Polish League Against Cancer, which describes the information of the ECAC in simple, easy to understand language, and was distributed free of charge to thousands of people throughout Poland (www.12sposobownazdrowie.pl/12_sposobow.pdf). Consequently, of those countries whose populations were surveyed regarding the awareness of the ECAC, Poland ranked as the joint highest, with a relatively high proportion (30%) of 25–34-year-olds surveyed, stating they knew of the ECAC [16]. This suggests that the consistent efforts to promote ECAC focused on children and young people in Poland have helped to maintain awareness of the ECAC.

Steps forward and recommendations

Experts and other stakeholders from the iPAAC JA [20], introduced above, suggested that the future ECAC editions:

- should broaden the scope to evidence-based individual and population level interventions and their implementation,
- have a multidisciplinary approach with synergies between cancer-targeted and NCDs-related recommendations,

- be tailored to different target groups and audiences (e.g., healthcare professionals and policymakers).

Finally, they recommended using the ECAC as a unifying tool for cancer prevention in the EU (the “toolbox” mentioned above). Most of these recommendations will not only be addressed in the new edition of the ECAC (5th edition), currently under development and due to launch in 2025 but will also inform the global methodology of the World Code Against Cancer Framework. The conclusions of the iPAAC JA were published in June 2021 and, since then, other initiatives have been introduced to improve the new edition of the ECAC and its further implementation. One example is the joint call by IARC, Institut National du Cancer (INCA) in France, and the Association of European Cancer Leagues (ECL) for the EC to commit to establishing a thorough, robust and systematic evaluation of the ECAC, which would be best served by the re-introduction of the ECAC-dedicated Eurobarometer survey to be implemented in 2024, before the launch of the 5th edition of the ECAC. Its results would be used as a baseline for EU citizens’ level of awareness of cancer prevention and, ideally, through periodic surveys, monitoring and evaluating the impact of the ECAC across the EU will be possible.

Hence, monitoring and evaluating not only the impact of the Code on public awareness, but also its development process is key in ensuring ECAC’s sustainability and a path to optimizing and enhancing its methodology.

Conclusions

The ECAC, under the umbrella of the World Code Against Cancer Framework, is a health education tool aimed at improving health literacy in cancer prevention to the public and nurturing the development of evidence-based cancer control policies. This initiative is constantly evolving to include the latest scientific data, and to respond to the needs of the European population and stakeholders as regards cancer prevention.

Article information and declarations

Funding

None declared

Acknowledgments

The authors alone are responsible for the views expressed in this manuscript. Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.

Conflict of interest

None declared

Ariadna Feliu

International Agency for Research on Cancer
Environment and Lifestyle Epidemiology Branch
25 av. Tony Garnier CS 90627
69366 Lyon CEDEX 07, France
e-mail: felijusaa@iarc.who.int

Received: 28 Jul 2023

Accepted: 28 Aug 2023

References

1. Cancer burden statistics and trends across Europe | ECIS [Internet]. <https://ecis.jrc.ec.europa.eu/> (15.06.2023).
2. European Parliament. Strengthening Europe in the fight against cancer [Internet]. 2020. <http://www.europarl.europa.eu/supporting-analyses>.
3. Dyba T, Randi G, Bray F, et al. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. *Eur J Cancer*. 2021; 157: 308–347, doi: 10.1016/j.ejca.2021.07.039, indexed in Pubmed: 34560371.
4. Stein CJ, Colditz GA. Modifiable risk factors for cancer. *Br J Cancer*. 2004; 90(2): 299–303, doi: 10.1038/sj.bjc.6601509, indexed in Pubmed: 14735167.
5. European Parliament and the Council. Europe’s Beating Cancer Plan Brussels, 2021.
6. Winn AN, Ekwueme DU, Guy GP, et al. Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic Review. *Am J Prev Med*. 2016; 50(2): 241–248, doi: 10.1016/j.amepre.2015.08.009, indexed in Pubmed: 26470806.
7. Tran KB, Lang JJ, Compton K, et al. The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2022; 400(10352): 563–591, doi: 10.1016/S0140-6736(22)01438-6.
8. Schüz J, Espina C, Villain P, et al. Working Groups of Scientific Experts. European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. *Cancer Epidemiol*. 2015; 39 Suppl 1: S1–10, doi: 10.1016/j.canep.2015.05.009, indexed in Pubmed: 26164654.
9. Oxman AD, Paulsen EJ. Who can you trust? A review of free online sources of “trustworthy” information about treatment effects for patients and the public. *BMC Med Inform Decis Mak*. 2019; 19(1): 35, doi: 10.1186/s12911-019-0772-5, indexed in Pubmed: 30786889.
10. Kington RS, Arnesen S, Chou WYS, et al. Identifying Credible Sources of Health Information in Social Media: Principles and Attributes. *NAM Perspect*. 2021; 2021, doi: 10.31478/202107a, indexed in Pubmed: 34611600.
11. Karasiewicz M, Chawłowska E, Lipiak A, et al. How to Improve Cancer Prevention Knowledge? A Way to Identify Gaps and Tackle the Limited Availability of Health Education Services in Primary Health Care Using the European Code Against Cancer. *Front Public Health*. 2022; 10: 878703, doi: 10.3389/fpubh.2022.878703, indexed in Pubmed: 35586014.
12. Ryan P. Integrated Theory of Health Behavior Change: background and intervention development. *Clin Nurse Spec*. 2009; 23(3): 161–70; quiz 171, doi: 10.1097/NUR.0b013e3181a42373, indexed in Pubmed: 19395894.
13. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. *Implement Sci*. 2011; 6: 42, doi: 10.1186/1748-5908-6-42, indexed in Pubmed: 21513547.
14. Golechha M. Health Promotion Methods for Smoking Prevention and Cessation: A Comprehensive Review of Effectiveness and the Way Forward. *Int J Prev Med*. 2016; 7: 7, doi: 10.4103/2008-7802.173797, indexed in Pubmed: 26941908.
15. Usher-Smith JA, Sharp SJ, Luben R, et al. Development and Validation of Lifestyle-Based Models to Predict Incidence of the Most Common Potentially Preventable Cancers. *Cancer Epidemiol Biomarkers Prev*. 2019; 28(1): 67–75, doi: 10.1158/1055-9965.EPI-18-0400, indexed in Pubmed: 30213791.
16. Ritchie D, Mallafre-Larrosa M, Ferro G, et al. Evaluation of the impact of the European Code against Cancer on awareness and attitudes towards cancer prevention at the population and health promoters’ levels. *Cancer Epidemiol*. 2021; 71(Pt A): 101898, doi: 10.1016/j.canep.2021.101898, indexed in Pubmed: 33611135.
17. Espina C, Soerjomataram I, Forman D, et al. Cancer prevention policy in the EU: Best practices are now well recognised; no reason for coun-

- tries to lag behind. *J Cancer Policy*. 2018; 18: 40–51, doi: 10.1016/j.jcpo.2018.09.001, indexed in Pubmed: 30510896.
18. Minozzi S, Armaroli P, Espina C, et al. European Code against Cancer 4th Edition: Process of reviewing the scientific evidence and revising the recommendations. *Cancer Epidemiol*. 2015; 39 Suppl 1: S11–S19, doi: 10.1016/j.canep.2015.08.014, indexed in Pubmed: 26439654.
 19. Innovative Partnership for Action Against Cancer (IPAAC) [Internet]. <https://www.ipaac.eu/> (30.06.2023).
 20. Espina C, Yared W, Ritchie D, et al. Sustainability and monitoring of the European Code Against Cancer: Recommendations. *Cancer Epidemiol*. 2021; 72: 101933, doi: 10.1016/j.canep.2021.101933, indexed in Pubmed: 33838462.
 21. World Code Against Cancer Framework [Internet]. <https://cancer-code-world.iarc.who.int/> (29.06.2023).
 22. Espina C, Herrero R, Sankaranarayanan R, et al. Toward the World Code Against Cancer. *J Glob Oncol*. 2018; 4: 1–8, doi: 10.1200/JGO.17.00145, indexed in Pubmed: 30241265.
 23. Espina C, Feliu A, Maza M, Almonte M, Ferreccio C, Finck C, et al. Latin America and the Caribbean Code Against Cancer 1st Edition: 17 cancer prevention recommendations to the public and to policy-makers (World Code Against Cancer Framework). *Cancer Epidemiology*. 2023 [embargoed, Oct 2023].
 24. Stubbings S, Robb K, Waller J, et al. Development of a measurement tool to assess public awareness of cancer. *Br J Cancer*. 2009; 101 Suppl 2(Suppl 2): S13–S17, doi: 10.1038/sj.bjc.6605385, indexed in Pubmed: 19956157.
 25. Simon AE, Forbes LJJ, Boniface D, et al. ICBP Module 2 Working Group, ICBP Programme Board and Academic Reference Group. An international measure of awareness and beliefs about cancer: development and testing of the ABC. *BMJ Open*. 2012; 2(6), doi: 10.1136/bmjopen-2012-001758, indexed in Pubmed: 23253874.
 26. French National Cancer Institute. Cancer Barometer: Attitudes and behaviours among French people in relation to cancer 2021.
 27. Asociación Española Contra el Cáncer. *Oncobarómetro* [Internet]. Madrid; 2021. www.aecc.es.
 28. Belgische Kankerbarometer. 2021. www.kanker.be.
 29. Ryan AM, Cushen S, Schellekens H, et al. Poor awareness of risk factors for cancer in Irish adults: results of a large survey and review of the literature. *Oncologist*. 2015; 20(4): 372–378, doi: 10.1634/theoncologist.2014-0453, indexed in Pubmed: 25746344.
 30. Lagerlund M, Hvidberg L, Hajdarevic S, et al. Awareness of risk factors for cancer: a comparative study of Sweden and Denmark. *BMC Public Health*. 2015; 15: 1156, doi: 10.1186/s12889-015-2512-9, indexed in Pubmed: 26596679.
 31. Petrova D, Pollán M, García-Retamero R, et al. Cancer awareness in older adults: Results from the Spanish Onco-barometer cross-sectional survey. *Int J Nurs Stud*. 2023; 140: 104466, doi: 10.1016/j.ijnurstu.2023.104466, indexed in Pubmed: 36871541.
 32. Sanderson SC, Waller Jo, Jarvis MJ, et al. Awareness of lifestyle risk factors for cancer and heart disease among adults in the UK. *Patient Educ Couns*. 2009; 74(2): 221–227, doi: 10.1016/j.pec.2008.08.003, indexed in Pubmed: 19059747.
 33. Petrova D, Borrás JM, Pollán M, et al. Public Perceptions of the Role of Lifestyle Factors in Cancer Development: Results from the Spanish Onco-Barometer 2020. *Int J Environ Res Public Health*. 2021; 18(19), doi: 10.3390/ijerph181910472, indexed in Pubmed: 34639771.
 34. Lamore K, Ducrot P, Latino-Martel P, et al. Diet, Physical Activity, Obesity, and Breastfeeding: How French People Perceive Factors Associated with Cancer Risk. *Nutrients*. 2019; 11(10), doi: 10.3390/nu11102491, indexed in Pubmed: 31623260.
 35. Kickbusch I, Maag D. Health Literacy. *International Encyclopedia of Public Health*. 2008: 204–211, doi: 10.1016/b978-012373960-5.00584-0.
 36. Fernandez DM, Larson JL, Zikmund-Fisher BJ. Associations between health literacy and preventive health behaviors among older adults: findings from the health and retirement study. *BMC Public Health*. 2016; 16: 596, doi: 10.1186/s12889-016-3267-7, indexed in Pubmed: 27430477.
 37. Ferrer R, Klein WM. Risk perceptions and health behavior. *Curr Opin Psychol*. 2015; 5: 85–89, doi: 10.1016/j.copsyc.2015.03.012, indexed in Pubmed: 26258160.
 38. Fleary SA, Paasche-Orlow MK, Joseph P, et al. The Relationship Between Health Literacy, Cancer Prevention Beliefs, and Cancer Prevention Behaviors. *J Cancer Educ*. 2019; 34(5): 958–965, doi: 10.1007/s13187-018-1400-2, indexed in Pubmed: 30022378.
 39. Vaccarella S, Georges D, Bray F, et al. Socioeconomic inequalities in cancer mortality between and within countries in Europe: a population-based study. *Lancet Reg Health Eur*. 2023; 25: 100551, doi: 10.1016/j.lanep.2022.100551, indexed in Pubmed: 36818237.
 40. Civil society and health: contributions and potential [Internet]. <https://apps.who.int/iris/handle/10665/326290> (17.07.2023).
 41. Azenha G, Bass LP, Caleffi M, et al. The role of breast cancer civil society in different resource settings. *Breast*. 2011; 20 Suppl 2: S81–S87, doi: 10.1016/j.breast.2011.02.005, indexed in Pubmed: 21345677.
 42. Ritchie D. Contribution of cancer leagues to the promotion and organisation of cancer screening programmes. *J Heal Inequalities*. 2017; 3(2): 157–161, doi: 10.5114/jhi.2017.74210.
 43. Mallafré-Larrosa M, Ritchie D, Papi G, et al. CBIG-SCREEN Consortium. Survey of current policies towards widening cervical screening coverage among vulnerable women in 22 European countries. *Eur J Public Health*. 2023; 33(3): 502–508, doi: 10.1093/eurpub/ckad055, indexed in Pubmed: 37043751.
 44. Bigaard J, Franceschi S. Vaccination against HPV: boosting coverage and tackling misinformation. *Mol Oncol*. 2021; 15(3): 770–778, doi: 10.1002/1878-0261.12808, indexed in Pubmed: 33058497.
 45. Dunn J, Herron L, Adams C, et al. Engaging NGOs in national cancer-control efforts. *Lancet Oncol*. 2013; 14(11): 1044–1046, doi: 10.1016/S1470-2045(13)70390-5, indexed in Pubmed: 24079863.
 46. Cancer prevention and control in the context of an integrated approach [Internet]. <https://apps.who.int/iris/handle/10665/275676> (17.07.2023).
 47. Ortenzi F, Marten R, Valentine NB, et al. Whole of government and whole of society approaches: call for further research to improve population health and health equity. *BMJ Glob Health*. 2022; 7(7), doi: 10.1136/bmjgh-2022-009972, indexed in Pubmed: 35906017.
 48. Janik-Konieczny K, Ritchie D, Blicharz U, et al. Towards systematic evaluation of the European Code Against Cancer. Dissemination of the Code in Poland. *J Heal Inequalities*. 2017; 3(2): 162–166, doi: 10.5114/jhi.2017.74211.

Rare case of recurrent myofibroblastoma in a female patient

Stanisław Ciechanowicz ^{ID}, Piotr Kupidłowski ^{ID}, Mateusz Wichtowski ^{ID}

Surgical Oncology Clinic, Poznan University of Medical Sciences, Poznan, Poland




Figure 1. Microscopic display of hematoxylin and eosin-stained section of classic myofibroblastoma




Figure 2. Spindle shaped, slender, bland and uniform cells closely packed in short fascicles intermixed with hyalinised, thick collagen bundles

A 61-year-old female patient presented with a painless lump located in the right breast. In 2015 she was diagnosed with mammary-type myofibroblastoma (MFB) in the right breast and underwent a resection. In 2016 there was a unilateral relapse and the second tumorectomy was performed. The patient underwent core needle biopsy, which indicated a non-epithelial spindle cell lesion with immunohistochemistry results CD34+; S100-; p63-; CKPAN-; ER-. On the MRI there was a lobular tumour (37 x 42 x 57 mm) with 2 satellite lesions. Due to the size of the tumour and previous breast surgeries, a nipple sparing mastectomy with reconstruction was performed. Histopathology confirmed MFB (fig. 1, fig. 2). MFB is a rare benign spindle cell tumour of the breast. Due to its rare incidence, no risk factors or genetic predispositions

are identified [1]. As MFB is well encapsulated, the treatment of choice is surgery without further adjuvant therapy. Only one relapse of MFB has been reported in the literature so far [2]. There is little data concerning recurrence of MFB [2], therefore careful observation and documentation of recurrent MFBs could prove beneficial in studying the nature of MFB and treating patients.

References

1. Magro G. Mammary myofibroblastoma: a tumor with a wide morphologic spectrum. *Arch Pathol Lab Med.* 2008; 132(11): 1813–1820, doi: 10.5858/132.11.1813, indexed in Pubmed: 18976021.
2. Scardina L, Franceschini G, Biondi E, et al. Myofibroblastoma of the breast: two case reports and literature review. *J Surg Case Rep.* 2021; 2021(4): rjab133, doi: 10.1093/jscr/rjab133, indexed in Pubmed: 33927867.

Jak cytować / How to cite:

Ciechanowicz S, Kupidłowski P, Wichtowski M. *Rare case of recurrent myofibroblastoma in a female patient.* NOWOTWORY J Oncol 2023; 73: 323.

Pneumoconiosis mimicking lung metastases of medullary thyroid carcinoma

Karolina Gasz¹, Agnieszka Żyłka², Joanna Długosińska², Marek Dedecjus²

¹Students Scientific Society „Thyroidea” of Department of Oncological Endocrinology and Nuclear Medicine,
Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

²Department of Oncological Endocrinology and Nuclear Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland



Figure 1. CT images of the thorax showing a pulmonary nodule in the SR segment




Figure 2. CT images of the thorax showing a right hilar lymphadenopathy

A 63-year-old man diagnosed with pT3N1b medullary thyroid carcinoma (MTC) was referred for further consultation three months after a total thyroidectomy with a left lateral lymphadenectomy. On admission the levels of carcinoembryonic antigen (CEA) and calcitonin (CT) were slightly elevated (CT – 51.1 pg/ml; CEA – 5.13 ng/ml). The patient underwent radiotherapy three months after surgical treatment. A follow-up CT of the thorax performed after the subsequent three months, revealed numerous pulmonary nodules (fig. 1) and a mediastinal lymphadenopathy (fig. 2) suspected of metastases. CT levels remained elevated (43 pg/ml) with a decrease of CEA level equally (3.61 ng/ml); the patient did not exhibit any respiratory symptoms. A histopathological examination of the retrieved lymph nodes did not show any abnormalities. Since the possibility of metastases could not be ruled out, the patient underwent an anterior thoracotomy. The removed lung masses unveiled black-grey nodules which turned out to be pneumoconiosis.

The patient history revealed exposure to dust and fumes. This is the first described case of pneumoconiosis mimicking MTC metastases. What is particularly worthy of attention is the short period of time from the radical surgery to the occurrence of initially absent multiple pulmonary lesions with a relatively insignificant growth of calcitonin. This pattern is characteristic for singular nodular MTC metastases rather than multiple micronodular metastases in solid organs [1]. It is worth emphasizing that in such cases we should take into consideration different respiratory system comorbidities, including occupational diseases.

References

1. Jarzab B, Dedecjus M, Lewiński A, et al. Diagnosis and treatment of thyroid cancer in adult patients – Recommendations of Polish Scientific Societies and the National Oncological Strategy. 2022 Update [Diagnostyka i leczenie raka tarczycy u chorych dorosłych – Rekomendacje Polskich Towarzystw Naukowych oraz Narodowej Strategii Onkologicznej. Aktualizacja na rok 2022]. *Endokrynologia Polska*. 2022; 73(2): 173–300, doi: 10.5603/ep.a.2022.0028.

Jak cytować / How to cite:

Gasz K, Żyłka A, Długosińska J, Dedecjus M. *Pneumoconiosis mimicking lung metastases of medullary thyroid carcinoma*. *NOWOTWORY J Oncol* 2023; 73: 324.

Prof. Maciej Krzakowski: *Nowotwory stanowiły dla mnie zawsze platformę współpracy ze znakomitymi onkologami*



Czasopismo *Nowotwory* towarzyszyło mojemu życiu zawodowemu od pierwszych dni pracy i od chwili zainteresowania się onkologią. W czasach, gdy zaczynałem specjalizację w dziedzinie radioterapii onkologicznej – mojej pierwszej specjalizacji – czasopismo to było najważniejszym źródłem wiedzy na ten temat, co miało szczególne znaczenie wobec ograniczonej dostępności zagranicznych źródeł. Ogromną zaletą *Nowotworów* była różnorodność tematyki artykułów. Publikowano prace ze wszystkich dziedzin związanych z postępowaniem przeciwnowotworowym – mogłem uzyskać wiadomości z zakresu epidemiologii i profilaktyki, diagnostyki i wszystkich metod leczenia. Mogę powiedzieć, że redaktorzy czasopisma – Profesor Jerzy Meyza i Profesor Edward Towpik – współtworzyli model wielospecjalistycznego postępowania przeciwnowotworowego. Wszechstronność *Nowotworów* jest do dzisiaj cechą charakterystyczną, co jest zasługą obecnego redaktora – Profesora Wojciecha Wysockiego.

Jeden z pierwszych artykułów oryginalnych, którego byłem pierwszym autorem, i który opublikowałem w czasopiśmie *Nowotwory*, dotyczył wykorzystania chemioterapii poprzedzającej radykalną radioterapię u chorych na nowotwory narządów regionu głowy i szyi [1]. Znaczenie miał nie tylko fakt, że artykuł został przyjęty. Bardzo ważne było dla mnie, że był następstwem badań rozpoczętych w nawiązaniu do szkoleniowego pobytu w Holandii oraz był inspirowany przez jednego z moich mistrzów, jakim był Profesor Andrzej Hliniak. Istotne było wówczas dla mnie znalezienie wartościowego miejsca leczenia systemowego w wielospecjalistycznym postępowaniu – myślę, że praca podczas przygotowania artykułu i wyniki badań przesądziły o moich późniejszych zainteresowaniach zawodowych. Jestem nadal wierny koncepcji kojarzenia metod leczenia miejscowego z systemowymi możliwościami – wówczas leczenie systemowe miało o wiele bardziej ograniczone możliwości w porównaniu do obecnej sytuacji, kiedy stanowi równorzędne uzupełnienie radykalnych resekcji i nowoczesnego napromieniania w modelu postępowania neoadiuwantowego lub adiuwantowego.

Czasopismo *Nowotwory* stanowiło dla mnie zawsze platformę współpracy ze znakomitymi onkologami, których było bardzo wielu. Jestem ogromnie wdzięczny za tę możliwość. Z okazji stuletniej tradycji życzę pismu dalszych sukcesów, kontynuowania linii programowej związanej z wielodyscyplinarnością, wprowadzania nowych elementów. Wyrażam ogromne uznanie dla wszystkich osób, które je tworzą. Wyrazy uznania są szczere, ponieważ znam dobrze – na podstawie osobistych doświadczeń redakcyjnych – wyzwania związane obecnie z redagowaniem naukowego periodyku. Jestem przekonany, że *Nowotwory* będą się rozwijać i będą źródłem wiedzy teoretycznej oraz praktycznej na temat postępowania przeciwnowotworowego.

Piśmiennictwo

1. Krzakowski M, Madej G. Chemioterapia indukcyjna u chorych na zaawansowanego miejscowo płaskonabłonkowego raka głowy i szyi - spostrzeżenia wstępne. *Nowotwory*. 1988. XXXVIII; 3: 174–179.

Prof. Jan Skołyszewski: *System punktowania, moim zdaniem, nie zawsze rozstrzyga o tym, czy dana praca jest wartościowa*



Kiedy zaczynałem pracę w krakowskim Instytucie Onkologii, z redakcją *Nowotworów* mocno już była związana prof. Hanna Kołodziejska. Potem, w 1975 roku, została redaktorem naczelnym. Pani Profesor była silną osobowością, bardzo dbała o jakość merytoryczną i językową artykułów – zwracała uwagę na konkrety, nie lubiła niepotrzebnych słów i była w tym bezkompromisowa. W jej gabinecie wisiała tablica z nazwiskami pracowników Instytutu i informacjami o ich ostatnich publikacjach w *Nowotworach*. Jednak ta tablica była dość dyskusyjnym pomysłem. I pani Profesor się z tego wycofała, bo wolała uniknąć atmosfery niezdrowej konkurencji wśród pracowników Instytutu.

Jako młody lekarz też chciałem łączyć praktykowanie medycyny z pracą naukową. To mi się w mniejszym lub większym stopniu udawało. W styczniu 1962 roku złożyłem w redakcji swoje dwa pierwsze artykuły. Oba dotyczyły raka sutka u mężczyzny i zostały opublikowane w tym samym roku. Ich tytuły to: *Pięcioletnie przeżycie po adrenalectomii chorego z zaawansowanym rakiem sutka* [1] i *Rak sutka u mężczyzny* [2]. Cieszyłem się, że swoją pracę mogę się podzielić z większym gronem kolegów, że dowiedzą się, czym się zajmuję.

Lubiłem czytać *Nowotwory* w wersji papierowej. Szkoda, że teraz pismo ukazuje się tylko w formie elektronicznej. Ale też rozumiem tę zmianę. Jest coraz większa konkurencja, większość pism ukazuje się w internecie. Obecnie polskim naukowcom także łatwiej publikować za granicą.

Muszę jednak powiedzieć, że ta pogoń za punktami w świecie naukowym jest bardzo dyskusyjna. Cały system punktowania, moim zdaniem, nie zawsze rozstrzyga o tym, czy dana praca jest wartościowa. Bo samo przyznawanie punktów czasopismom naukowym nie jest do końca transparentne. Dlatego jestem sceptycznie nastawiony do częstego obecnie publikowania tylko dla uzyskania odpowiedniej liczby punktów. Artykuły powinny być przede wszystkim ważne. Warto publikacji ze względu na to, co niosą.

Kiedy byłem jeszcze młodym lekarzem, zadawałem sobie pytanie o to, co w pracy onkologa jest najbardziej istotne. Miałem też szczęście pracować w dwóch ośrodkach, które wówczas uchodziły za wiodące, jeśli chodzi o radioterapię: w Instytucie Curie w Paryżu i w Christie Hospital w Manchesterze. Odważyłem się zapytać dyrektorów tych instytucji o to, co jest najważniejsze w naszej pracy. Zarówno Francuz jak i Anglik byli wyjątkowo zgodni: w onkologii chodzi o to, żeby każdy pacjent przychodzący do nas, uzyskał możliwie najlepsze leczenie i najlepszą opiekę.

A wracając do *Nowotworów* – życzę pismu, żeby autorzy mniej uwagi zwracali na punkty i zgłaszali tylko prace, które wnoszą do medycyny naprawdę coś nowego, które są przydatne i pomagają skutecznie leczyć pacjentów. I żeby byli dumni z tego, że ich artykuły ukazują się właśnie w tym czasopiśmie.

Piśmiennictwo

1. Skołyszewski J. Rak sutka u mężczyzny. *Nowotwory*. 1962; XII: 115.
2. Kołodziejska H, Marczyńska A, Skołyszewski J. pięcioletnie przeżycie po adrenalectomii chorego z zaawansowanym rakiem sutka. *Nowotwory*. 1962; XII: 147.



Z kalendarium Zarządu PTO

sierpień–wrzesień 2023 r.

Zapraszamy do rejestracji na VI Kongres Onkologii Polskiej, który odbędzie się w dniach 17–19.10.2024 r. Więcej informacji: <http://www.kongres.pto.med.pl>

Komunikaty PTO

29 sierpnia 2023 r. odbyło się posiedzenie Zarządu Głównego Polskiego Towarzystwa Onkologicznego. W porządku obrad znalazły się m.in. omówienie spraw organizacyjnych związanych z VI Kongresem Onkologii Polskiej oraz sprawy bieżące.

5 września 2023 r. odbyło się spotkanie Komitetu Naukowego VI Kongresu Onkologii Polskiej. Do udziału w pracach Komitetu PTO zaprosiło przedstawicieli medycznych towarzystw naukowych. Do końca września 2023 r. członkowie Komitetu mogli zgłaszać propozycje tematów wystąpień podczas Kongresu.

18 września 2023 r. odbyło się spotkanie Sekcji Standaryzacji Nadzoru po Leczeniu Onkologicznym, której przewodniczył dr n. med. Marcin Ziętek.

PTO ogłosiło konkurs dla onkologów poniżej 35. roku na stypendium zjazdowe na Kongres ESMO, który odbędzie się w dniach 20–24 października 2023 r. Komisja konkursowa wyłoniła dwóch laureatów, którzy otrzymają stypendium w wysokości 9 tys. zł.

Na stronie internetowej PTO ukazała się nowa zakładka *Diagnostyka molekularna nowotworów – podejście praktyczne*, gdzie można znaleźć wykaz badań genetycznych w poszczególnych nowotworach.

Wywiady i artykuły prasowe

Narodowa Strategia Onkologiczna: odsetek wyleczonych chorych się zwiększa

Poprawiają się wskaźniki przeżyć niektórych nowotworów w Polsce, m.in. raka gruczołu krokowego czy czerniaka, i ta różnica w stosunku do krajów Europy Zachodniej jest coraz mniejsza (pomimo znacząco niższych nakładów). Ostatni rok to również realizacja zadań Narodowej Strategii Onkologicznej, która w sposób ciągły zmienia sytuację onkologii w Polsce. Jest to najważniejszy dokument, który obecnie jest już trzeci rok wdrażany, za co odpowiedzialne jest Ministerstwo Zdrowia wspólnie z Narodowym Instytutem Onkologii im. Marii Skłodowskiej-Curie – Państwowym Instytutem Badawczym w Warszawie. Narodowa Strategia Onkologiczna w swych założeniach jest zgodna z Europe's Beating Cancer Plan: Let's strive for more. W celu lepszej koordynacji opieki nad pacjentem onkologicznym Ministerstwo Zdrowia jest również obecnie na etapie tworzenia Krajowej Sieci Onkologicznej (KSO), a ustawa dotycząca KSO została podpisana przez Prezydenta RP w 2023 roku.

Źródło: www.zdrowie.wprost.pl

Terapie skojarzone i określone w czasie. Debata o leczeniu przyszłości

– Leczenie skojarzone to nie tylko leczenie systemowe. To całość naszego leczenia onkologicznego. Kojarzemy między sobą leczenie systemowe, ale kojarzymy je też z radioterapią i chirurgią. Cała ścieżka terapeutyczna naszych chorych musi być bardzo dobrze rozplanowana. W onkologii jest tak, że jeżeli czegoś nie zrobimy na początku, nie zaplanujemy sobie tej ścieżki terapeutycznej, to już potem nigdy nie będziemy mogli do niej wrócić i poprowadzić pacjenta zgodnie z najnowszą wiedzą medyczną i standardami – wyjaśniła

Bożena Cybulska-Stopa z Kliniki Onkologii Klinicznej Narodowego Instytutu Onkologii im. Marii Skłodowskiej-Curie – Państwowego Instytutu Badawczego. Z uwagi na to, na pierwszy plan w leczeniu onkologicznym wysuwa się nie tylko sam dostęp do leków, ale organizacja leczenia chorego. Zdaniem dr Bożeny Cybulskiej-Stopy, *clue* problemu jest zachowanie odpowiedniej sekwencji terapeutycznej i dobry przepływ chorego między poszczególnymi ośrodkami.

Źródło: www.medexpress.pl

Pacjent z podejrzeniem nowotworu szybciej trafi do onkologa. „Karta e-DiLO uporządkuje nam system”

– Nowe podejście do koordynacji onkologicznej dopiero się kształtuje, a nam szczególnie zależy na tym, aby wprowadzane zmiany w jak największym stopniu służyły pacjentom. Dotychczas w mediach mieliśmy w tym zakresie do czynienia z wypowiedziami o charakterze teoretycznym albo opartymi na wyobrażeniach, które niekoniecznie oddają obraz faktycznych zmian i kierunków w procesie organizacji koordynacji – zauważa prof. Adam Maciejczyk, dyrektor Dolnośląskiego Centrum Onkologii, Pulmonologii i Hematologii we Wrocławiu. – Aby pacjent był prowadzony prawidłowo, ścieżka ta musi być jasno określona i możliwa do monitorowania. Posłuży do tego tworzona obecnie nowa karta DiLO, tzw. e-DiLO. Opracowuje ją Zespół ds. wdrożenia Krajowej Sieci Onkologicznej, powołany przez ministra zdrowia w styczniu br. Praca jest intensywna i zaawansowana. Zespół ma czas do października na dopracowanie i określenie nowej e-DiLO i mam nadzieję, że jeszcze w tym roku uda się ją wdrożyć. Kartą e-DiLO zainteresowani są także hematolodzy – zaznacza prof. Maciejczyk.

Źródło: www.rynekzdrowia.pl

Terażniejszość polskiej onkologii

Nowe metody leczenia nie zwiększą przeżywalności chorych onkologicznie, jeżeli nie zadba się o profilaktykę i diagnostykę, w tym badania molekularne. Fakt o którym często się zapomina: mutacja BRCA1 i BRCA2 dotyczy również mężczyzn, zwiększając ryzyko zachorowania na raka prostaty, jest też przekazywana dzieciom obojga płci. Ostatnie lata dla pacjentów onkologicznych w Polsce – to czas zwiększenia dostępności do nowych metod diagnostyki i leczenia. Oferowane są coraz bardziej spersonalizowane ścieżki terapeutyczne, a sposoby leczenia nowotworów zmierniejszą ku mniejszej inwazyjności. Problemy, które trapią polską onkologię są przede wszystkim natury organizacyjnej, co szczególnie dotyczy diagnostyki. Kuleje również profilaktyka.

Źródło: www.mzdrowie.pl

Aplikacje wspomagają leczenie i optymalizują jego koszty

Digitalizacja w medycynie staje się faktem, a Polska jest nawet pod tym względem liderem – podkreślił prof. dr hab. n. med.

Piotr Rutkowski, kierownik Kliniki Nowotworów Tkanek Miękkich, Kości i Czerniaków Centrum Onkologii – Instytutu im. Marii Skłodowskiej-Curie. Jest to proces nie tylko wspomagający diagnostykę i leczenie. Digitalizacja umożliwia dostęp do danych, które ułatwiają właściwą ocenę sytuacji w zakresie zdrowia publicznego, na przykład w onkologii. – Jednym z celów w zakresie ochrony zdrowia zbliżającej się polskiej prezydencji w Unii Europejskiej będzie właśnie cyfryzacja medycyny. Jest ona także jednym z punktów europejskiego planu walki z nowotworami. Robimy dużo w tym zakresie i jako towarzystwa i jako realizatorzy strategii onkologicznej, która obejmuje między innymi stosowanie odpowiednich mierników i analizowanie wybranych wskaźników w celu wprowadzania innowacyjnych terapii – powiedział profesor Rutkowski.

Źródło: www.biznes.wprost.pl

Konferencje i wydarzenia z udziałem członków Zarządu Głównego PTO

- 28 sierpnia 2023 r. odbyło się kolejne spotkanie Rady Ekspertów ds. Onkologii Medycznej Racji Stanu, które poświęcone było bezpieczeństwu chorych na raka w Polsce. W spotkaniu uczestniczył prof. Piotr Rutkowski.
- W dniach 31 sierpnia – 2 września 2023 r. w Gdańsku miał miejsce XXVI Kongres Polskiego Towarzystwa Onkologii Klinicznej z udziałem członków zarządu PTO.
- 6 września 2023 r. odbyła się debata w ramach cyklu *Jaka jest przyszłość polskiej onkologii? pt. „Polska onkologia wczoraj, dziś i jutro* zorganizowana przez *Puls Medycyny*. Uczestniczyli w niej prof. Bożena Cybulska-Stopa i prof. Piotr Rutkowski.
- W dniach 7-8 września 2023 r. w Narodowym Instytucie Onkologii – Państwowym Instytucie Badawczym w Warszawie zorganizowano międzynarodową konferencję *The 8th Warsaw Conference on Perspectives of Molecular Oncology* z udziałem członków zarządu PTO.
- W dniach 7-8 września 2023 r. miała miejsce konferencja *Baltic Congress of Oncologists and Surgeons 2023*, w której udział wzięli prof. Piotr Rutkowski oraz prof. Lucjan Wyrwicz.
- W dniach 7-9 września 2023 r. w Karpaczu odbyło się XXXII Forum Ekonomiczne. W sesjach poświęconych onkologii uczestniczyli prof. Piotr Rutkowski i dr hab. Adam Maciejczyk.
- 10 września 2023 r. po raz 16. odbył się Onkobieg pod hasłem *Razem po zdrowie* organizowany przez Stowarzyszenie Pomocy Chorym na Mięsaki i Czerniaki Sarcoma. Wydarzeniu patronowało Polskie Towarzystwo Onkologiczne.
- 13 września 2023 r. zorganizowano webinar *Virtual Sarcoma Meeting 2023*. Przewodniczącym Komitetu Naukowego cyklu jest prof. dr hab. Piotr Rutkowski.
- 14 września 2023 r. odbyło się spotkanie z cyklu *Virtual Meetings Nowotwory Skóry 2023. Update dla chirurgów*. Jego

temat to: *Czerniak – lokalizacje specjalne*. Przewodniczącym Komitetu Naukowego cyklu jest prof. dr hab. Piotr Rutkowski.

- 19 września 2023 r. miała miejsce konferencja na zakończenie realizacji projektu *Wsparcie procesu poprawy jakości w patomorfologii poprzez wdrożenie standardów akredytacyjnych oraz wzmocnienie kompetencji kadry zarządzającej podmiotami leczniczymi*, w której uczestniczył dr hab. Adam Maciejczyk.

- 19 września 2023 r. odbyła się kolejna debata z cyklu *Onkologia – Wspólna Sprawa* zorganizowana przez Polskie Towarzystwo Onkologiczne. Tematem spotkania były wyzwania w diagnostyce i leczeniu raka tarczycy.
- W dniach 20–23 września 2023 r. w Roswell Park Comprehensive Cancer Center, Buffalo, NY zorganizowano konferencję *3rd Marie Skłodowska-Curie Symposium on Cancer Research and Care*. Wziął w niej udział prof. Piotr Rutkowski.

Vorasidenib in *IDH1*- or *IDH2*-mutant low-grade glioma

Mellinghoff I., van den Bent M., Blumenthal D. i wsp.
N. Engl. J. Med., 2023; 389: 589–601

Glejak II stopnia z mutacją genu dehydrogenazy izocytrynia nowej (*isocitrate dehydrogenase* – *IDH*) to złośliwe nowotwory mózgu, które powodują znaczne upośledzenie sprawności i przedwczesny zgon. Wstępnie wykazano skuteczność worazydenibu, doustnego inhibitora zmutowanych enzymów *IDH1* i *IDH2*, przenikającego przez barierę krew–mózg, u chorych na glejaka z mutacją *IDH*.

Metody. W podwójnie zaślepionym badaniu klinicznym III fazy brali udział chorzy z masą resztkową nowotworu lub nawrotnym glejakiem II stopnia z mutacją *IDH*. Wcześniej nie byli oni leczeni innymi metodami niż zabieg operacyjny. Uczestników badania przydzielono losowo do leczenia worazydenibem (40 mg raz dziennie doustnie) lub stosowania placebo w 28-dniowych cyklach. Pierwszorzędowym punktem końcowym było przeżycie wolne od progresji widocznej w badaniach obrazowych. Oceny dokonywała niezależna komisja. Drugorzędowym punktem końcowym był czas do następnego leczenia przeciwnowotworowego. Dozwolone było przejście z placebo na worazydenib po potwierdzeniu progresji w badaniach obrazowych. Oceniono również bezpieczeństwo terapii.

Wyniki. Spośród łącznie 331 chorych 168 przydzielono do leczenia worazydenibem, a 163 do otrzymywania placebo. Po obserwacji, której mediana trwania wynosiła 14,2 miesiąca, 226 chorych (68,3%) kontynuowało leczenie przyjmując nadal worazydenib lub placebo. Przeżywalność wolna od progresji nowotworu (*progression-free survival* – PFS) była znacząco dłuższa w grupie otrzymującej worazydenib w porównaniu z grupą otrzymującą placebo (mediana przeżycia wolnego od progresji: 27,7 miesiąca vs 11,1 miesiąca; współczynnik ryzyka [*hazard ratio* – HR] progresji choroby lub zgonu wyniósł 0,39; 95% przedział ufności [*confidence interval* – CI] 0,27–0,56; $p < 0,001$). Czas do podjęcia następnego leczenia był znacząco dłuższy w grupie otrzymującej worazydenib w porównaniu z grupą placebo (HR 0,26; 95% CI 0,15–0,43; $p < 0,001$). Częstość działań niepożądanych 3. lub wyższego stopnia wyniosła 22,8% dla otrzymujących worazydenib oraz 13,5% u otrzymujących placebo. Wzrost stężenia aminotransferazy alaninowej 3. lub wyższego stopnia odnotowano u 9,6% chorych otrzymujących worazydenib, natomiast nie odnotowano takiego zwiększenia u żadnego chorego z grupy otrzymujących placebo.

Wniosek. Leczenie worazydenibem znacząco wydłużyło przeżywalność wolną od progresji u chorych na glejaka II stopnia z mutacją *IDH* oraz czas do podjęcia kolejnego leczenia.

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

Lee S.M., Schulz C., Prabhaskar K. i wsp.
Lancet, 2023, 402: 451–463

Pomimo istotnego postępu, jaki dotyczy leczenia chorych na zaawansowanego lub rozlanego płaskonabłonkowego niedrobnokomórkowego raka płuca (*non-small-cell lung cancer* – NSCLC) związanego z zastosowaniem immunoterapii, najważniejsze badania w zakresie pierwszej linii leczenia były przeprowadzone z udziałem chorych w dobrym stanie sprawności (0–1 według Eastern Cooperative Oncology Group [ECOG]), których mediana wieku wynosiła 65 lat lub mniej. Celem badania było porównanie skuteczności i bezpieczeństwa atezolizumabu stosowanego w pierwszej linii leczenia z jednolekową chemioterapią u chorych, którzy nie kwalifikują się do chemioterapii zawierającej pochodną platyny.

Metody. W otwartym badaniu III fazy z grupą kontrolną, przeprowadzonym w 91 ośrodkach w 23 krajach Azji, Europy, Ameryki Północnej i Południowej, chorych na płaskonabłonkowego NSCLC:

- w stadium zaawansowania IIIB lub IV, niekwalifikujących się do dwulekowej chemioterapii zawierającej pochodną platyny z powodu stanu sprawności ECOG 2 lub 3 lub wieku ≥ 70 lat;
 - w stanie sprawności ECOG 0–1 ale z istotnymi chorobami współistniejącymi, lub z przeciwwskazaniami do dwulekowej chemioterapii z udziałem pochodnej platyny,
- przydzielono losowo (w stosunku 2:1) do otrzymywania 1200 mg atezolizumabu (podawanego dożylnie co 3 tygodnie) lub do jednolekowej chemioterapii (winorelbina [doustnie lub dożylnie] lub gemcytabina [dożylnie]; dawkowanie zgodnie ze standardami ośrodka), którą prowadzono w cyklach co 3 lub co 4 tygodnie. Pierwszorzędowym punktem końcowym było przeżycie ogólne, oceniane w grupie zgodnej z zamiarem leczenia. W analizie bezpieczeństwa uwzględniono wszystkich

chorych, którzy otrzymali dowolną liczbę dawek atezolizumabu lub chemioterapeutyku.

Wyniki. Od 11 września 2017 roku do 23 września 2019 roku włączono do badania 453 chorych. Do otrzymywania atezolizumabu przydzielono losowo 302 chorych, a do chemioterapii 151. Atezolizumab poprawił całkowite przeżycie w porównaniu z chemioterapią (mediana całkowitego przeżycia wyniosła 10,3 miesiąca [95% CI 9,4–11,9] w porównaniu z 9,2 miesiąca [5,9–11,2]; HR 0,78 [0,63–0,97], $p = 0,028$), a udział dwuletnich przeżyć wyniósł 24% (95% CI 19,3–29,4) dla leczonych atezolizumabem w porównaniu z 12% (6,7–18,0) u poddanych chemioterapii. Leczenie atezolizumabem w porównaniu z chemioterapią wiązało się ze stabilizacją lub poprawą jakości życia związanej ze stanem zdrowia – w ocenie chorych – oraz z mniejszą liczbą działań niepożądanych związanych z leczeniem o nasileniu 3.–4. stopnia (49 spośród 300 [16%] w porównaniu z 49 spośród 147 [33%]) oraz zgonów związanych z leczeniem (3 [1%] w porównaniu z 4 [3%]).

Wnioski. Leczenie atezolizumabem w pierwszej linii wiązało się z wydłużeniem czasu całkowitego przeżycia, podwojeniem udziału dwuletnich przeżyć, utrzymaniem jakości życia oraz korzystnym profilem bezpieczeństwa w porównaniu z jednolekową chemioterapią. Atezolizumab stanowi opcję leczenia pierwszej linii u chorych na zaawansowanego NSCLC niekwalifikujących się do leczenia pochodnymi platyny.

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Dasari A., Lonardi S., Garcia-Carbonero R. i wsp.

Lancet, 2023; 402: 41–53

Nie ma skutecznych metod leczenia systemowego dla chorych na zaawansowanego, opornego na chemioterapię raka jelita grubego. Celem badania była ocena skuteczności i bezpieczeństwa frukwintynibu – wysoce selektywnego i silnego doustnego inhibitora receptorów czynnika wzrostu śródbłonna naczyń (*vascular endothelial growth factor* receptor – VEGFR) 1, 2 i 3 – u chorych na intensywnie leczonego rozlanego raka jelita grubego.

Metody. Przeprowadzono międzynarodowe, podwójnie zaślepienie badanie III fazy z grupą kontrolną otrzymującą placebo (FRESCO-2). Wzięły w nim udział 124 szpitale i ośrodki onkologiczne w 14 krajach. Do udziału włączono chorych (w wieku ≥ 18 lat, ≥ 20 lat w Japonii) na histologicznie lub cytologicznie potwierdzonego, rozlanego gruczolakoraka jelita grubego, którzy otrzymali wszystkie aktualnie zatwierdzone standardowe linie leczenia cytotoksycznego i celowanego. Chorzy byli w trakcie progresji nowotworu lub wystąpiła u nich nietolerancja triflurydyny-typiracylu, regorafenibu albo obu leków. Uczestników badania przydzielono losowo (2:1) do leczenia

frukwintynibem (kapsułka 5 mg doustnie raz dziennie) lub do przyjmowania dopasowanego placebo w dniach 1.–21. w 28-dniowych cyklach, wraz z najlepszym leczeniem wspomagającym. Czynniki stratyfikacji podczas leczenia były: wcześniejsze leczenie triflurydyną-typiracylem, regorafenibem lub oboma lekami, stan mutacji *RAS* i czas trwania rozlanej choroby. Chorzy, badacze, personel ośrodka badawczego i sponsorzy – z wyjątkiem wybranego personelu nadzoru nad bezpieczeństwem farmakoterapii sponsora – nie znali przydziału do grup. Pierwszorzędownym punktem końcowym było przeżycie całkowite, określone jako czas od randomizacji do zgonu z jakiegokolwiek przyczyny. Niewiązącą analizę daremności przeprowadzono, gdy wystąpiła około jedna trzecia oczekiwanych zdarzeń związanych z przeżyciem całkowitym. Ostateczna analiza miała miejsce po 480 zdarzeniach związanych z przeżyciem całkowitym.

Wyniki. Od 12 sierpnia 2020 roku do 2 grudnia 2021 roku spośród 934 ocenianych chorych, 691 włączono i losowo przydzielono do grupy otrzymującej frukwintynib ($n = 461$) lub placebo ($n = 230$). Chorzy otrzymali wcześniej średnio cztery linie leczenia systemowego z powodu rozsiewu choroby, a 502 spośród 691 chorych (73%) otrzymało więcej niż trzy linie. Mediana całkowitego przeżycia wyniosła 7,4 miesiąca (95% CI 6,7–8,2) w grupie frukwintynibu w porównaniu z 4,8 miesiąca (4,0–5,8) w grupie placebo (HR 0,66, 95% CI 0,55–0,80; $p < 0,0001$). Zdarzenia niepożądane 3. lub wyższego stopnia wystąpiły u 286 spośród 456 (63%) leczonych frukwintynibem i u 116 spośród 230 (50%) otrzymujących placebo. Najczęstszymi zdarzeniami niepożądanymi 3. lub wyższego stopnia w grupie frukwintynibu było nadciśnienie ($n = 62$ [14%]), osłabienie ($n = 35$ [8%]) oraz zespół ręka–stopa ($n = 29$ [6%]). W obu grupach odnotowano po jednym zgonie związanym z leczeniem: doszło do niego w wyniku perforacji jelita u chorego z grupy leczonej frukwintynibem i w wyniku zatrzymania akcji serca u chorego z grupy placebo.

Wnioski. Leczenie frukwintynibem w porównaniu z placebo znamienne wydłużyło czas całkowitego przeżycia u chorych na opornego na leczenie, rozlanego raka jelita grubego. Frukwintynib stanowi opcję leczenia dla tej grupy chorych. Tocząca się analiza danych dotyczących jakości życia pozwoli na dalsze określenie korzyści klinicznych ze stosowania frukwintynibu.

Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer

Provencio M., Nadal E., González-Larriba J. i wsp.

N. Engl. J. Med., 2023; 389: 504–513

U około 20% chorych na niedrobnokomórkowego raka płuca (NSCLC) stwierdza się III stadium zaawansowania nowotworu. Nie ma obecnie jednoznacznych wytycznych co do najlepszego leczenia tej grupy chorych.

Metody. W otwartym badaniu II fazy chorych na operacyjnego NSCLC w stopniach zaawansowania IIIA lub IIIB przydzielono losowo do przedoperacyjnego leczenia niwolumabem w połączeniu z chemioterapią zawierającą pochodną platyny (grupa badana) lub do wyłącznej chemioterapii (grupa kontrolna), a następnie poddano zabiegowi operacyjnemu. Chorzy w grupie badanej po resekcji R0 otrzymali niwolumab jako leczenie uzupełniające przez 6 miesięcy. Głównym punktem końcowym była całkowita odpowiedź patologiczna (0% komórek nowotworowych w usuniętym płucu i węzłach chłonnych), a drugorzędowymi: czas wolny od progresji, całkowite przeżycie po 24 miesiącach oraz bezpieczeństwo terapii.

Wyniki. Łącznie 86 chorych przydzielono losowo do leczenia: 57 do grupy badanej, a 29 do grupy kontrolnej. Udział całkowitych odpowiedzi patologicznych w grupie badanej wyniósł 37%, a w grupie kontrolnej – 7% (HR 5,34; 95% CI 1,34–21,23; $p = 0,02$). Zabieg operacyjny przeprowadzono u 93% chorych z grupy badanej i u 69% z grupy kontrolnej (ryzyko względne [relative risk – RR] 1,35; 95% CI 1,05–1,74). Przewidywany odsetek przeżywalności bez progresji choroby po 24 miesiącach wyniósł 67,2% w grupie badanej i 40,9% w grupie kontrolnej (HR progresji, nawrotu choroby lub zgonu 0,47; 95% CI 0,25–0,88). Przewidywane całkowite przeżycie po 24 miesiącach wyniosło 85,0% w grupie badanej i 63,6% w grupie kontrolnej (HR zgonu 0,43; 95% CI 0,19–0,98). Poważne działania niepożądane w stopniu 3.–4. stwierdzono u 11 chorych z grupy badanej (19%) oraz u 3 z grupy kontrolnej (10%).

Wnioski. W porównaniu z wyłączną chemioterapią okołoooperacyjne leczenie niwolumabem w połączeniu z chemioterapią skutkowało większą częstością całkowitych odpowiedzi patologicznych oraz dłuższym przeżyciem chorych na operacyjnego płaskonabłonkowego lub gruczolowego NSCLC w stopniu zaawansowania IIIA lub IIIB.

Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer

Whelan T., Smith S., Parpia S. i wsp.
N. Engl. J. Med., 2023; 389: 612–619

Uzupełniającą radioterapię stosuje się po leczeniu oszczędzającym piersi w celu zmniejszenia ryzyka nawrotu miejscowego. Radioterapia jest uciążliwa, kosztowna i wiąże się zarówno z wczesnymi, jak i odległymi działaniami niepożądanymi. Wyniki kliniczno-patologiczne mają ograniczoną wartość jeśli chodzi o określenie niskiego ryzyka miejscowego nawrotu w celu wyłonienia chorych, u których radioterapię można by pominąć. W tym celu dodatkowych informacji rokowniczych mogłoby dostarczyć określenie molekularnego podtypu raka piersi.

Metody. Przeprowadzono prospektywne badanie kohortowe obejmujące kobiety w wieku ≥ 55 lat, po operacji oszczędzającej piersi z powodu raka T1N0 (rozmiar guza < 2 cm, brak zajęcia węzłów chłonnych), G1 lub G2, podtyp luminalny A (określony

jako obecność receptorów estrogenowych $\geq 1\%$, obecność receptorów progesteronowych $> 20\%$, brak ekspresji receptora naskórkowego czynnika wzrostu typu 2 oraz wskaźnik Ki-67 $\leq 13,25\%$), które otrzymały uzupełniającą hormonoterapię. Chore spełniające kryteria kliniczne zostały zarejestrowane, a analizę immunohistochemiczną wskaźnika Ki-67 przeprowadzono centralnie. Chore ze wskaźnikiem Ki-67 $\leq 13,25\%$ zakwalifikowano do badania i nie poddawano ich radioterapii. Pierwszorzędnym punktem końcowym był nawrót miejscowy w tej samej piersi. Po konsultacji ze specjalistami radioterapii onkologicznej i chorymi na raka piersi ustalono, że jeśli górna granica CI na poziomie 90% dla kumulatywnej częstości występowania w ciągu 5 lat będzie mniejsza niż 5%, to będzie to stanowiło akceptowalne ryzyko miejscowego nawrotu w ciągu 5 lat.

Wyniki. Spośród 740 zarejestrowanych kobiet do badania zakwalifikowano 500. Po 5 latach udział nawrotów wyniósł 2,3% (90% CI 1,3–3,8; 95% CI 1,2–4,1), co spełniło wcześniej ustalone kryterium. Rak piersi wystąpił w drugiej piersi u 1,9% chorych (90% CI 1,1–3,2), a nawrót dowolnego typu zaobserwowano u 2,7% (90% CI 1,6–4,1).

Wnioski. Udział nawrotów miejscowych po upływie 5 lat był niski wśród chorych (w wieku co najmniej 55 lat) na raka piersi T1N0, G1 lub G2, typ luminalny A, u których zastosowano leczenie oszczędzające piersi oraz leczenie hormonalne a pominięto radioterapię.

Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation

Sacher A., LoRusso P., Patel M. i wsp.
N. Engl. J. Med., 2023; 389: 710–721

Dywarazyb (GDC-6036), kowalentny inhibitor KRAS G12C, został stworzony z myślą o wysokiej skuteczności i selektywności.

Metody. W badaniu klinicznym I fazy oceniono dywarazyb (podawany doustnie w dawkach 50–400 mg raz dziennie) u chorych na zaawansowane lub rozlane nowotwory lite z mutacją KRAS G12C. Głównym celem była ocena bezpieczeństwa; oceniano również farmakokinetykę, aktywność przeciwnowotworową (według opinii badacza) oraz biomarkery odpowiedzi i oporności.

Wyniki. Łącznie 137 chorych (60 chorych na płaskonabłonkowego NSCLC, 55 na raka jelita grubego i 22 na inne nowotwory lite) otrzymało dywarazyb. Nie stwierdzono działań niepożądanych, które wymagałyby ograniczenia dawki, ani zgonów związanych z leczeniem. Działania niepożądane związane z leczeniem stwierdzono u 127 chorych (93%); w tym 3. stopnia u 15 chorych (11%), a 4. stopnia u 1 chorego (1%). Działania niepożądane związane z leczeniem spowodowały zmniejszenie dawki u 19 chorych (14%) i przerwanie leczenia przez 4 chorych (3%). Wśród chorych na NSCLC udział odpowiedzi wyniósł 53,4% (95% CI 39,9–66,7), a mediana czasu

przeżycia wolnego od progresji wyniosła 13,1 miesiąca (95% CI 8,8–niemożliwe do oszacowania). Wśród chorych na raka jelita grubego udział odpowiedzi wyniósł 29,1% chorych (95% CI 17,6–42,9), a mediana czasu wolnego od progresji 5,6 miesiąca (95% CI 4,1–8,2). Odpowiedzi obserwowano również u chorych na inne nowotwory łagodne. Ocena krążącego nowotworowego DNA wykazała zmniejszenie częstości występowania allelu wariantowego *KRAS* G12C u chorych z odpowiedzią oraz pozwoliła na określenie zaburzeń genetycznych, które mogą się przyczynić do oporności na dywarazyb.

Wnioski. Leczenie dywarazybem prowadzi do trwałych odpowiedzi klinicznych u chorych na nowotwory z mutacją *KRAS* G12C, przy głównie łagodnych działaniach niepożądanych.

BRAF-MEK inhibition in newly diagnosed papillary craniopharyngiomas

Brastianos P.K., Twohy E., Geyer S. i wsp.
N. Engl. J. Med., 2023; 389: 118–126

Czaszkogardlaki – pierwotne nowotwory osi przysadkowo-podwzgórzowej mózgu – mogą powodować klinicznie istotne następstwa. Leczenie z zastosowaniem chirurgii, radioterapii lub połączenie obu tych metod, często wiąże się ze znacznie zwiększonym ryzykiem utraty wzroku, dysfunkcji układu neuroendokrynnego i zaburzeń pamięci.

Badania genetyczne wykazały obecność mutacji *BRAF* V600E u ponad 90% chorych na brodawkowate czaszkogardlaki. Nie ma danych na temat bezpieczeństwa i skuteczności zastosowania inhibitorów BRAF–MEK u chorych na czaszkogardlaka brodawkowatego, którzy nie zostali poddani wcześniejszej radioterapii.

Metody. Do badania II fazy z jedną grupą kontrolną rekrutowano chorych na czaszkogardlaka brodawkowatego z mutacją *BRAF*, którzy wcześniej nie zostali poddani radioterapii oraz mieli zmiany mierzalne. Uczestnicy badania otrzymywali połączenie inhibitorów BRAF–MEK (wemurafenib–kobimetynib) w 28-dniowych cyklach. Pierwszorzędowym punktem końcowym badania była ocena obiektywnej odpowiedzi na leczenie po 4 miesiącach, określona przez centralną komisję.

Wyniki. Spośród 16 chorych biorących udział w badaniu u 15 (94%; 95% CI 70–100) stwierdzono trwałą, obiektywną, częściową lub lepszą odpowiedź na zastosowane leczenie. Mediana zmniejszenia objętości guza wyniosła 91% (zakres: 68–99), mediana obserwacji wyniosła 22 miesiące (95% CI 19–30), a mediana liczby cykli leczenia 8. Czas wolny od progresji po 12 miesiącach wynosił 87% (95% CI 57–98) a po 24 miesiącach 58% (95% CI 10–89). U 3 chorych w trakcie obserwacji po przerwaniu leczenia doszło do progresji choroby; żaden z nich nie zmarł. Jedyń chore, u którego nie uzyskano odpowiedzi na leczenie, przerwał je po 8 dniach z powodu toksyczności. Zdarzenia niepożądane 3. stopnia prawdopodobnie związane z leczeniem wystąpiły u 12 chorych, w tym u 6 była to

wysypka. 2 chorych zgłosiło zdarzenia niepożądane 4. stopnia (hiperglikemia u jednego chorego i zwiększone stężenie kinazy kreatynowej u jednego chorego); 3 chorych przerwało leczenie z powodu zdarzeń niepożądanych.

Wnioski. W niewielkim badaniu u 15 spośród 16 chorych na czaszkogardlaka brodawkowatego odnotowano częściową lub lepszą odpowiedź na zastosowanie skojarzonego leczenia inhibitorami BRAF–MEK (wemurafenib–kobimetynib).

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

Pal K.S., Albiges L., Tomczak P. i wsp.
Lancet, 2023; 402: 185–195

Zastosowanie inhibitorów punktów kontrolnych układu immunologicznego jest obecnie standardem w pierwszej linii leczenia chorych na rozlanego raka nerkowokomórkowego. Nieznane jest jednak skuteczne leczenie dla chorych z progresją po tym leczeniu. Celem badania było ustalenie, czy dodanie atezolizumabu do kabozantynibu opóźnia progresję choroby i wydłuża przeżywalność u chorych w trakcie progresji w czasie leczenia lub po wcześniejszym leczeniu inhibitorami punktów kontrolnych układu immunologicznego.

Metody. Przeprowadzono wieloośrodkowe, otwarte badanie III fazy CONTACT-03, w 135 ośrodkach badawczych, w 15 krajach w Azji, Europie, Ameryce Północnej i Ameryce Południowej. Biorących w nim udział chorych (w wieku ≥ 18 lat) na miejscowo zaawansowanego lub rozlanego raka nerkowokomórkowego, z progresją choroby w trakcie stosowania inhibitorów punktów kontrolnych, przydzielano losowo (1:1) do grupy otrzymującej atezolizumab (1200 mg dożylnie co 3 tygodnie) w skojarzeniu z kabozantynibem (60 mg doustnie raz na dobę) lub do wyłącznego leczenia kabozantynibem. Chorych stratyfikowano według grup ryzyka International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), zastosowanej wcześniej linii leczenia inhibitorami punktów kontrolnych oraz typu histologicznego raka nerkowokomórkowego. Pierwszorzędowymi punktami końcowymi były: przeżywalność wolna od progresji (określona centralnie przez niezależnych ekspertów na podstawie zaślepionego przeglądu wyników) i całkowity czas przeżycia. Pierwszorzędowe punkty końcowe oceniano w grupie zgodnej z zamiarem leczenia, a bezpieczeństwo u wszystkich chorych, którzy otrzymali co najmniej jedną dawkę badanego leku. Rekrutacja chorych do badania została zakończona.

Wyniki. Spośród zgłoszonych – od 28 lipca 2020 roku do 27 grudnia 2021 roku – 692 chorych, zakwalifikowano do badania 522 i przydzielono do grupy otrzymującej atezolizumab

z kabozantynibem (263 chorych) lub wyłącznie kabozantynib (259 chorych). Łącznie w tym badaniu obserwowano 401 mężczyzn (77%) i 121 kobiet (23%). W chwili zbierania danych (3 stycznia 2023 r.) mediana obserwacji wyniosła 15,2 miesiąca (IQR 10,7–19,3). Według oceny centralnej komisji u 171 chorych (65%) otrzymujących atezolizumab z kabozantynibem i u 166 (64%) otrzymujących kabozantynib stwierdzono progresję choroby lub zgon. Mediana przeżywalności wolnej od progresji wyniosła 10,6 miesiąca (95% CI 9,8–12,3) wśród leczonych atezolizumabem w połączeniu z kabozantynibem i 10,8 miesiąca (10,0–12,5) wśród leczonych wyłącznie kabozantynibem (współczynnik ryzyka progresji lub zgonu 1,03 [95% CI 0,83–1,28]; $p = 0,78$). Zmarło 89 chorych (34%) z grupy otrzymującej atezolizumab oraz kabozantynib i 87 (34%) z grupy otrzymującej kabozantynib. Mediana całkowitego przeżycia wyniosła 25,7 miesiąca (95% CI 21,5–brak możliwości oceny) dla grupy otrzymującej atezolizumab oraz kabozantynib i była nie do oceny (21,1–brak możliwości oceny) wśród leczonych wyłącznie kabozantynibem (HR zgonu 0,94 [95% CI 0,70–1,27], $p = 0,69$). Poważne zdarzenia niepożądane wystąpiły u 126 spośród 262 chorych (48%) leczonych atezolizumabem z kabozantynibem i u 84 spośród 256 chorych (33%) leczonych kabozantynibem. Zgony w wyniku zdarzeń niepożądanych wystąpiły u 17 chorych (6%) leczonych atezolizumabem w połączeniu z kabozantynibem i u 9 (4%) w grupie otrzymującej kabozantynib.

Wnioski. Dodanie atezolizumabu do kabozantynibu nie poprawiło wyników leczenia oraz zwiększyło toksyczność leczenia. Wyniki te powinny odwieść lekarzy od sekwencyjnego leczenia chorych przy użyciu inhibitorów punktów kontrolnych poza badaniami klinicznymi.

Cilta-cel or standard care in lenalidomide-refractory multiple myeloma

San-Miguel J., Dhakal B., Yong K. i wsp.

N. Engl. J. Med., 2023; 389: 335–347

Ciltakabtagen autoleucel (cilta-cel) zawierający chimeryczny receptor antygenowy komórek T (CAR-T), ukierunkowany na antygen dojrzewania limfocytów B (BCMA), jest skuteczny u chorych na opornego lub nawrotowego szpiczaka mnogiego po wielu liniach leczenia. Porównywano skuteczność leczenia cilta-celem we wcześniejszych liniach leczenia u chorych na szpiczaka mnogiego opornego na leczenie lenalidomidem.

Metody. W otwartym badaniu III fazy przydzielono losowo chorych na szpiczaka mnogiego w fazie odpornej na leczenie lenalidomidem, do leczenia cilta-celem lub do kolejnej linii leczenia zgodnie z przyjętym standardem wybranym przez lekarza prowadzącego. Wszyscy chorzy otrzymali od jednej do trzech wcześniejszych linii leczenia. Pierwszorzędownym punktem końcowym była przeżywalność wolna od progresji.

Wyniki. W badaniu wzięło udział 419 chorych, z których 208 przydzielono losowo do leczenia cilta-celem, a pozostałych 211 do kolejnej standardowej linii leczenia. Mediana obserwacji wyniosła 15,9 miesiąca (zakres 0,1–27,3 miesiąca). Mediana przeżycia wolnego od progresji nie została osiągnięta w grupie otrzymującej cilta-cel, a w grupie leczonej standardowo wyniosła 11,8 miesiąca (HR 0,26; 95% CI 0,18–0,38; $p < 0,001$). Udział 12-miesięcznych przeżyć wolnych od progresji wyniósł 75,9% (95% CI 69,4–81,1) w grupie otrzymującej cilta-cel i 48,6% (95% CI 41,5–55,3) w grupie poddawanej standardowej terapii. Udział ogólnych odpowiedzi był wyższy w grupie otrzymującej cilta-cel niż w grupie leczonej standardowo (84,6% w porównaniu z 67,3%). Całkowitą odpowiedź na leczenie lub lepszą uzyskało 73,1% chorych leczonych cilta-celem w porównaniu z 21,8% spośród leczonych standardowo. Minimalna choroba resztkowa była niewykrywalna u 60,6% otrzymujących cilta-cel oraz u 15,6% leczonych standardowo. Zgon z dowolnej przyczyny stwierdzono odpowiednio u 39 i 46 chorych (HR dla zgonu 0,78; 95% CI 0,5–1,2). W trakcie leczenia u większości chorych wystąpiły zdarzenia niepożądane 3. lub 4. stopnia. U 134 spośród 176 chorych (76,1%) leczonych cilta-celem wystąpiły zdarzenia niepożądane w postaci zespołu uwalniania cytokin (w stopniu 3. lub 4. 1,1%; brak stopnia 5.), a u 8 chorych (4,5%) – zespół neurotoksyczności związanej z komórkami efektorowymi układu odpornościowego (tylko stopień 1. oraz 2.), u jednego chorego stwierdzono zaburzenia ruchowe oraz neurokognitywne (stopień 1.), u 16 chorych (9,1%) porażenie nerwu czaszkowego (stopień 2. – 8,0%; stopień 3. – 1,1%), a u 5 chorych (2,8%) neuropatię obwodową związaną z leczeniem CAR-T (stopień 1. lub 2. – 2,3%; stopień 3. – 0,6%).

Wnioski. Ryzyko progresji lub zgonu wśród chorych na szpiczaka mnogiego opornego na leczenie lenalidomidem, po 1–3 poprzednich liniach leczenia, którzy otrzymali jednorazowy wlew cilta-celu było mniejsze niż po leczeniu standardowym.

Perioperative pembrolizumab for early-stage non-small-cell lung cancer

Wakelee H., Liberman M., Kato T. i wsp.

N. Engl. J. Med., 2023; 389: 491–503

Leczenie okołoperacyjne, obejmujące zarówno indukcyjne, jak i uzupełniające hamowanie punktów kontrolnych układu immunologicznego, u chorych na resekcyjnego niedrobnokomórkowego raka płuca (NSCLC) we wczesnym stadium, może zapewnić więcej korzyści niż stosowanie tych metod osobno.

Metody. Przeprowadzono badanie III fazy z podwójnie ślepą próbą, w celu określenia skuteczności okołoperacyjnego leczenia pembrolizumabem u chorych na NSCLC we wczesnym stadium. Chorych na resekcyjnego NSCLC w stopniu II, IIIA lub IIIB (cecha N2) przydzielono losowo (w stosunku 1:1) do indukcyjnego leczenia pembrolizumabem (200 mg) lub do otrzymywania placebo (podawanego co 3 tygodnie)

skojarzonego z 4. cyklami chemioterapii zawierającej cispłatyne, poprzedzającego zabieg operacyjny oraz do uzupełniającego leczenia pembrolizumabem (200 mg) lub placebo (podawane co 3 tygodnie przez maksymalnie 13 cykli). Dwoma pierwszorzędownymi punktami końcowymi były: przeżywalność wolna od zdarzeń niepożądanych (określana jako czas od randomizacji do pierwszego wystąpienia miejscowej progresji, która wykluczała planowany zabieg operacyjny, nieoperacyjny guz, uogólnioną progresję, nawrót po remisji lub zgon z jakiegokolwiek przyczyny – w zależności od tego, co nastąpiło wcześniej) oraz przeżycie całkowite. Drugorzędowe punkty końcowe obejmowały znaczną i całkowitą odpowiedź patologiczną oraz bezpieczeństwo leczenia.

Wyniki. Ogółem 397 chorych przydzielono do leczenia pembrolizumabem, a 400 do otrzymywania placebo. W pierwszej analizie okresowej mediana obserwacji wyniosła 25,2 miesiąca. Udział przeżyć wolnych od zdarzeń niepożądanych po 24 miesiącach w grupie pembrolizumabu wyniósł 62,4%, a w grupie placebo 40,6% (HR progresji, nawrotu lub zgonu 0,58; 95% CI 0,46–0,72; $p < 0,001$). Udział szacunkowych 24-miesięcznych przeżyć całkowitych w grupie pembrolizumabu wyniósł 80,9%, a w grupie placebo 77,6% ($p = 0,02$, nie spełniało kryterium znamienności). Częstość znacznych odpowiedzi patologicznych oceniono na 30,2% w grupie pembrolizumabu i 11,0% w grupie placebo (różnica 19,2 punktów procentowych; 95% CI 13,9–24,7; $p < 0,0001$; próg $p = 0,0001$), a udział całkowitych odpowiedzi patologicznych, odpowiednio: 18,1% i 4,0% (różnica 14,2 punktów procentowych; 95% CI 10,1–18,7; $p < 0,0001$; próg $p = 0,0001$). We wszystkich fazach leczenia u 44,9% chorych w grupie otrzymującej pembrolizumab i 37,3% chorych w grupie placebo wystąpiły związane z leczeniem zdarzenia niepożądane stopnia 3. lub wyższego, w tym odpowiednio u 1,0% i 0,8% zdarzenia stopnia 5.

Wnioski. Zastosowanie indukcyjnej immunoterapii pembrolizumabem w skojarzeniu z chemioterapią przed zabiegiem operacyjnym oraz uzupełniającej immunoterapii pembrolizumabem znamienne wydłużyło czas wolny od progresji oraz zwiększyło udział znacznych i całkowitych odpowiedzi patologicznych u chorych na resekcyjnego wczesnego NSCLC w porównaniu z indukcyjną chemioterapią poprzedzającą zabieg operacyjny. Czas całkowitego przeżycia był w obu grupach podobny.

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

Siddiqi T., Maloney D.G., Kenderian S.S. i wsp.

Lancet, 2023; 402: 641–654

Chorzy na oporną na leczenie lub nawrotową przewlekłą białaczkę limfocytową lub chłoniaka z małych limfocytów, u któ-

rych leczenie inhibitorami kinazy tyrozynowej Brutona (BTK) oraz wenetoklaksem zakończyło się niepowodzeniem, mają niewiele możliwości leczenia oraz niekorzystne rokowanie. Celem badania była ocena skuteczności oraz bezpieczeństwa leczenia lizokabtagenem maraleucelu (lizo-cel) u chorych na nawrotową lub oporną na leczenie przewlekłą białaczką limfocytową lub chłoniaka z małych limfocytów.

Metody. Przedstawiono wyniki pierwotnej analizy przeprowadzonego w USA otwartego, jednoramiennego badania fazy I–II TRANSCEND CLL 004. Chorzy (w wieku 18 lat lub starsi) na nawrotową lub oporną na leczenie przewlekłą białaczkę limfocytową lub chłoniaka z małych limfocytów, po dwóch liniach leczenia systemowego (w tym z zastosowaniem inhibitorów BTK), otrzymywali dożylny wlew lizo-celu (limfocytów T z chimerycznymi receptorami antygenów) w jednej z dwóch należnych dawek: 50×10^6 (stężenie nr 1; *dose level* – DL1) lub 100×10^6 (stężenie nr 2 – DL2). Pierwszorzędownym punktem końcowym była całkowita odpowiedź lub remisja (w tym z niepełną regeneracją szpiku), oceniana w niezależnym podsumowaniu, zgodnie z kryteriami International Workshop on Chronic Lymphocytic Leukemia z 2018 roku, u chorych po niepowodzeniu leczenia inhibitorami BTK oraz wenetoklaksem (pierwotna analiza skuteczności) przy DL2 (hipoteza zerowa $\leq 5\%$).

Wyniki. Od 2 stycznia 2018 roku do 16 czerwca 2022 roku 137 chorych włączonych do badania poddano leukaferizie w 27 ośrodkach w USA. Lizo-cel otrzymało 117 chorych (mediana wieku: 65 lat [IQR 59–70]; 37 kobiet [32%] i 80 mężczyzn [68%]; 99 chorych rasy białej [85%], 5 [4%] – rasy czarnej lub Afroamerykanów, 2 innej rasy [2%] i 11 nieznaney rasy [9%]; mediana poprzednich linii leczenia wyniosła 5 [IQR 3–7]); u wszystkich 117 chorych leczenie inhibitorem BTK zakończyło się niepowodzeniem. U części uczestników doszło również do niepowodzenia leczenia wenetoklaksem ($n = 70$). W pierwotnej analizie skuteczności ustalonej dla DL2 ($n = 49$) udział całkowitych odpowiedzi lub remisji (w tym z niepełną regeneracją szpiku) był znamienny i wyniósł 18% ($n = 9$; 95% CI 9–32; $p = 0,0006$). Zespół uwalniania cytokin w stopniu 3. zgłoszono u dziesięciu spośród 117 chorych (9%) leczonych lizo-celem (nie wystąpiły zdarzenia niepożądane 4. lub 5. stopnia). Neurologiczne zdarzenia niepożądane 3. stopnia stwierdzono u 21 chorych (18%); 4. stopnia u 1 chorego [1%], nie było zdarzeń 5. stopnia.

Spośród 51 zgonów 43 wystąpiły po wlewie lizo-celu, w tym 5 jako wynik zdarzeń niepożądanych w trakcie leczenia (w ciągu 90 dni od wlewu lizo-celu). Jeden zgon był związany z zespołem aktywacji makrofagów (limfohistiocytozą hemofagocytarną).

Wnioski. Pojedynczy wlew lizo-celu indukuje całkowitą odpowiedź lub remisję (w tym z niepełną regeneracją szpiku) u chorych na nawrotową lub oporną na leczenie przewlekłą białaczkę limfocytową lub chłoniaka z małych limfocytów, u których leczenie inhibitorami kinazy tyrozynowej Brutona (BTK) oraz

wenetoklaksem zakończyło się niepowodzeniem. Powyższe leczenie wykazywało również możliwy do kontrolowania profil bezpieczeństwa.

Pirtobrutynib after a covalent BTK inhibitor in chronic lymphocytic leukemia

Mato A., Woyach J., Brown J. i wsp.
N. Engl. J. Med., 2023; 389: 33–44

Chorzy na przewlekłą białaczkę limfocytową (*chronic lymphocytic leukemia* – CLL) lub chłoniaka z małych limfocytów (*small-lymphocyte leukemia* – SLL) mają niekorzystne rokowanie po niepowodzeniu leczenia inhibitorami kinazy tyrozynowej Brutona (BTK). Potrzebne są nowe możliwości leczenia dla tej grupy chorych. Pirtobrutynib, wysoce selektywny, niekowalencyjny (odwracalny) inhibitor BTK, został stworzony w celu przywrócenia hamowania BTK.

Metody. Przeprowadzono badanie I–II fazy, w którym chorzy na nawrotowe lub oporne na leczenie nowotwory B-komórkowe otrzymywali pirtobrutynib. Przedstawiono wyniki skuteczności leczenia chorych na CLL lub SLL, po wcześniejszym leczeniu inhibitorem BTK, a także wyniki działań niepożądanych u wszystkich chorych na CLL lub SLL. Pierwszorzędowym punktem końcowym była ogólna odpowiedź (częściowa lub lepsza) oceniana przez niezależną komisję, a drugorzędowymi – przeżywalność wolna od progresji oraz bezpieczeństwo terapii.

Wyniki. Łącznie 317 chorych na CLL lub SLL otrzymało pirtobrutynib, w tym 247 osoby wcześniej leczone inhibitorem BTK. Wśród 247 chorych mediana wcześniejszych linii leczenia wynosiła 3 (zakres 1–11), a 100 chorych (40,5%) otrzymało również inhibitor limfocytów B2 (BCL2), np. wenetoklaks. Udział chorych z ogólną odpowiedzią na pirtobrutynib wyniósł 73,3% (95% CI 67,3–78,7), a 82,2% (95% CI, 76,8–86,7), gdy uwzględniono częściową odpowiedź z limfocytozą. Mediana przeżywalności wolnej od progresji wyniosła 19,6 miesiąca (95% CI, 16,9–22,1). Wśród wszystkich 317 chorych na CLL lub SLL, którzy otrzymali pirtobrutynib, najczęstszymi działaniami niepożądanymi były zakażenia (u 71,0% chorych), krwawienia (u 42,6%) oraz neutropenia (u 32,5%). Przy medianie leczenia wynoszącej 16,5 miesiąca (zakres 0,2–39,9), niektóre działania niepożądane zwykle związane z inhibitorami BTK wystąpiły stosunkowo rzadko, w tym nadciśnienie tętnicze (u 14,2% chorych), migotanie lub trzepotanie przedsionków (u 3,8%) oraz poważne krwawienia (u 2,2%). Jedynie 9 spośród 317 chorych (2,8%) zakończyło stosowanie pirtobrutynibu z powodu działania niepożądanego związanego z leczeniem.

Wnioski. Pirtobrutynib wykazał skuteczność u chorych na CLL lub SLL po kilku liniach leczenia, którzy otrzymywali inhibitor BTK. Najczęstszymi działaniami niepożądanymi były zakażenia, krwawienia i neutropenia.

Overall survival with osimertinib in resected EGFR-mutated NSCLC

Tsuboi M., Herbst R., John T. i wsp.
N. Engl. J. Med., 2023; 389: 137–147

W badaniu ADAURA uzupełniające leczenie ozymertynibem, z lub bez wcześniejszej uzupełniającej chemioterapii, znacząco wydłużyło przeżywalność wolną od choroby u chorych po usunięciu niedrobnokomórkowego raka płuca (NSCLC) w stopniu zaawansowania IB–IIIA, z obecnością mutacji receptora naskórkowego czynnika wzrostu (*EGFR*), w porównaniu z placebo. Przedstawiono wyniki planowanej analizy końcowej dotyczącej czasu całkowitego przeżycia.

Metody. W podwójnie zaślepionym badaniu III fazy chorych przydzielano losowo (w stosunku 1:1) do otrzymywania ozymertynibu (80 mg raz dziennie) lub placebo – do nawrotu choroby, zakończenia badania (3 lata) lub spełnienia kryterium przerwania. Pierwszorzędowym punktem końcowym była oceniana przez badacza przeżywalność wolna od choroby w stopniu zaawansowania II–IIIA, drugorzędowymi: przeżywalność wolna od choroby w stopniu zaawansowania IB–IIIA, czas całkowitego przeżycia i bezpieczeństwo.

Wyniki. Spośród 682 chorych poddanych randomizacji, 339 otrzymało ozymertynib, a 343 placebo. Wśród chorych w stopniu zaawansowania II do IIIA, udział pięcioletnich całkowitych przeżyć wyniósł 85% wśród leczonych ozymertynibem i 73% – w grupie placebo (wskaźnik ogólnego ryzyka zgonu 0,49; 95,03% CI 0,33–0,73; $p < 0,001$). Udział pięcioletnich całkowitych przeżyć w całej grupie (chorzy w stopniu zaawansowania IB–IIIA) wyniósł 88% w grupie leczonej ozymertynibem i 78% w grupie placebo (wskaźnik ogólnego ryzyka zgonu 0,49; 95,03% CI 0,34–0,70; $p < 0,001$). Po poprzednio opublikowanej dacie zakończenia gromadzenia danych, zgłoszono jedno nowe poważne działanie niepożądane: zapalenie płuc związane z zakażeniem koronawirusem 2019 (COVID-19). Zdarzenie nie było związane z leczeniem, a chory w pełni wyzdrowiał. Profil bezpieczeństwa uzupełniającego leczenia ozymertynibem był zgodny z przedstawionym w analizie głównej.

Wnioski. Uzupełniające leczenie ozymertynibem znacząco wydłużyło czas całkowitego przeżycia chorych po całkowitym usunięciu NSCLC z mutacją *EGFR* w stopniu zaawansowania IB do IIIA.

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial

Coles C., Haviland J., Kirby A. i wsp.
Lancet, 2023; 401: 2124–2137

Podwyższenie dawki w obszarze łoży po usuniętym guzie po napromieniowaniu całej piersi zwiększa kontrolę miejscową

nowotworu, ale wymaga większej liczby wizyt i może powodować stwardnienie piersi. W badaniu IMPORT HIGH porównano jednoczesne i sekwencyjne podanie dodatkowego napromieniowania, aby ocenić możliwość skrócenia leczenia przy zachowaniu doskonałej kontroli miejscowej i podobnej lub mniejszej toksyczności.

Metody. W otwartym badaniu III fazy z grupą kontrolną, typu *non-inferiority*, IMPORT HIGH, chore na inwazyjnego raka piersi w stopniu zaawansowania pT1–3 pN0–3a M0, po operacji oszczędzającej pierś, ze specjalistycznych ośrodków radioterapii w Wielkiej Brytanii, przydzielano losowo do jednego z trzech schematów leczenia (w stosunku 1:1:1) i stratyfikowano według ośrodków. Grupa kontrolna otrzymywała 40 Gy w 15 frakcjach na całą pierś, a następnie 16 Gy w 8 frakcjach na obszar łoża po usuniętym guzie. Wyłoniono dwie grupy badane: 1. grupa badana – 36 Gy w 15 frakcjach na całą pierś, 40 Gy w 15 frakcjach na część piersi i 48 Gy w 15 frakcjach jako jednoczesne napromienianie obszaru łoża po usuniętym guzie; 2. grupa badana – 36 Gy w 15 frakcjach na całą pierś, 40 Gy w 15 frakcjach na część piersi i 53 Gy w 15 frakcjach jako jednoczesne napromienianie obszaru łoża po usuniętym guzie. Stosowano promieniowanie fotonowe. Objętość obszaru łoża po guzie objętego dodatkową dawką określano na podstawie klipsów umieszczonych w łożu. Chore i badacze nie byli zaślepieni pod względem przypisanego leczenia. Pierwszorzędownym punktem końcowym był nawrót raka piersi po tej samej stronie (*ipsilateral breast tumor recurrence* – IBTR) oceniany w grupie zgodnej z zamiarem leczenia; przy założeniu 5% wskaźnika zachorowalności w ciągu 5 lat w grupie kontrolnej, nie mniejsza skuteczność została określona jako nieprzekraczający 3% wzrost w grupach badanych (górny limit dwustronnego CI 95%). Działania niepożądane były oceniane przez badaczy, chore oraz przy użyciu fotografii.

Wyniki. Od 4 marca 2009 roku do 16 września 2015 roku włączono do badania 2617 chorych, w tym 871 – do grupy kontrolnej, 874 – do 1. grupy badanej i 872 – do 2. grupy badanej. Mediana objętości obszaru dodatkowego napromieniania wyniosła 13 cm³ (IQR 7–22). Po obserwacji, której mediana wyniosła 74 miesiące, stwierdzono 76 IBTR (20 w grupie kontrolnej, 21 w 1. grupie badanej i 35 w 2. grupie badanej). Udział 5-letnich IBTR określono jako 1,9% (95% CI 1,2–3,1) w grupie kontrolnej, 2,0% (1,2–3,2) w 1. grupie badanej i 3,2% (2,2–4,7) w 2. grupie badanej. Szacowane różnice bezwzględne wyniosły 0,1% (–0,8–1,7) w 1. grupie badanej i 1,4% (0,03–3,8) w 2. grupie badanej w porównaniu do grupy kontrolnej. Górny przedział ufności dla 1. grupy badanej w porównaniu z grupą kontrolną wskazywał na nie mniejszą skuteczność dla 48 Gy. Skumulowany wskaźnik umiarkowanego lub poważnego obrzęku piersi zgłaszanego przez badaczy w ciągu 5 lat wyniósł 11,5% w grupie kontrolnej, 10,6% w 1. grupie badanej ($p = 0,40$ w porównaniu z grupą kontrolną) i 15,5% w 2. grupie badanej ($p = 0,015$ w porównaniu z grupą kontrolną).

Wnioski. Udział IBTR we wszystkich grupach był niższy niż pierwotnie oczekiwano, niezależnie od sposobu podania dodatkowej dawki na obszar po usunięciu guza. Zmiany dawki nie przyniosły korzyści. Działania umiarkowanych lub poważnych działań niepożądanych po 5 latach były niskie dla małych objętości napromieniowania. Jednoczesne podanie dodatkowego napromieniania w badaniu IMPORT HIGH było bezpieczne i ograniczyło liczbę wizyt.

Anna Kowalczyk
Ewa Szutowicz-Zielińska
Magdalena Dróżka
Paweł Szymański

V Międzynarodowa Konferencja Postępy w Chirurgii Onkologicznej

20 października 2023 r.

Lublin

Aula Collegium Maius Uniwersytetu Medycznego w Lublinie

W tym roku wykładowcy konferencji podejmą próbę odpowiedzi na pytanie:
Czy pierwsze ćwierćwiecze XXI wieku przyniosło przełom w leczeniu (chirurgii) nowotworów?
Konferencję poprzedzi uroczystość nadania tytułu Doktora Honoris Causa Uniwersytetu
Medycznego w Lublinie profesorowi Janowi van Lanschotowi z Erasmus University
w Rotterdamie. Okazją do spotkania jest również jubileusz 20-lecia objęcia przez
prof. Wojciecha Polkowskiego kierownictwa Kliniki Chirurgii Onkologicznej UM w Lublinie.

Więcej informacji na stronie: <https://med-space.pl>

XXX Zjazd Polskiego Towarzystwa Chirurgii Onkologicznej XLI Konferencja Naukowo-Szkoleniowa PTChO

16–18 maja 2024 r.

Kraków

Więcej informacji na stronie: <https://ptcho.pl>

VI Kongres Onkologii Polskiej 2024

17–19 października 2024 r.

Warszawa

Motywy przewodnim kongresu będzie interdyscyplinarna opieka onkologiczna. W programie zaplanowano ponad 50 sesji edukacyjnych, w tym blisko 150 wykładów, a udział potwierdziło ponad 150 wykładowców – ekspertów w zakresie przedstawianych zagadnień. Wśród gości zagranicznych będzie Prezydent ESMO (European Society for Medical Oncology).

Więcej informacji na stronie: <https://www.pto.med.pl>

VI Kongres Onkologii Polskiej

Warszawa,
17–19 października 2024 roku



www.kongres.pto.med.pl



23-0308.001.012

ORGANIZATOR



ORGANIZATOR
TECHNICZNY



30
LAT

Kongres jest skierowany do wszystkich osób zainteresowanych tematyką. Sesje satelitarne firm farmaceutycznych, sesje firm farmaceutycznych oraz wystawy firm farmaceutycznych są skierowane tylko do osób uprawnionych do wystawiania recept lub osób prowadzących obrót produktami leczniczymi — podstawa prawna: Ustawa z dnia 6 września 2001 r. Prawo farmaceutyczne (Dz. U. z 2017 r. poz. 2211, z późn. zm.).



Programy lekowe w onkologii

— aspekty medyczne,
organizacyjne i ekonomiczne



SZCZEGÓŁY



29 listopada 2023 roku

Przewodniczący Komitetu Naukowego

prof. dr hab. n. med. Jacek Jassem

prof. dr hab. n. med. Maciej Krzakowski

www.programylekowe.viamedica.pl

Virtual Meeting jest skierowany tylko do osób uprawnionych do wystawiania recept lub osób prowadzących obrót produktami leczniczymi — podstawa prawna: Ustawa z dnia 6 września 2001 r. Prawo farmaceutyczne (t. j. Dz.U. z 2019 r. poz. 499).

PATRONAT



PATRONAT MEDIALNY



PARTNER

